<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>

<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp. - Form 10-K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 10-K </FONT></B></P>
<P align=center>(Mark One) </P>
<P align=center>[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 </P>
<P align=center>For the fiscal year ended <B><U>September 30, 2014</U></B></P>
<P align=center>[&nbsp; &nbsp;] TRANSITION REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </P>
<P align=center>For the transition period from ________________ to
________________</P>
<P align=center>Commission file number<B>: <U>000-51652 </U></B></P>
<P align=center><B><U><FONT size=5>ANAVEX LIFE SCIENCES CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
  <TD align=center width="50%"><B><U>98-0608404 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of incorporation or
      organization) </TD>
  <TD align=center width="50%">(I.R.S. Employer Identification No.) </TD>
  </TR>
  <TR>
    <TD align=center>&nbsp; </TD>
  <TD align=center width="50%">&nbsp; </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center><B><U>51 W 52</U></B><B><U><SUP>nd
      </SUP></U></B><B><U>Street, 7</U></B><B><U><SUP>th
      </SUP></U></B><B><U>Floor, New York, NY USA </U></B></TD>
  <TD align=center width="50%"><B><U>10019 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
  <TD align=center width="50%">(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code
<B><U>1-844-689-3939 </U></B></P>
<P align=center>Securities registered under Section 12(b) of the Act: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>None </U></B></TD>
  <TD align=center width="50%"><B><U>N/A </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>Title of each class </TD>
    <TD align=center width="50%">Name of each exchange on which registered  </TD>
  </TR></TABLE>
<P align=center>Securities registered pursuant to Section 12(g) of the Act:
<BR><B><U>Common Stock, $0.001 par value</U></B><B> </B><BR>(Title of class)
<BR></P>
<P align=justify>Indicate by checkmark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act. <BR>Yes
[&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No [X] </P>
<P align=justify>Indicate by checkmark if the registrant is not required to file
reports pursuant to Section 13 or 15(d) of the Act. <BR>Yes [&nbsp;&nbsp;
]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No [X] </P>
<P align=justify>Indicate by checkmark whether the registrant has (1) filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. <BR>Yes [X]&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;No [&nbsp;&nbsp; ] </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify>Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files).
<BR>Yes [X]&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No [&nbsp; &nbsp;] </P>
<P align=justify>Indicate by checkmark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K (&#167; 229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrant&#146;s
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K.
[&nbsp;&nbsp; ]</P>
<P align=justify>Indicate by checkmark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148;
&#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the
Exchange Act. </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>Large accelerated filer [&nbsp; &nbsp;] </TD>
    <TD align=left width="44%" >&nbsp; </TD>
    <TD align=left width="27%">Accelerated
      filer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      [&nbsp; &nbsp;] </TD></TR>
  <TR vAlign=top>
    <TD align=left>Non-accelerated filer&nbsp;&nbsp; [&nbsp; &nbsp;] </TD>
    <TD align=left width="44%" >(Do not check if a smaller
      reporting company) </TD>
    <TD align=left width="27%">Smaller reporting company [X]
</TD></TR></TABLE></DIV>
<P align=justify>Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Act). <BR>Yes&nbsp;[&nbsp;
&nbsp;]&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;No [X] </P>
<P align=justify>State the aggregate market value of the voting and non-voting
common equity held by non-affiliates computed by reference to the price at which
the common equity was last sold, or the average bid and asked price of such
common equity, as of the last business day of the registrant&#146;s most recently
completed second fiscal quarter: $14,865,420 based on a price of $0.45 per
share, being the closing price of the registrant&#146;s common stock on March 31,
2014. </P>
<P align=justify>Indicate the number of shares outstanding of each of the
registrant&#146;s classes of common stock, as of the latest practicable date
54,684,905 issued and outstanding as of December 15, 2014. </P>
<P align=center>DOCUMENTS INCORPORATED BY REFERENCE </P>
<P align=justify>None. </P>
<P align=center>ii </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center><B><U>TABLE OF CONTENTS</U></B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_5"><B>PART
      I</B> </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee >&nbsp; </TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_5">1</a></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="80%" >&nbsp; </TD>
    <TD align="right" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_5">Item
      1. </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_5">Business.
      </A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_5">1</a></TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_11">Item
      1A. </A></TD>
    <TD align=left width="80%" ><A
      href="#page_11">Risk
      Factors. </A></TD>
    <TD align=right ><a href="#page_11">7</a></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_22">Item
      1B. </A></TD>
    <TD align=left width="80%"  bgColor=#eeeeee ><A
      href="#page_22">Unresolved
      Staff Comments. </A></TD>
    <TD align=right  bgColor=#eeeeee ><a href="#page_22">18</a></TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_22">Item
      2. </A></TD>
    <TD align=left width="80%" ><A
      href="#page_22">Properties.
      </A></TD>
    <TD align=right ><a href="#page_22">18</a></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_22">Item
      3. </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_22">Legal
      Proceedings. </A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_22">18</a></TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_22">Item
      4. </A></TD>
    <TD align=left width="80%" ><A
      href="#page_22">Mine
      safety disclosures. </A></TD>
    <TD align=right ><a href="#page_22">18</a></TD></TR>
  <TR>
    <TD bgColor=#eeeeee width="10%">&nbsp;</TD>
    <TD width="80%" bgColor=#eeeeee >&nbsp; </TD>
    <TD bgColor=#eeeeee align="right" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_23"><B>PART
      II</B> </A></TD>
    <TD align=left width="80%" >&nbsp; </TD>
    <TD align=right ><a href="#page_23">19</a></TD>
  </TR>
  <TR>
    <TD bgColor=#eeeeee width="10%">&nbsp;</TD>
    <TD width="80%" bgColor=#eeeeee >&nbsp; </TD>
    <TD bgColor=#eeeeee align="right" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_23">Item
      5. </A></TD>
    <TD align=left width="80%" ><A
      href="#page_23">Market
      for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer
      Purchases of Equity Securities </A></TD>
    <TD align=right ><a href="#page_23">19</a></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_25">Item
      6. </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_25">Selected
      Financial Data </A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_25">21</a></TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_25">Item
      7. </A></TD>
    <TD align=left width="80%" ><A
      href="#page_25">Management's
      Discussion and Analysis of Financial Condition and Results of Operations
      </A></TD>
    <TD align=right ><a href="#page_25">21</a></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_32">Item
      7A. </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_32">Quantitative
      and Qualitative Disclosures about Market Risk. </A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_32">28</a></TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_33">Item
      8. </A></TD>
    <TD align=left width="80%" ><A
      href="#page_33">Financial
      Statements and Supplementary Data. </A></TD>
    <TD align=right ><a href="#page_32">28</a></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_34">Item
      9. </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_34">Changes
      In and Disagreements with Accountants on Accounting and Financial
      Disclosure. </A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_35">29</a></TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_34">Item
      9A </A></TD>
    <TD align=left width="80%" ><A
      href="#page_34">Controls
      and Procedures</A></TD>
    <TD align=right ><a href="#page_35">29</a></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_36">Item
      9B </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_36">Other
      Information</A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_36">31</a></TD></TR>
  <TR>
    <TD width="10%"></TD>
    <TD width="80%" ></TD>
    <TD align="right" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_37"><B>PART
      III</B> </A></TD>
    <TD align=left width="80%"  bgColor=#eeeeee
      >&nbsp;</TD>
    <TD align=right  bgColor=#eeeeee
      ><a href="#page_37">32</a></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="80%" >&nbsp; </TD>
    <TD align="right" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_37">Item
      10. </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_37">Directors,
      Executive Officers and Corporate Governance. </A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_37">32</a></TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_40">Item
      11. </A></TD>
    <TD align=left width="80%" ><A
      href="#page_40">Executive
      Compensation. </A></TD>
    <TD align=right ><a href="#page_40">35</a></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_43">Item
      12. </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_43">Security
      Ownership of Certain Beneficial Owners and Management and Related
      Stockholder Matters. </A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_43">38</a></TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_44">Item
      13. </A></TD>
    <TD align=left width="80%" ><A
      href="#page_44">Certain
      Relationships and Related Transactions, and Director Independence
  </A></TD>
    <TD align=right ><a href="#page_44">39</a></TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_45">Item
      14. </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_45">Principal
      Accountant Fees and Services </A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_45">40</a></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="80%" >&nbsp; </TD>
    <TD align="right" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_46"><B>PART
      IV</B> </A></TD>
    <TD align=left width="80%"  bgColor=#eeeeee
      >&nbsp;</TD>
    <TD align=right  bgColor=#eeeeee
      ><a href="#page_46">41</a></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="80%" >&nbsp; </TD>
    <TD align="right" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee width="10%"><A
      href="#page_46">Item
      15. </A></TD>
    <TD align=left width="80%" bgColor=#eeeeee ><A
      href="#page_46">Exhibits
      and Financial Statement Schedules </A></TD>
    <TD align=right bgColor=#eeeeee ><a href="#page_46">41</a></TD></TR>
  <TR vAlign=top>
    <TD align=left width="10%"><A
      href="#page_52">Signatures
      </A></TD>
    <TD align=left width="80%"  >&nbsp;</TD>
    <TD align=right  >&nbsp;</TD>
  </TR></TABLE>
<P align=center>iii </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_4></A>
<P align=justify><B>Forward Looking Statements. </B></P>
<P align=justify>This Annual Report on Form 10-K includes forward-looking
statements. All statements other than statements of historical facts contained
in this Annual Report on Form 10-K, including statements regarding our
anticipated future clinical and regulatory milestone events, future financial
position, business strategy and plans and objectives of management for future
operations, are forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148;
&#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;expect&#148; and similar
expressions, as they relate to us, are intended to identify forward-looking
statements. Such forward-looking statements include, without limitation,
statements regarding the anticipated start dates, durations and completion dates
of our ongoing and future clinical studies, statements regarding the anticipated
designs of our future clinical studies, statements regarding our anticipated
future regulatory submissions and statements regarding our anticipated future
cash position. We have based these forward-looking statements largely on our
current expectations and projections about future events, including the
responses we expect from the U.S. Food and Drug Administration, or FDA, and
other regulatory authorities and financial trends that we believe may affect our
financial condition, results of operations, business strategy, preclinical and
clinical trials and financial needs. These forward-looking statements are
subject to a number of risks, uncertainties and assumptions including without
limitation the risks described in &#147;Risk Factors&#148; in Part I, Item 1A of this
Annual Report on Form 10-K. These risks are not exhaustive. Other sections of
this Annual Report on Form 10-K include additional factors which could adversely
impact our business and financial performance. Moreover, we operate in a very
competitive and rapidly changing environment. New risk factors emerge from time
to time and it is not possible for our management to predict all risk factors,
nor can we assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual results to differ
materially from those contained in any forward-looking statements. You should
not rely upon forward-looking statements as predictions of future events. We
cannot assure you that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and actual results could
differ materially from those projected in the forward-looking statements. Except
as required by applicable laws including the securities laws of the United
States and Canada, we assume no obligation to update or supplement
forward-looking statements. </P>
<P align=justify>As used in this Annual Report on Form 10-K, the terms &#147;we,&#148;
&#147;us,&#148; &#147;our,&#148; and &#147;Anavex&#148; mean Anavex Life Sciences Corp., unless the context
clearly requires otherwise.</P>
<P align=center>iv </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_5"></A>

<P align="justify">
<B>PART I </B></P>
<P align="justify">
<B>ITEM 1. BUSINESS</B></P>
<P align="justify">
We are a clinical stage biopharmaceutical company engaged in the development of drug candidates to treat Alzheimer&rsquo;s disease, other central nervous system (CNS) diseases, and various types of cancer. Our lead compounds ANAVEX 2-73 and ANAVEX
PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), are being developed to treat Alzheimer&rsquo;s disease and potentially other central nervous system (CNS) diseases. </P>
<P align="justify">
In December 2014 a Phase 2a clinical trial was initiated for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer&rsquo;s disease. The randomized trial is designed to assess the safety and exploratory efficacy of ANAVEX 2-73 alone as
well as in combination with donepezil (ANAVEX PLUS) in patients with mild to moderate Alzheimer&rsquo;s disease. ANAVEX 2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress levels in the brain
and to reverse the pathological hallmarks observed in Alzheimer&rsquo;s disease. ANAVEX 2-73 showed no serious adverse events in a previously performed Phase 1 study. In pre-clinical studies, ANAVEX 2-73 demonstrated anti-amnesic and neuroprotective
properties in various animal models including the transgenic mouse model Tg2576. </P>
<P align="justify">
We intend to identify and initiate discussions with potential partners in the next 12 months. Further, we may acquire or develop new intellectual property and assign, license, or otherwise transfer our intellectual property to further our goals. </P>
<P align="justify">
<B><I>Our Pipeline</I></B> </P>
<P align="justify">
Our pipeline includes one clinical drug candidate and several compounds in different stages of pre-clinical study. </P>
<P align="justify">
Our proprietary SIGMACEPTOR&trade; Discovery Platform produced small molecule drug candidates with unique modes of action, based on our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases,
including Alzheimer&rsquo;s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease. </P>
<P align="justify">
Compounds that have been subjects of our research include the following: </P>
<P align="justify">
<B>ANAVEX 2-73</B> </P>
<P align="justify">
ANAVEX 2-73 may offer a disease-modifying approach in Alzheimer&rsquo;s disease (AD) by using ligands that activate sigma-1 receptors. </P>
<P align="justify">
In AD animal models, ANAVEX 2-73 has shown pharmacological, histological and behavioral evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent affinity to sigma-1 receptors and
moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX 2-73 has shown a potential dual mechanism which may impact both amyloid and tau pathology. In a transgenic AD animal model Tg2576 ANAVEX 2-73 induced a statistically
significant neuroprotective effect against the development of oxidative stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that is apparently
amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time in the animals, regardless of sex, both in terms of spatial working memory and long-term spatial reference memory. </P>

<P align="center">
1</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_6"></A>
<P align="justify">
Based on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX 2-73 in 2011. In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg.
This dose is above the equivalent dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram (ECG) parameters. ANAVEX 2-73 was well tolerated below the 55-60 mg dose with only mild
adverse events in some subjects. Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity and reversible. These side effects are often seen with drugs that target
central nervous system (CNS) conditions, including AD. </P>
<P align="justify">
The ANAVEX 2-73 Phase 1 SAD trial was conducted as a randomized, placebo-controlled study. Healthy male volunteers between the ages of 18 and 55 received single, ascending oral doses over the course of the trial. Study endpoints included safety and
tolerability together with pharmacokinetic parameters. Pharmacokinetics includes the absorption and distribution of a drug, the rate at which a drug enters the blood and the duration of its effect, as well as chemical changes of the substance in the
body. This study was conducted in Germany in collaboration with ABX-CRO, a clinical research organization that has conducted several Alzheimer&rsquo;s disease studies, and the Technical University of Dresden. </P>
<P align="justify">
<B>ANAVEX PLUS</B> </P>
<P align="justify">
ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept&reg;) is a potential novel combination drug for Alzheimer&rsquo;s disease. Aricept&reg; (donepezil) is now generic. ANAVEX 2-73 showed in combination with donepezil an unexpected and
clear synergic effect of memory improvement by up to 80% in animal models. A patent application was filed in the US for the combination of donepezil and ANAVEX 2-73 and if granted would give patent protection at least until 2033. </P>
<P align="justify">
In a humanized calibrated cortical network computer model the unexpected pre-clinical synergy between ANAVEX 2-73 and donepezil was confirmed and ANAVEX PLUS showed an anticipated ADAS-Cog response of 7 points at 12 weeks and 5.5 points at 26 weeks,
which represents more than 2x the ADAS-Cog of donepezil alone. </P>
<P align="justify">
<B>ANAVEX 3-71 </B></P>
<P align="justify">
ANAVEX 3-71, previously named AF710B is a preclinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation, which has shown to enhance neuroprotection and cognition in Alzheimer's
disease. ANAVEX 3-71 is a CNS-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications. It is highly effective in very small doses against the major Alzheimer's hallmarks in transgenic (3xTg-AD) mice,
including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX 3-71 indicates extensive therapeutic advantages in Alzheimer's and other protein-aggregation-related
diseases given its ability to enhance neuroprotection and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation. </P>
<P align="justify">
<B>ANAVEX 1-41 </B></P>
<P align="justify">
ANAVEX 1-41 is a sigma-1 agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from degeneration or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which
damages and destroys cells and is believed by some scientists to be a primary cause of AD. In addition, in animal models,
ANAVEX 1-41 prevented the expression of caspase-3, an enzyme that plays a key
role in apoptosis (programmed cell death) and loss of cells in the hippocampus,
the part of the brain that regulates learning, emotion and memory. These
activities involve both muscarinic and sigma-1 receptor systems through a novel
mechanism of action.</P>

<P align="center">
2</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_7></A>
<P align=justify><B>ANAVEX 1037 </B></P>
<P align=justify>ANAVEX 1037 is designed for the treatment of prostate cancer.
It is a low molecular weight, synthetic compound exhibiting high affinity for
sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2
receptors and sodium channels at micromolar levels. In advanced pre-clinical
studies, this compound revealed antitumor potential with no toxic side effects.
It has also been shown to selectively kill human cancer cells without affecting
normal/healthy cells and also to significantly suppress tumor growth in
immune-deficient mice models. Scientific publications describe sigma receptor
ligands positively, highlighting the possibility that these ligands may stop
tumor growth and induce selective cell death in various tumor cell lines. Sigma
receptors are highly expressed in different tumor cell types. Binding by
appropriate sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In
addition, through tumor cell membrane reorganization and interactions with ion
channels, our drug candidates may play an important role in inhibiting the
processes of metastasis (spreading of cancer cells from the original site to
other parts of the body), angiogenesis (the formation of new blood vessels) and
tumor cell proliferation. </P>
<P align=justify>Our compounds are in the pre-clinical and clinical testing
stages of development, and there is no guarantee that the activity demonstrated
in pre-clinical models will be shown in human testing. </P>
<P align=justify><B><I>Our Target Indications</I></B> </P>
<P align=justify>We have developed compounds with potential application to two
broad categories and several specific indications. The two categories are
diseases of the central nervous system, and cancer. Specific indications
include:</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>Alzheimer&#146;s disease &#150; In 2014, an estimated 5.2 million Americans are
  suffering from Alzheimer&#146;s disease. The Alzheimer&#146;s Association&#174; reports that
  by 2025, 7.1 million Americans will be afflicted by the disease, a 40 percent
  increase from currently affected patients. Medications on the market today
  treat only the symptoms of AD and do not have the ability to stop its onset or
  its progression. There is an urgent and unmet need for both a disease
  modifying cure for Alzheimer&#146;s disease as well as for better symptomatic
  treatments. </P>
  <LI>
  <P>Depression - Depression is a major cause of morbidity worldwide according
  to the World Health Organization (WHO). Pharmaceutical treatment for
  depression is dominated by blockbuster brands, with the leading nine brands
  accounting for approximately 75% of total sales. However, the dominance of the
  leading brands is waning, largely due to the effects of patent expiration and
  generic competition. Our market research leads us to believe that the
  worldwide market for pharmaceutical treatment of depression exceeds $11
  billion annually. </P>
  <LI>
  <P>Epilepsy - Epilepsy is a common chronic neurological disorder characterized
  by recurrent unprovoked seizures. These seizures are transient signs and/or
  symptoms of abnormal, excessive or synchronous neuronal activity in the brain.
  According to the Centers for Disease Control and Prevention, epilepsy affects
  2.2 million Americans. Today, epilepsy is often controlled, but not cured,
  with medication that is categorized as older traditional anti-epileptic drugs
  and second generation anti epileptic drugs. Because epilepsy afflicts
  sufferers in different ways, there is a need for drugs used in combination
  with both traditional anti-epileptic drugs and second generations anti-epileptic drugs. Decision Resources, one of the world&rsquo;s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the epilepsy market will increase from &#36;2.9 billion in 2011 to nearly&#36;3.7 billion in 2016. <br>
</P>
<P align="center">
3</P>

  </LI>
</UL>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_8"></A>

<UL style="text-align:justify;"><LI>
Neuropathic Pain &ndash; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not
respond well to normal pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane stabilizing drugs or antidepressants. Our market research leads us to believe the worldwide market
for pharmaceutical treatment of neuropathic pain exceeds &#36;5 billion annually.<br>
<br>
</LI>
<LI>
Malignant Melanoma - Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes surgical removal
of the tumor, adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide Malignant Melanoma market is expected to grow from about &#36;900 million in 2012 to &#36;4.4 billion by 2022.<br>
<br>
</LI>
<LI>
Prostate Cancer &ndash; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. The cancer cells may metastasize from the prostate to other parts of the body, particularly the
bones and lymph nodes. Drug therapeutics for Prostate Cancer are expected to increase from &#36;8.1 billion in 2012 to nearly &#36;18.6 billion in 2017 according to BCC Research.<br>
<br>
</LI>

<LI>
Pancreatic Cancer - Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States approximately 45,000 new cases of pancreatic cancer will be diagnosed this year and approximately 38,000 patients will die as a result of their
cancer. Our market research leads us to believe that the market for the pharmaceutical treatment of pancreatic cancer will exceed &#36;1.2 billion by 2015.</LI>
</UL>
<P align="justify">
<B><I>Competition</I></B> </P>
<P align="justify">
The pharmaceutical industry is intensely competitive. </P>
<P align="justify">
At this time, we view our competition as biomedical development companies that are trying to discover and develop compounds to be used in the treatment of Alzheimer&rsquo;s disease, and those companies already doing so. Those companies include Prana
Biotechnology Ltd. (NASDAQ:PRAN), Perrigo Company PLC (NYSE:PRGO), Pfizer Inc. (NYSE:PFE), Actavis Plc. (NYSE:ACT), Novartis AG (NYSE:NVS), GlaxoSmithKline PLC (NYSE:GSK), Merck &amp; Co. Inc. (NYSE:MRK), Eli Lilly &amp; Co. (NYSE: LLY), Johnson
&amp; Johnson (NYSE:JNJ) and Roche Holding AG (VTX:ROG). </P>
<P align="justify">
Each of our competitors have greater capital resources, larger overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory approval, and pharmaceutical product manufacturing
and marketing than we do. With these additional resources, our competitors will be able to respond to the rapid and significant technological changes in the biotechnology and pharmaceutical industries faster than we can. Our future success will
depend in large part on our ability to acquire funding for our research and development. To continue to acquire funding for our research and development, we will likely have to show progress toward our goals and we will eventually be expected to
develop a compound that may result in a transaction with another pharmaceutical company </P>

<p align="center">4</p>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_9"></A>

<P align="justify">
<B><I>Patents, Trademarks and Intellectual Property </I></B></P>
<P align="justify">
Anavex holds one issued U.S. patent and five U.S. patent applications with various international counterpart applications. The most recent U.S. patent application was filed October 20, 2014. Anavex is awaiting formal patent documents from a
co-inventor as to two applications, and seeking one assignment from the same co-inventor to an application assigned to Anavex by another co-inventor. We regard patents and other intellectual property rights as corporate assets. Accordingly, we
attempt to optimize the value of intellectual property in developing our business strategy including the selective development, protection, and exploitation of our intellectual property rights. </P>
<P align="justify">
In addition to filings made with intellectual property organizations, we protect our intellectual property and confidential information by means of carefully considered processes of communication and the sharing of information, and by the use of
confidentiality and non-disclosure agreements and provisions for the same in contractor&rsquo;s agreements. While no agreement offers absolute protection, such agreements provide some form of recourse in the event of disclosure, or anticipated
disclosure. </P>
<P align="justify">
Our intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical questions for which important legal principles are unresolved. We may file additional patent applications in the United
States, or in other jurisdictions for further inventions. We may not be successful in obtaining critical claims or in protecting our potential drug compounds or processes. Even if we do obtain patents, they may not adequately protect the technology
we own or have licensed. In addition, others may challenge, seek to invalidate, infringe or circumvent any patents we own or license, and rights we receive under those patents may not provide competitive advantages to us. Further, the manufacture,
use or sale of our potential drug compounds may infringe the patent rights of others </P>
<P align="justify">
Our success will also depend in part on our ability to commercialize our compounds without infringing the proprietary rights of others. We have not conducted extensive freedom of use patent searches and no assurance can be given that patents do not
exist or could not be filed which would have an adverse effect on our ability to market our technology or maintain our competitive position with respect to our technology. If our compounds or other subject matter are claimed under other existing
United States or other patents or are otherwise protected by third party proprietary rights, we may be subject to infringement actions. In such event, we may challenge the validity of such patents or other proprietary rights or we may be required to
obtain licenses from such companies in order to develop, manufacture or market our technology. There can be no assurances that we would be able to obtain such licenses or that such licenses, if available, could be obtained on commercially reasonable
terms. Furthermore, the failure to either develop a commercially viable alternative or obtain such licenses could result in delays in marketing all of our potential drug compounds based on our drug technology or the inability to proceed with the
development, manufacture or sale of potential drug compounds requiring such licenses, which could have a material adverse effect on our business, financial condition and results of operations. If we defend ourselves against charges of patent
infringement or to protect our proprietary rights against third parties, substantial costs will be incurred regardless of whether we are successful. Such proceedings are typically protracted with no certainty of success. An adverse outcome could
subject us to significant liabilities to third parties and force us to curtail or cease our research and development of our technology. </P>
<P align="justify">
<B><I>Government Approval </I></B></P>
<P align="justify">
Regulation by governmental authorities in the United States and foreign countries is a significant factor in the development, manufacture, and expected marketing of our potential drug compounds and in potential future research and development
activities. The nature and extent to which such regulation will apply to us will vary depending on the nature of any potential drug compounds developed. We anticipate that all of
our potential drug compounds will require regulatory approval by governmental agencies prior to commercialization. </P>

<p align="center">5</p>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_10"></A>
<P align="justify">
In particular, human therapeutic products are subject to rigorous non-clinical and clinical testing and other approval procedures of the FDA and similar regulatory authorities in other countries. Various federal statutes and regulations also govern
or influence testing, manufacturing, safety, labeling, storage, and record-keeping related to such products and their marketing. The process of obtaining these approvals and the subsequent compliance with the appropriate federal statutes and
regulations requires substantial time and financial resources. Any failure by us or our collaborators to obtain, or any delay in obtaining, regulatory approval could adversely affect the marketing of any potential drug compounds developed by us, our
ability to receive product revenues, and our liquidity and capital resources. </P>
<P align="justify">
The steps ordinarily required before a new drug may be marketed in the United States, which are similar to steps required in most other countries, include: </P>
<UL style="text-align:justify;">
<LI>
non-clinical laboratory tests, non-clinical studies in animals, formulation studies and the submission to the FDA of an investigational new drug application;</LI>
<LI>
adequate and well-controlled clinical trials to establish the safety and efficacy of the drug;</LI>
<LI>
the submission of a new drug application or biologic license application to the FDA; and</LI>
<LI>
FDA review and approval of the new drug application or biologics license application.</LI>
</UL>
<P align="justify">
Non-clinical tests include laboratory evaluation of potential drug compound chemistry, formulation and toxicity, as well as animal studies. The results of non-clinical testing are submitted to the FDA as part of an investigational new drug
application. A 30-day waiting period after the filing of each investigational new drug application is required prior to commencement of clinical testing in humans. At any time during the 30-day period or at any time thereafter, the FDA may halt
proposed or ongoing clinical trials until the FDA authorizes trials under specified terms. The investigational new drug application process may be extremely costly and substantially delay the development of our potential drug compounds. Moreover,
positive results of non-clinical tests will not necessarily indicate positive results in subsequent clinical trials. The FDA may require additional animal testing after an initial investigational new drug application is approved and prior to Phase
III trials. </P>
<P align="justify">
Clinical trials to support new drug applications are typically conducted in three sequential phases, although the phases may overlap. During Phase I, clinical trials are conducted with a small number of subjects to assess metabolism,
pharmacokinetics, and pharmacological actions and safety, including side effects associated with increasing doses. Phase II usually involves studies in a limited patient population to assess the efficacy of the drug in specific, targeted
indications; assess dosage tolerance and optimal dosage; and identify possible adverse effects and safety risks. </P>
<P align="justify">
If a compound is found to be potentially effective and to have an acceptable safety profile in Phase I and II evaluations, Phase III trials are undertaken to further demonstrate clinical efficacy and to further test for safety within an expanded
patient population at geographically dispersed clinical trial sites. </P>
<P align="justify">
After successful completion of the required clinical trials, a new drug application is generally submitted. The FDA may request additional information before accepting the new drug application for filing, in which case the new drug application must
be resubmitted with the additional information. Once the submission has been accepted for filing, the FDA reviews the new drug application and responds to the applicant. The FDA&rsquo;s requests for additional information or clarification often
significantly extends the review process. The FDA may refer the new drug application to an appropriate advisory committee for
review, evaluation, and recommendation as to whether the new drug application should be approved, although the FDA is not bound by the recommendation of an advisory committee. </P>

<P align="center">
6</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_11"></A>
<P align="justify">
Sales outside the United States of potential drug compounds we develop will also be subject to foreign regulatory requirements governing human clinical trials and marketing for drugs. The requirements vary widely from country to country, but
typically the registration and approval process takes several years and requires significant resources. In most cases, if the FDA has not approved a potential drug compound for sale in the United States, the potential drug compound may be exported
for sale outside of the United States, only if it has been approved in any one of the following: the European Union, Canada, Australia, New Zealand, Japan, Israel, Switzerland and South Africa. There are specific FDA regulations that govern this
process. </P>
<P align="justify">
<B><I>Research and Development Expenses</I></B> </P>
<P align="justify">
Historically, a significant portion of our operating expenses has related to research and development. See &ldquo;Financial Statements and Supplementary Data&rdquo; of this Annual Report for costs and expenses related to research and development,
and other financial information for fiscal years 2014 and 2013. </P>
<P align="justify">
<B><I>Scientific Advisors</I></B> </P>
<P align="justify">
We are advised by scientists and physicians with experience relevant to our Company and our product candidates. In the past twelve months, our advisors included Dr. Michael Gold, John Harrison, Ph.D., Dr, Ottavio Arancio, Dr. Norman Relkin, Ph.D.,
Ph.D., Tangui Nicolas Maurice, Ph.D., Abraham Fisher, Ph.D., Dr. Paul Aisen, and Dr. Jeffrey Cummings. </P>
<P align="justify">
<B><I>Officers</I></B> </P>
<P align="justify">
One of our directors is engaged as an officer-employee of the Company serving in the capacity of president, secretary, treasurer, chief executive officer and chief financial officer. </P>
<P align="justify">
<B><I>Employees</I></B> </P>
<P align="justify">
We currently have four (4) full-time employees, and we retain several independent contractors on an as-needed basis. We believe that we have good relations with our employees. </P>
<P align="justify">
<B>ITEM 1 A. RISK FACTORS </B></P>
<P align="justify">
In addition to other information in this Annual Report on Form 10-K, the following risk factors should be carefully considered in evaluating our business because such factors may have a significant impact on our business, operating results,
liquidity and financial condition. As a result of the risk factors set forth below, actual results could differ materially from those projected in any forward-looking statements. Additional risks and uncertainties not presently known to us, or that
we currently consider to be immaterial, may also impact our business, operating results, liquidity and financial condition. If any such risks occur, our business, operating results, liquidity and financial condition could be materially affected in
an adverse manner. Under such circumstances, the trading price of our securities could decline, and you may lose all or part of your investment. </P>
<P align="justify">
<B><I>Risks Related to our Company</I></B> </P>

<P align="center">
7</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_12"></A>

<P align="justify">
<B><I>We have had a history of losses and no revenue, which raise substantial doubt about our ability to continue as a going concern.</I></B> </P>
<P align="justify">
Since inception on January 23, 2004 through September 30, 2014, we have an accumulated deficit of &#36;52,573,325. We can offer no assurance that we will ever operate profitably or that we will generate positive cash flow in the future. To date, we
have not generated any revenues from our operations. Our history of losses and no revenues raise substantial doubt about our ability to continue as a going concern. As a result, our management expects the business to continue to experience negative
cash flow for the foreseeable future and cannot predict when, if ever, our business might become profitable. We will need to raise additional funds, and such funds may not be available on commercially acceptable terms, if at all. If we are unable to
raise funds on acceptable terms, we may not be able to execute our business plan, take advantage of future opportunities, or respond to competitive pressures or unanticipated requirements. This may seriously harm our business, financial condition
and results of operations. </P>
<P align="justify">
<B><I>We are a clinical stage biopharmaceutical company and may never be able to successfully develop marketable products or generate any revenue. We have a very limited relevant operating history upon which an
evaluation of our performance and prospects can be made. There is no assurance that our future operations will result in profits. If we cannot generate sufficient revenues, we may suspend or cease operations.</I></B> </P>
<P align="justify">
We are an early development stage company and have not generated any revenues to date and have no operating history. All of our potential drug compounds are in the concept stage or early clinical development stage. Moreover, we cannot be certain
that our research and development efforts will be successful or, if successful, that our potential drug compounds will ever be approved for sales to pharmaceutical companies or generate commercial revenues. We have no relevant operating history upon
which an evaluation of our performance and prospects can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen capital requirements, failure of potential drug
compounds either in non-clinical testing or in clinical trials, failure to establish business relationships and competitive disadvantages against larger and more established companies. If we fail to become profitable, we may suspend or cease
operations. </P>
<P align="justify">
<B><I>We will need additional funding and may be unable to raise additional capital when needed, which would force us to delay, reduce or eliminate our research and development activities.</I></B> </P>
<P align="justify">
We will need to raise additional funding and the current economic conditions may have a negative impact on our ability to raise additional needed capital on terms that are favorable to our Company or at all. We may not be able to generate
significant revenues for several years, if at all. Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through equity or debt financing. We cannot be certain that additional funding will be available on
acceptable terms, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research and development activities. </P>
<P align="justify">
<B><I>Risks Related to our Business</I></B> </P>
<P align="justify">
<B><I>Even if we are able to develop our potential drug compounds, we may not be able to receive regulatory approval, or if approved, we may not be able to generate significant revenues or successfully commercialize our products, which will
adversely affect our financial results and financial condition and we will have to delay or terminate some or all of our research and development plans which may force us to cease operations.</I></B> </P>

<P align="center">
8</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_13"></A>

<P align="justify">
All of our potential drug compounds will require extensive additional research and development, including non-clinical testing and clinical trials, as well as regulatory approvals, before we can market them. We cannot predict if or when any of the
potential drug compounds we intend to develop will be approved for marketing. There are many reasons that we may fail in our efforts to develop our potential drug compounds. These include: </P>
<UL style="text-align:justify;">
<LI>
the possibility that non-clinical testing or clinical trials may show that our potential drug compounds are ineffective and/or cause harmful side effects;</LI>
<LI>
our potential drug compounds may prove to be too expensive to manufacture or administer to patients;</LI>
<LI>
our potential drug compounds may fail to receive necessary regulatory approvals from the United States Food and Drug Administration or foreign regulatory authorities in a timely manner, or at all;</LI>
<LI>
even if our potential drug compounds are approved, we may not be able to produce them in commercial quantities or at reasonable costs;</LI>
<LI>
even if our potential drug compounds are approved, they may not achieve commercial acceptance;</LI>
<LI>
regulatory or governmental authorities may apply restrictions to any of our potential drug compounds, which could adversely affect their commercial success; and</LI>
<LI>
the proprietary rights of other parties may prevent us or our potential collaborative partners from marketing our potential drug compounds.</LI>
</UL>
<P align="justify">
If we fail to develop our potential drug compounds, our financial results and financial condition will be adversely affected, we will have to delay or terminate some or all of our research and development plans and may be forced to cease operations.
</P>
<P align="justify">
<B><I>Our research and development plans will require substantial additional future funding which could impact our operational and financial condition. Without the required additional funds, we will likely cease operations.</I></B> </P>
<P align="justify">
It will take several years before we are able to develop potentially marketable products, if at all. Our research and development plans will require substantial additional capital, arising from costs to: </P>
<UL style="text-align:justify;">
<LI>
conduct research, non-clinical testing and human studies;</LI>
<LI>
establish pilot scale and commercial scale manufacturing processes and facilities; and</LI>
<LI>
establish and develop quality control, regulatory, marketing, sales, finance and administrative capabilities to support these programs.</LI>
</UL>
<P align="justify">
Our future operating and capital needs will depend on many factors, including: </P>
<UL style="text-align:justify;">
<LI>
the pace of scientific progress in our research and development programs and the magnitude of these programs;</LI>
<LI>
the scope and results of pre-clinical testing and human studies;</LI>
<LI>
the time and costs involved in obtaining regulatory approvals;</LI>
<LI>
the time and costs involved in preparing, filing, prosecuting, securing, maintaining and enforcing patents;</LI>
<LI>
competing technological and market developments;</LI>
<LI>
our ability to establish additional collaborations;</LI>
<LI>
changes in our existing collaborations;</LI>
<LI>
the cost of manufacturing scale-up; and<P align="center">
9</P>

</LI>
</UL>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_14"></A>

<UL style="text-align:justify;">
<LI>
the effectiveness of our commercialization activities.</LI>
</UL>
<P align="justify">
We base our outlook regarding the need for funds on many uncertain variables. Such uncertainties include the success of our research initiatives, regulatory approvals, the timing of events outside our direct control such as negotiations with
potential strategic partners and other factors. Any of these uncertain events can significantly change our cash requirements as they determine such one-time events as the receipt or payment of major milestones and other payments. </P>
<P align="justify">
Additional funds will be required to support our operations and if we are unable to obtain them on favorable terms, we may be required to cease or reduce further research and development of our drug product programs, sell some or all of our
intellectual property, merge with another entity or cease operations. </P>
<P align="justify">
<B><I>If we fail to demonstrate efficacy in our non-clinical studies and clinical trials our future business prospects, financial condition and operating results will be materially adversely affected.</I></B> </P>
<P align="justify">
The success of our research and development efforts will be greatly dependent upon our ability to demonstrate potential drug compound efficacy in non-clinical studies, as well as in clinical trials. Non-clinical studies involve testing potential
drug compounds in appropriate non-human disease models to demonstrate efficacy and safety. Regulatory agencies evaluate these data carefully before they will approve clinical testing in humans. If certain non-clinical data reveals potential safety
issues or the results are inconsistent with an expectation of the potential drug compound&rsquo;s efficacy in humans, the regulatory agencies may require additional more rigorous testing before allowing human clinical trials. This additional testing
will increase program expenses and extend timelines. We may decide to suspend further testing on our potential drug compounds if, in the judgment of our management and advisors, the non-clinical test results do not support further development. </P>
<P align="justify">
Moreover, success in non-clinical testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials
and non-clinical testing. The clinical trial process may fail to demonstrate that our potential drug compounds are safe for humans and effective for indicated uses. This failure would cause us to abandon a drug candidate and may delay development of
other potential drug compounds. Any delay in, or termination of, our non-clinical testing or clinical trials will delay the filing of an investigational new drug application and new drug application with the Food and Drug Administration or the
equivalent applications with pharmaceutical regulatory authorities outside the United States and, ultimately, our ability to commercialize our potential drug compounds and generate product revenues. In addition, we expect that our early clinical
trials will involve small patient populations. Because of the small sample size, the results of these early clinical trials may not be indicative of future results. </P>
<P align="justify">
Following successful non-clinical testing, potential drug compounds will need to be tested in a clinical development program to provide data on safety and efficacy prior to becoming eligible for product approval and licensure by regulatory agencies.
From the first human trial through to regulatory approval can take many years and 10-12 years is not unusual for certain compounds. </P>
<P align="justify">
If any of our future clinical development potential drug compounds become the subject of problems, our ability to sustain our development programs will become critically compromised. For example, efficacy or safety concerns may arise, whether or not
justified, that could lead to the suspension or termination of our clinical programs. Examples of problems that could arise include, among others: </P>
<UL style="text-align:justify;">
<LI>
efficacy or safety concerns with the potential drug compounds, even if not justified;<P align="center">
10</P>

</LI>
</UL>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_15"></A>

<UL style="text-align:justify;">
<LI>
manufacturing difficulties or concerns;</LI>
<LI>
regulatory proceedings subjecting the potential drug compounds to potential recall;</LI>
<LI>
publicity affecting doctor prescription or patient use of the potential drug compounds;</LI>
<LI>
pressure from competitive products; or</LI>
<LI>
introduction of more effective treatments.</LI>
</UL>
<P align="justify">
Each clinical phase is designed to test attributes of the drug and problems that might result in the termination of the entire clinical plan can be revealed at any time throughout the overall clinical program. The failure to demonstrate efficacy in
our clinical trials would have a material adverse effect on our future business prospects, financial condition and operating results. </P>
<P align="justify">
<B><I>If we do not obtain the support of qualified scientific collaborators, our revenue, growth and profitability will likely be limited, which would have a material adverse effect on our business.</I></B> </P>
<P align="justify">
We will need to establish relationships with leading scientists and research institutions. We believe that such relationships are pivotal to establishing products using our technologies as a standard of care for various indications. Additionally,
although in discussion, there is no assurance that our current research partners will continue to work with us or that we will be able to attract additional research partners. If we are not able to establish scientific relationships to assist in our
research and development, we may not be able to successfully develop our potential drug compounds. If this happens, our business will be adversely affected. </P>
<P align="justify">
<B><I>We may not be able to develop, market or generate sales of our products to the extent anticipated. Our business may fail and investors could lose all of their investment in our Company.</I></B> </P>
<P align="justify">
Assuming that we are successful in developing our potential drug compounds and receiving regulatory clearances to market our products, our ability to successfully penetrate the market and generate sales of those products may be limited by a number
of factors, including the following: </P>
<UL style="text-align:justify;">
<LI>
If our competitors receive regulatory approvals for and begin marketing similar products in the United States, the European Union, Japan and other territories before we do, greater awareness of their products as compared to ours will cause our
competitive position to suffer;</LI>
<LI>
Information from our competitors or the academic community indicating that current products or new products are more effective or offer compelling other benefits than our future products could impede our market penetration or decrease our future
market share; and</LI>
<LI>
The pricing and reimbursement environment for our future products, as well as pricing and reimbursement decisions by our competitors and by payers, may have an effect on our revenues.</LI>
</UL>
<P align="justify">
If this happens, our business will be adversely affected. </P>
<P align="justify">
<B><I>None of our potential drug compounds may reach the commercial market for a number of reasons and our business may fail.</I></B> </P>
<P align="justify">
Successful research and development of pharmaceutical products is high risk. Most products and development candidates fail to reach the market. Our success depends on the discovery of new drug compounds that we can commercialize. It is possible that
our products may never reach the market for a number of reasons. They may be found ineffective or may cause harmful side-effects during non-clinical testing or clinical trials or fail to receive necessary regulatory approvals. We may find that
certain products cannot be manufactured at a commercial scale and, therefore, they may not be economical to produce. Our potential products could also fail to achieve market acceptance or be precluded from
commercialization by proprietary rights of third parties. Our patents, patent applications, trademarks and other intellectual property may be challenged and this may delay or prohibit us from effectively commercializing our products. Furthermore, we
do not expect our potential drug compounds to be commercially available for a number of years, if at all. If none of our potential drug compounds reach the commercial market, our business will likely fail and investors will lose all of their
investment in our Company. If this happens, our business will be adversely affected. </P>

<P align="center">
11</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_16"></A>
<P align="justify">
<B><I>If our competitors succeed in developing products and technologies that are more effective or with a better profile than our own, or if scientific developments change our understanding of the potential scope and utility of our potential
products, then our technologies and future products may be rendered undesirable or obsolete.</I></B> </P>
<P align="justify">
We face significant competition from industry participants that are pursuing technologies in similar disease states to those that we are pursuing and are developing pharmaceutical products that are competitive with our products. Nearly all of our
industry competitors have greater capital resources, larger overall research and development staffs and facilities, and a longer history in drug discovery and development, obtaining regulatory approval and pharmaceutical product manufacturing and
marketing than we do. With these additional resources, our competitors may be able to respond to the rapid and significant technological changes in the biotechnology and pharmaceutical industries faster than we can. Our future success will depend in
large part on our ability to maintain a competitive position with respect to these technologies. Rapid technological development, as well as new scientific developments, may result in our products becoming obsolete before we can recover any of the
expenses incurred to develop them. For example, changes in our understanding of the appropriate population of patients who should be treated with a targeted therapy like we are developing may limit the drug&rsquo;s market potential if it is
subsequently demonstrated that only certain subsets of patients should be treated with the targeted therapy. </P>
<P align="justify">
<B><I>Our reliance on third parties, such as university laboratories, contract manufacturing organizations and contract or clinical research organizations, may result in delays in completing, or a failure to complete, non-clinical testing or
clinical trials if they fail to perform under our agreements with them.</I></B> </P>
<P align="justify">
In the course of product development, we may engage university laboratories, other biotechnology companies or contract or clinical manufacturing organizations to manufacture drug material for us to be used in non-clinical and clinical testing and
contract research organizations to conduct and manage non-clinical and clinical studies. If we engage these organizations to help us with our non-clinical and clinical programs, many important aspects of this process have been and will be out of our
direct control. If any of these organizations we may engage in the future fail to perform their obligations under our agreements with them or fail to perform non-clinical testing and/or clinical trials in a satisfactory manner, we may face delays in
completing our clinical trials, as well as commercialization of any of our potential drug compounds. Furthermore, any loss or delay in obtaining contracts with such entities may also delay the completion of our clinical trials, regulatory filings
and the potential market approval of our potential drug compounds. </P>
<P align="justify">
<B><I>If we fail to compete successfully with respect to partnering, licensing, mergers, acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to research and develop our potential drug
compounds.</I></B> </P>
<P align="justify">
Our competitors compete with us to attract established biotechnology and pharmaceutical companies or organizations for partnering, licensing, mergers, acquisitions, joint ventures or other collaborations. Collaborations include contracting with
academic research institutions for the performance of specific scientific testing. If our competitors successfully enter into
partnering arrangements or license agreements with academic research
institutions, we will then be precluded from pursuing those specific
opportunities. Since each of these opportunities is unique, we may not be able
to find a substitute. Other companies have already begun many drug development
programs, which may target diseases that we are also targeting, and have already
entered into partnering and licensing arrangements with academic research
institutions, reducing the pool of available opportunities. </P>

<P align="center">
12</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_17></A>
<P align=justify>Universities and public and private research institutions also
compete with us. While these organizations primarily have educational or basic
research objectives, they may develop proprietary technology and acquire patent
applications and patents that we may need for the development of our potential
drug compounds. In some instances, we will attempt to license this proprietary
technology, if available. These licenses may not be available to us on
acceptable terms, if at all. If we are unable to compete successfully with
respect to acquisitions, joint venture and other collaboration opportunities, we
may be limited in our ability to develop new products. </P>
<P align=justify><B><I>The use of any of our products in clinical trials may
expose us to liability claims, which may cost us significant amounts of money to
defend against or pay out, causing our business to suffer.</I></B> </P>
<P align=justify>The nature of our business exposes us to potential liability
risks inherent in the testing, manufacturing and marketing of our products. We
currently have one drug compound in clinical trials, however, when any of our
products enter into clinical trials or become marketed products, they could
potentially harm people or allegedly harm people possibly subjecting us to
costly and damaging product liability claims. Some of the patients who
participate in clinical trials are already ill when they enter a trial or may
intentionally or unintentionally fail to meet the exclusion criteria. The
waivers we obtain may not be enforceable and may not protect us from liability
or the costs of product liability litigation. Although we intend to obtain
product liability insurance which we believe is adequate, we are subject to the
risk that our insurance will not be sufficient to cover claims. The insurance
costs along with the defense or payment of liabilities above the amount of
coverage could cost us significant amounts of money and management distraction
from other elements of the business, causing our business to suffer. </P>
<P align=justify><B><I>The patent positions of biopharmaceutical products and
processes are complex and uncertain and we may not be able to protect our
patented or other intellectual property. If we cannot protect this property, we
may be prevented from using it or our competitors may use it and our business
could suffer significant harm. Also, the time and money we spend on acquiring
and enforcing patents and other intellectual property will reduce the time and
money we have available for our research and development, possibly resulting in
a slow down or cessation of our research and development.</I></B> </P>
<P align=justify>We hold ownership rights to one patent and five U.S. patent
applications with various international counterpart, all of which relate to drug
candidates. We are seeking the remaining rights as to one application, and
declarations from the same co-inventor. However, neither patents nor patent
applications ensure the protection of our intellectual property for a number of
reasons, including the following: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>Competitors may interfere with our patenting process in a
      variety of ways. Competitors may claim that they invented the claimed
      invention prior to us. Competitors may also claim that we are infringing
      their patents and restrict our freedom to operate. Competitors may also
      contest our patents and patent applications, if issued, by showing in
      various patent offices that, among other reasons, the patented subject
      matter was not original, was not novel or was obvious. In litigation, a
      competitor could claim that our patents and patent applications are not
      valid or enforceable for a number of reasons. If a court agrees, we would
      lose some or all of our patent protection. As a company, we have no
      meaningful experience with competitors interfering
with our patents or patent applications.</P></TD></TR></TABLE>
<P align="center">
13<BR>
</P>

<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_18></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>Because of the time, money and effort involved in
      obtaining and enforcing patents, our management may spend less time and
      resources on developing potential drug compounds than they otherwise
      would, which could increase our operating expenses and delay product
      programs.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>Issuance of a patent may not provide much practical
      protection. If we receive a patent of narrow scope, then it may be easier
      for competitors to design products that do not infringe our
    patent(s).</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify>No patents have yet been issued in the United
    States.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">5. </TD>
    <TD>
      <P align=justify>Our primary patent application for the combination of
      ANAVEX 2-73 with donepezil is pending only in the United States Patent and
      Trademark Office. The lack of patent protection in global markets may
      inhibit our ability to advance our compounds and may make Anavex less
      attractive to potential partners.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">6. </TD>
    <TD>
      <P align=justify>Defending a patent lawsuit takes significant time and can
      be very expensive.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">7. </TD>
    <TD>
      <P align=justify>If a court decides that our drug compound, its method of
      manufacture or use, infringes on the competitor&#146;s patent, we may have to
      pay substantial damages for infringement.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">8. </TD>
    <TD>
      <P align=justify>A court may prohibit us from making, selling or licensing
      the potential drug compound unless the patent holder grants a license. A
      patent holder is not required to grant a license. If a license is
      available, we may have to pay substantial royalties or grant cross
      licenses to our patents, and the license terms may be
  unacceptable.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">9. </TD>
    <TD>
      <P align=justify>Redesigning our potential drug compounds so that they do
      not infringe on other patents may not be possible or could require
      substantial funds and time.</P></TD></TR></TABLE>
<P align=justify>It is also unclear whether our trade secrets are adequately
protected. While we use reasonable efforts to protect our trade secrets, our
employees or consultants may unintentionally or willfully disclose our
information to competitors. Enforcing a claim that someone illegally obtained
and is using our trade secrets, like patent litigation, is expensive and time
consuming, and the outcome is unpredictable. In addition, courts outside the
United States are sometimes less willing to protect trade secrets. Our
competitors may independently develop equivalent knowledge, methods and
know-how. </P>
<P align=justify>We may also support and collaborate in research conducted by
government organizations, hospitals, universities or other educational
institutions. These research partners may be unable or unwilling to grant us
exclusive rights to technology or products derived from these collaborations
prior to entering into the relationship. </P>
<P align=justify>If we do not obtain required intellectual property licenses or
rights, we could encounter delays in our product development efforts while we
attempt to design around other patents or even be prohibited from developing,
manufacturing or selling potential drug compounds requiring these rights or
licenses. There is also a risk that disputes may arise as to the rights to
technology or potential drug compounds developed in collaboration with other
parties. </P>
<P align=justify><B><I>Our substantial debt and other financial obligations
could impair our financial condition and our ability to fulfill our debt
obligations. Any refinancing of this substantial debt could be at significantly
higher interest rates.</I></B> </P>
<P align=justify>As of September 30, 2014, we had total liabilities of
$7,160,876 and accumulated deficit of $52,573,325. Our substantial indebtedness
and other current financial obligations and any that we may become a party to in
the future could: </P>
<UL style="TEXT-ALIGN: justify">
  <LI>impair our ability to obtain financing in the future for working capital,
  capital expenditures, or general corporate purposes;
<P align="center">
14</P>

  </LI></UL>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_19"></A>

<UL style="text-align:justify;">
<LI>
have a material adverse effect on us if we fail to comply with financial and affirmative and
restrictive covenants in debt agreements and an event of default occurs as a result of a failure
that is not cured or waived;</LI>
<LI>
require us to dedicate a substantial portion of our cash flow for interest payments on our
indebtedness and other financial obligations, thereby reducing the availability of our cash flow
to fund working capital and capital expenditures;</LI>
<LI>
limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate; and
place us at a competitive disadvantage compared to our competitors that have proportionally</LI>
<LI>
less debt.</LI>
</UL>
<P align="justify">
If we are unable to meet our debt service obligations and other financial obligations, we could be forced to restructure or refinance our indebtedness and other financial transactions, seek additional equity capital, sell our assets or curtail our
operations. We might then be unable to obtain such financing or capital or sell our assets on satisfactory terms, if at all. Any refinancing of our indebtedness could be at significantly higher interest rates, and/or incur significant transaction
fees. </P>
<P align="justify">
<B><I>In the past we have experienced material weaknesses in our internal control over financial reporting, which if continued, could impair our financial condition.</I></B> </P>
<P align="justify">
As reported here in this Annual Report on Form 10-K, our management concluded that our internal control over financial reporting was not effective as of September 30, 2014. Such ineffectiveness was due to material weaknesses regarding our control
environment (the maintenance of sufficient personnel with an appropriate level of accounting knowledge, experience, and training in the applicable of GAAP commensurate with our financial reporting requirements, and an insufficient segregation of
duties in our finance and accounting functions due to limited personnel), a lack of monitoring controls to determine the adequacy or our internal control over financial reporting and related policies, and we did not establish and maintain effective
controls to ensure the correct application of GAAP related to equity transactions. Due to our size and nature, segregation of all conflicting duties has not always been possible and may not be economically feasible. We endeavor to take appropriate
and reasonable steps to make improvements to remediate these deficiencies, and intend to consider the results of our remediation efforts and related testing as part of our year-end 2015 assessment of the effectiveness of our internal control over
financial reporting in light of our strategic plan and make any changes that our management deems appropriate. If we have continued material weaknesses in our internal financial reporting, our financial condition could be impaired. </P>
<P align="justify">
<B><I>Risks Related to our Common Stock</I></B> </P>
<P align="justify">
<B><I>A decline in the price of our common stock could affect our ability to raise further working capital and adversely impact our operations and would severely dilute existing or future investors if we were to raise funds at lower prices.</I></B>
</P>
<P align="justify">
A prolonged decline in the price of our common stock could result in a reduction in our ability to raise capital. Because our operations have been financed through the sale of equity securities, a decline in the price of our common stock could be
especially detrimental to our continued operations. Any reduction in our ability to raise equity capital in the future would force us to reallocate funds from other planned uses and would have a significant negative effect on our business plans and
operations, including our ability to develop new products and continue our current operations. If our stock price declines, there can be no assurance that we can raise additional capital or generate funds from operations sufficient to meet our
obligations. We believe the following factors could cause the market price of our common stock to
continue to fluctuate widely and could cause our common stock to trade at a price below the price at which you purchase your shares of common stock: </P>

<P align="center">
15</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_20"></A>
<UL style="text-align:justify;">
<LI>
actual or anticipated variations in our quarterly operating results;</LI>
<LI>
announcements of new services, products, acquisitions or strategic relationships by us or our competitors;</LI>
<LI>
changes in accounting treatments or principles;</LI>
<LI>
changes in earnings estimates by securities analysts and in analyst recommendations; and</LI>
<LI>
general political, economic, regulatory and market conditions.</LI>
</UL>
<P align="justify">
The market price for our common stock may also be affected by our ability to meet or exceed expectations of analysts or investors. Any failure to meet these expectations, even if minor, could materially adversely affect the market price of our
common stock. </P>
<P align="justify">
<B><I>If we issue additional shares of common stock in the future it will result in the dilution of our existing stockholders.</I></B> </P>
<P align="justify">
Our articles of incorporation authorize the issuance of 150,000,000 shares of common stock. Our board of directors has the authority to issue additional shares of common stock up to the authorized capital stated in the articles of incorporation. Our
board of directors may choose to issue some or all of such shares of common stock to acquire one or more businesses or to provide additional financing in the future. The issuance of any such shares of common stock will result in a reduction of the
book value or market price of the outstanding shares of our common stock. If we do issue any such additional shares of common stock, such issuance also will cause a reduction in the proportionate ownership and voting power of all other stockholders.
Further, any such issuance may result in a change of control of our corporation. </P>
<P align="justify">
<B><I>Trading of our common stock may be volatile and sporadic, which could depress the market price of our common stock and make it difficult for our stockholders to resell their shares.</I></B> </P>
<P align="justify">
There is currently a limited market for our common stock and the volume of our common stock traded on any day may vary significantly from one period to another. Our common stock is quoted on OTC Market&rsquo;s OTCQX. Trading in stock quoted on OTC
Market&rsquo;s OTCQX is often thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our operations or business prospects. The availability of buyers and sellers represented by this
volatility could lead to a market price for our common stock that is unrelated to operating performance. Moreover, OTC Market&rsquo;s OTCQX is not a stock exchange, and trading of securities quoted on OTC Market&rsquo;s OTCQX is often more sporadic
than the trading of securities listed on a stock exchange like NASDAQ. There is no assurance that a sufficient market will develop in the stock, in which case it could be difficult for our stockholders to resell their stock. </P>
<P align="justify">
<B><I>Our stock is classed as a &ldquo;penny stock.&rdquo; Trading of our stock may be restricted by the Securities and Exchange Commission&rsquo;s penny stock regulations which may limit a stockholder&rsquo;s ability to buy and sell our
stock.</I></B> </P>
<P align="justify">
Our stock is a penny stock. The Securities and Exchange Commission has adopted Rule 15g-9 which generally defines &ldquo;penny stock&rdquo; to be any equity security that has a market price (as defined) less than &#36;5.00 per share or an exercise
price of less than &#36;5.00 per share, subject to certain exceptions. Our securities are covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers
and &ldquo;accredited investors.&rdquo; The term &ldquo;accredited investor&rdquo; refers generally to institutions with assets in excess of &#36;5,000,000 or individuals
with a net worth in excess of &#36;1,000,000 (excluding the value of the primary residence of such individuals) or annual income exceeding &#36;200,000 or &#36;300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior
to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the Securities and Exchange Commission which provides information about penny stocks and the nature and
level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account
statements showing the market value of each penny stock held in the customer&rsquo;s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to
effecting the transaction and must be given to the customer in writing before or with the customer&rsquo;s confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules;
the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser&rsquo;s written agreement to the transaction. These disclosure requirements may have the effect of
reducing the level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the
penny stock rules discourage investor interest in and limit the marketability of our common stock. </P>

<P align="center">
16</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_21"></A>
<P align="justify">
<B><I>The Financial Industry Regulatory Authority sales practice requirements may also limit a stockholder&rsquo;s ability to buy and sell our stock.</I></B> </P>
<P align="justify">
In addition to the &ldquo;penny stock&rdquo; rules described above, the Financial Industry Regulatory Authority or FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds
for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the
customer&rsquo;s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at
least some customers. The FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for shares
of our common stock. </P>
<P align="justify">
<B><I>The sale or issuance of our common stock to Lincoln Park may cause dilution and the sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to
fall</I></B>. </P>
<P align="justify">
On July 5, 2013, we entered into a Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;) with Lincoln Park Capital Fund, LLC (&ldquo;<U>Lincoln Park</U>&rdquo;), pursuant to which Lincoln Park committed to purchase up to &#36;10,000,000
of our common stock. Concurrently with the execution of the Purchase Agreement, we issued 341,858 shares of our common stock to Lincoln Park as a fee for its commitment to purchase shares of our common stock under the Purchase Agreement. The
purchase shares that may be sold pursuant to the Purchase Agreement may be sold by us to Lincoln Park at our discretion from time to time over a 25-month period commencing after the SEC declared effective the related registration statement. The
purchase price for the shares that we may sell to Lincoln Park under the Purchase Agreement will fluctuate based on the price of our common stock. Depending on market liquidity at the time, sales of such shares may cause the trading price of our
common stock to fall. </P>
<P align="justify">
We generally have the right to control the timing and amount of any sales of our shares to Lincoln Park, except that, pursuant to the terms of our agreements with Lincoln Park, we would be unable to sell shares
to Lincoln Park if and when the closing sale price of our common stock is below &#36;0.50 per share, subject to adjustment as set forth in the Purchase Agreement. Additional sales of our common stock, if any, to Lincoln Park will depend upon market
conditions and other factors to be determined by us. Lincoln Park may ultimately purchase all of the shares of our common stock that may be sold pursuant to the Purchase Agreement and, after it has acquired shares, Lincoln Park may sell all, some or
none of those shares. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Lincoln Park, or
the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales. </P>

<P align="center">
17</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_22"></A>
<P align="justify">
<B><I>The exercise or conversion of the Warrants and Debentures issued to Private Placement Investors and Placement Agent may cause dilution.</I></B> </P>
<P align="justify">
On March 13, 2014, we entered into a Securities Purchase Agreement (the &ldquo;<U>Securities Purchase</U> <U>Agreement</U>&rdquo;) with the certain investors pursuant to which the Company agreed to sell, and the investors agreed to purchase, Senior
Convertible Debentures due March 18, 2044 (the &ldquo;<U>Debentures</U>&rdquo;) in the aggregate principal amount of &#36;10,000,000. In addition to the Debentures, we agreed to issue to the investors and the placement agent two (2) series of
warrants representing the right to purchase up to an aggregate of 67,666,666 shares of the Company&rsquo;s common stock (the &ldquo;<U>Warrants</U>&rdquo; and together with the Debentures, the &ldquo;<U>Securities</U>&rdquo;). The purchase and sale
of the Securities was consummated on March 18, 2014, and resulted in gross proceeds to the Company in the amount of &#36;10,000,000, before deducting agent fees and other transaction-related expenses. The exercise or conversion of the Securities
could result in the dilution to the interests of other holders of our common stock. </P>
<P align="justify">
<B>ITEM 1B. UNRESOLVED STAFF COMMENTS</B></P>
<P align="justify">
Not Applicable. </P>
<P align="justify">
<B>ITEM 2. PROPERTIES </B></P>
<P align="justify">
We do not own  any properties. We maintain offices at 7<SUP>th</SUP> Floor, 51 West 52<SUP>nd</SUP> Street, New York, NY, USA which we lease at a cost of &#36;4,000 per month. The lease is on a month to month basis. We believe our offices are
suitable and adequate to operate our business from at this time as they and provide us with sufficient space to conduct our operations. We fully utilize our current premises. </P>
<P align="justify">
<B>ITEM 3. LEGAL PROCEEDINGS </B></P>
<P align="justify">
We know of no material, existing or pending legal proceedings to which we are a party or of which any of our properties is the subject. In addition, we do not know of any such proceedings contemplated by any governmental authorities. We know of no
proceedings in which any of our directors, officers or affiliates, or any registered or beneficial stockholder is a party adverse to our company or has a material interest adverse to our company.</P>
<P align="justify">
<B>ITEM 4. MINE SAFETY DISCLOSURES </B></P>
<P align="justify">
Not applicable. </P>

<P align="center">
18</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_23></A>
<P align=justify><B>PART II </B></P>
<P align=justify><B>ITEM 5. MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED
STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </B></P>
<P align=justify><B><I>Market information </I></B></P>
<P align=justify>Our common stock is quoted on the OTCQX under the symbol &#147;AVXL.&#148;
</P>
<P align=justify>The following table shows the quarterly range of high and low
bid information for our common stock over the fiscal quarters for the last two
fiscal years as quoted on OTCQX. We obtained the following high and low bid
information from the OTC-Markets. These over-the-counter market quotations
reflect inter-dealer prices without retail mark-up, mark-down or commission, and
may not represent actual transactions. Investors should not rely on historical
prices of our common stock as an indication of its future price performance. On
December 15, 2014, the closing price of our common stock as reported by OTCQX
was $0.19 per share. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center >Quarter Ended </TD>
    <TD align=center width="30%">High </TD>
    <TD align=center width="30%">Low </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >September 30, 2014 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.35 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.18 </TD></TR>
  <TR vAlign=top>
    <TD align=left >June 30, 2014 </TD>
    <TD align=center width="30%">$046 </TD>
    <TD align=center width="30%">$0.27 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >March 31, 2014 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.53 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.25 </TD></TR>
  <TR vAlign=top>
    <TD align=left >December 31, 2013 </TD>
    <TD align=center width="30%">$0.65 </TD>
    <TD align=center width="30%">$0.25 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >September 30, 2013 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.75 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.49 </TD></TR>
  <TR vAlign=top>
    <TD align=left >June 30, 2013 </TD>
    <TD align=center width="30%">$0.83 </TD>
    <TD align=center width="30%">$0.45 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >March 31, 2013 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.81 </TD>
    <TD align=center width="30%" bgColor=#e6efff>$0.51 </TD></TR>
  <TR vAlign=top>
    <TD align=left >December 31, 2012 </TD>
    <TD align=center width="30%">$1.12 </TD>
    <TD align=center width="30%">$.072 </TD></TR></TABLE>
<P align=justify><B><I>Transfer Agent </I></B></P>
<P align=justify>Shares of our common stock are issued in registered form. The
Nevada Agency and Trust Company, 50 West Liberty Street, Reno, Nevada
(Telephone: (775) 322-0626; Facsimile: (775) 322-5623) is the registrar and
transfer agent for shares of our common stock. </P>
<P align=justify><B><I>Holders of Common Stock</I></B></P>
<P align=justify>As of December 15, 2014, there were approximately 79 holders of
record of our common stock. As of such date, 54,684,905 shares of our common
stock were issued and outstanding. </P>
<P align=justify><B><I>Dividends</I></B></P>
<P align=justify>We have not paid any cash dividends on our common stock and
have no intention of paying any dividends on the shares of our common stock. Our
current policy is to retain earnings, if any, for use in our operations and in
the development of our business. Our future dividend policy will be determined
from time to time by our board of directors. </P>
<P align="center">
19</P>

<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_24></A>
<P align=justify><B><I>Securities Authorized for Issuance under Equity
Compensation Plans or Individual Compensation Arrangements</I></B></P>
<P align=justify>The following table summarizes certain information regarding
our equity compensation plan or individual compensation arrangements as at
September 30, 2014: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=bottom>
    <TD colspan="4" align=center>&nbsp;<B>Equity Compensation Plan Information</B>&nbsp;    </TD>
    </TR>
  <TR vAlign=top>
    <TD align=center><BR><BR><BR><BR><BR><BR><B>Plan Category</B> <BR><BR></TD>
    <TD align=center width="25%"><BR><BR><BR><B>Number of securities</B>
      <BR><B>to be issued upon</B> <BR><B>exercise of</B> <BR><B>outstanding
      options,</B> <BR><B>warrants and rights</B> <BR><B>(a)</B> </TD>
    <TD align=center width="25%"><BR><BR><BR><B>Weighted-average</B>
      <BR><B>exercise price of</B> <BR><B>outstanding options,</B>
      <BR><B>warrants and rights</B> <BR><B>(b)</B> <BR></TD>
    <TD align=center width="25%"><B>Number of securities</B> <BR><B>remaining
      available</B> <BR><B>for future issuances</B> <BR><B>under equity</B>
      <BR><B>compensation plans</B> <BR><B>(excluding securities</B>
      <BR><B>reflected in column</B> <BR><B>(a))</B> <BR><B>(c)</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>Equity compensation plans approved by security holders </TD>
    <TD vAlign=bottom align=right width="25%">3,170,000 </TD>
    <TD vAlign=bottom align=right width="25%">0.70 </TD>
    <TD vAlign=bottom align=right width="25%">830,000 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Equity compensation plans not approved by security holders    </TD>
    <TD vAlign=bottom align=right width="25%">Nil </TD>
    <TD vAlign=bottom align=right width="25%">NA </TD>
    <TD vAlign=bottom align=right width="25%">NA </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Total</B> </TD>
    <TD vAlign=bottom align=right width="25%"><B>3,170,000</B> </TD>
    <TD vAlign=bottom align=right width="25%"><B>0.70</B> </TD>
  <TD vAlign=bottom align=right width="25%"><B>830,000</B></TD></TR></TABLE>
</DIV>
<P align=justify><B><I>Stock Option Plan</I></B></P>
<P align=justify>On April 17, 2007, our directors adopted the 2007 Stock Option
Plan. On May 25, 2007, our stockholders ratified and approved the 2007 Stock
Option Plan at the annual meeting of stockholders. As of September 30, 2014,
3,170,000 options have been granted to employees, directors, officers and
consultants of our company. </P>
<P align=justify>The purpose of the 2007 Stock Option Plan is to retain the
services of valued key employees and consultants of our company and such other
persons as will be select in accordance with the 2007 Stock Option Plan, and to
encourage such persons to acquire a greater proprietary interest in our company,
thereby strengthening their incentive to achieve the objectives of the
shareholders of our company, and to serve as an aid and inducement in the hiring
of new employees and to provide an equity incentive to consultants. </P>
<P align=justify>On February 2, 2011 we amended and restated our 2007 stock
option plan to increase the number of shares authorized to be issued under the
plan to 4,000,000.</P>
<P align=justify><B><I>Recent Sales of Unregistered Securities</I></B></P>
<P align="center">
20</P>

<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_25"></A>

<P align="justify">
Since the beginning of our fiscal year ended September 30, 2014, we have not sold any equity securities that were not registered under the Securities Act of 1933 that were not previously reported in a quarterly report on Form 10-Q or in a current
report on Form 8-K.</P>
<P align="justify">
<B><I>Purchases of Equity Securities by Our Company and Affiliated Purchasers </I></B></P>
<P align="justify">
None. </P>
<P align="justify">
<B>ITEM 6 SELECTED FINANCIAL DATA </B></P>
<P align="justify">
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide information under this item.</P>
<P align="justify">
<B>ITEM 7 MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</B></P>
<P align="justify">
The following discussion should be read in conjunction with our audited consolidated financial statements and notes thereto for the fiscal year ended September 30, 2014, included elsewhere in this Annual Report on Form 10-K. The following
Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations contains &ldquo;forward-looking statements&rdquo;. Forward-looking statements are generally written in the future tense and/or are preceded by words such as
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;forecast,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;suggest,&rdquo; &ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; or other similar words. The
forward-looking statements contained in this Annual Report on Form 10-K involve a number of risks and uncertainties, many of which are outside of our control. Factors that could cause actual results to differ materially from projected results
include, but are not limited to, those discussed in &ldquo;Risk Factors&rdquo; elsewhere in this Annual Report on Form 10-K. Readers are expressly advised to review and consider those Risk Factors, which include risks associated with (1) our ability
to successfully conduct clinical and preclinical trials for our product candidates, (2) our ability to obtain required regulatory approvals to develop and market our product candidates, (3) our ability to raise additional capital on favorable terms,
(4) our ability to execute our development plan on time and on budget, (5) our ability to obtain commercial partners, (6) our ability, whether alone or with commercial partners, to successfully commercialize any of our product candidates that may be
approved for sale, and (7) our ability to identify and obtain additional product candidates. Although we believe that the assumptions underlying the forward-looking statements contained in this Annual Report on Form 10-K are reasonable, any of the
assumptions could be inaccurate, and therefore there can be no assurance that such statements will be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information
should not be regarded as a representation by us or any other person that the results or conditions described in such statements or our objectives and plans will be achieved. Furthermore, past performance in operations and share price is not
necessarily indicative of future performance. Except as required by applicable laws including the securities laws of the United States and Canada, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as
a result of new information, future events or otherwise. </P>

<P align="center">
21</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_26></A>
<P align=justify><B><I>Our Business </I></B></P>
<P align=justify>We are a clinical stage biopharmaceutical company engaged in
the development of drug candidates to treat Alzheimer&#146;s disease, other central
nervous system (CNS) diseases, and various types of cancer. Our lead compounds
ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil
(Aricept&#174;) are being developed to treat Alzheimer&#146;s disease and potentially
other central nervous system (CNS) diseases. </P>
<P align=justify>In December 2014 a Phase 2a clinical trial was initiated for
ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer&#146;s disease.
The randomized trial is designed to assess the safety and exploratory efficacy
of ANAVEX 2-73 alone as well as in combination with donepezil (ANAVEX PLUS) in
patients with mild to moderate Alzheimer&#146;s disease. ANAVEX 2-73 targets sigma-1
and muscarinic receptors, which have been shown in preclinical studies to reduce
stress levels in the brain and to reverse the pathological hallmarks observed in
Alzheimer&#146;s disease. ANAVEX 2-73 showed no serious adverse events in a
previously performed Phase 1 study. In pre-clinical studies ANAVEX 2-73
demonstrated anti-amnesic and neuroprotective properties in various animal
models including the transgenic mouse model Tg2576.</P>
<P align=justify>We intend to identify and initiate discussions with potential
partners in the next 12 months. Further, we may acquire or develop new
intellectual property and assign, license, or otherwise transfer our
intellectual property to further our goals. </P>
<P align=justify><B><I>Recent Corporate Developments </I></B></P>
<P align=justify>Since the commencement of our fourth quarter ended September
30, 2014, we have experienced the following significant corporate developments:
</P>
<UL style="TEXT-ALIGN: justify">
  <LI>
  <P>On October 22, 2014, we entered into a Securities Purchase Agreement (the
  &#147;Purchase Agreement&#148;) with Lincoln Park Capital Fund, LLC, a long time
  investor of our company, for an equity investment of $500,000 at a price of
  $0.25 per unit. Pursuant to the terms of the Purchase Agreement, we agreed to
  sell, and Lincoln Park agreed to purchase, 2,000,000 shares of common stock.
  In addition, we agreed to issue to Lincoln Park an aggregate of 4,000,000
  stock purchase warrants, of which 2,000,000 are exercisable at $0.30 per share
  and 2,000,000 are exercisable at $0.42 per share, each for a period of five
  years, subject to adjustment for stock splits, combinations, and
  reclassification events. </P>
  <LI>
  <P>On November 3, 2014, we announced our Company has received regulatory
  approval from the Ethics Committee in Australia to initiate a Phase 2a
  clinical trial of our proprietary compound, ANAVEX 2-73, as well as ANAVEX
  PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept&#174;). The approved
  Phase 2a clinical trial is the first study of ANAVEX 2-73 in Alzheimer&#146;s
  patients. </P>
  <LI>
  <P>Effective as of December 12, 2014, our Company&#146;s common stock began being
  quoted on the OTC Market Group&#146;s OTCQX tier under the Company&#146;s existing stock
  ticker &#147;AVXL&#148;. The OTCQX is the highest tier of the OTC Market Group&#146;s trading
  marketplace. </P></LI></UL>
<P align=justify><B>RESULTS OF OPERATIONS </B></P>
<P align="center">
22</P>

<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_27"></A>

<P align="justify">
<B><I>Revenue </I></B></P>
<P align="justify">
We have not earned any revenues since our inception on January 23, 2004. We are still in the development stage and do not anticipate earning any revenues until we can establish an alliance with other companies to develop, co-develop, license,
acquire or market our products.</P>
<P align="justify">
<B><I>Operating Expenses</I></B></P>
<P align="justify">
Our operating expenses for the year ended September 30, 2014 were &#36;2,968,975, which represents an increase of &#36;831,608 compared to &#36;2,137,367 for the year ended September 30, 2013. The increase was mainly attributable to (i) an increase
in investor relations expenses and other professional fees and bonus payment as a result of our capital raising efforts related to a &#36;10,000,000 convertible Debenture financing, which resulted in one-time compensation charges in the aggregate
amount of &#36;1,010,000, including a non-cash charge of &#36;610,000 for the vesting of common stock under our President&rsquo;s employment agreement and (ii) an increase in research and development activities in the current year, including
clinical trial work, as a result of funding secured. </P>
<P align="justify">
<B><I>Other income (expenses) </I></B></P>
<P align="justify">
The aggregate amount in the other income (expense) for the year ended September 30, 2014, amounted to &#36;(8,399,378) as compared to &#36;(1,562,679) for the comparable year ended September 30, 2013. The largest single increase in this loss was as
a result of certain non-cash, non-operational accounting charges related to certain amendments to the Debentures.</P>
<P align="justify">
Generally accepted accounting principles in the United States (US GAAP) accounting rules deemed the amendments to the terms of the Debentures to require extinguishment accounting to be applied to them. This resulted in a net non-cash,
non-operational accounting charge being recorded in our consolidated statement of operations of &#36;8,099,137, net of the recovery of a finance charge of &#36;459,912, being the total accrued liquidating damages owed to the holders of the
convertible debentures at the date of the  amendment, though these amounts were satisfied through the modification of the conversion price. </P>
<P align="justify">Further, we do not have a sufficient number of authorized and unissued shares of common stock available to
  satisfy the additional shares that could be issued under the terms of the Debentures. As a result, US GAAP accounting rules require that we account for such shares underlying the Debentures as derivative liabilities. It is the requirement of these
  accounting rules, that we re-measure derivative financial instruments to their respective fair values at each reporting period, with the changes in fair value being reported as a non-operating item on the consolidated statement of operations.
  Consequently, we were required to record non-cash, non-operational gains related to the change in the calculated value of derivative liabilities of &#36;2,955,000 for the year ended September 30, 2014. </P>
<P align="justify">
These accounting charges did not result in an actual cash impact on our Company. Removing the effect of all financing related accelerated charges and adjustments to our consolidated statement of operations, results in a net loss of &#36;(2,760,714),
or &#36;(0.09) per share, as shown below: </P>

<P align="center">
23</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_28></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="15%">As
      Reported </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="15%">Net
      impact </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">Adjusted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Operating expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >General and administrative </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="15%">&nbsp;2,236,580 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="15%">&nbsp;2,236,580 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Research and development </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>732,395 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="15%"
    bgColor=#e6efff>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>732,395 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Total operating expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>(2,968,975</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>- </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>(2,968,975</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Other income (expenses) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Interest and finance expenses, net </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">(7,089</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">(7,089</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Gain on settlement of
      accounts payable </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>199,655 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>199,655 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Financing related charges and adjustments </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">(8,624,986</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">8,607,639 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">(17,347</TD>
    <TD align=left width="2%" >) </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Foreign exchange loss </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>33,042 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="15%"
    bgColor=#e6efff>&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>33,042 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Total other income
      (expenses), net </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>(8,399,378</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>8,607,639 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>208,261 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Net loss and comprehensive
      loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;(11,368,353</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;8,607,639 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&nbsp;(2,760,714</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>) </TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp; </TD>
    <TD width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff bordercolor="#000000" >Loss per share - diluted </TD>
    <TD align=left width="1%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">$</TD>
    <TD align=right width="15%" bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">&nbsp;(0.30</TD>
    <TD align=left width="2%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">) </TD>
    <TD align=left width="1%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">$</TD>
    <TD align=right width="15%" bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">&nbsp;(0.09</TD>
    <TD align=left width="2%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">)
</TD></TR></TABLE>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left bgColor=#e6efff bordercolor="#000000" >Net loss and
    comprehensive loss - GAAP basis</TD>
    <TD align=left width="1%"  bgColor=#e6efff bordercolor="#000000">$</TD>
    <TD align=right width="15%" bgColor=#e6efff bordercolor="#000000">
    &nbsp;(11,368,353</TD>
    <TD align=left width="2%"  bgColor=#e6efff bordercolor="#000000">) </TD>
    </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#FFFFFF bordercolor="#000000" >Add back:</TD>
    <TD align=left width="1%"  bgColor=#FFFFFF bordercolor="#000000">&nbsp;</TD>
    <TD align=right width="15%" bgColor=#FFFFFF bordercolor="#000000">&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#FFFFFF bordercolor="#000000">&nbsp;</TD>
    </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff bordercolor="#000000" >&nbsp;&nbsp; Non-cash
    financing related charged and adjustments</TD>
    <TD align=left width="1%"  bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff style="border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">
    8,607,639</TD>
    <TD align=left width="2%"  bgColor=#e6efff bordercolor="#000000">&nbsp;</TD>
    </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#FFFFFF bordercolor="#000000" >Net loss and
    comprehensive loss - Non-GAAP basis</TD>
    <TD align=left width="1%"  bgColor=#FFFFFF style="border-top-style: solid; border-top-width: 1; border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">$</TD>
    <TD align=right width="15%" bgColor=#FFFFFF style="border-top-style: solid; border-top-width: 1; border-bottom-style: solid; border-bottom-width: 1" bordercolor="#000000">
    &nbsp;(2,760,714</TD>
    <TD align=left width="2%"  bgColor=#FFFFFF bordercolor="#000000">) </TD>
    </TR></TABLE>
<P align=justify><B><I>Liquidity and Capital Resources</I></B></P>
<P align=justify><B><I>Working Capital </I></B></P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="80%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="22%"><B>2014</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="22%"><B>2013</B> </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Current Assets </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="22%" bgColor=#e6efff>&nbsp;7,351,255 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="22%" bgColor=#e6efff>&nbsp;393,449 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Current Liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="22%">1,441,149 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="22%">1,952,660 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >Working Capital (Deficiency)
    </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="22%" bgColor=#e6efff>&nbsp;5,910,106 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="22%" bgColor=#e6efff>&nbsp;(1,559,211</TD>
    <TD align=left width="2%"  bgColor=#e6efff>)
</TD></TR></TABLE></DIV>
<P align=justify>As of September 30, 2014, we had $7,262,138 in cash, an
increase of $6,917,064 from September 30, 2013. The principal reason for this
increase is due to cash received in respect of the issuance of the Debentures in
the aggregate principal amount of $10,000,000 that were issued in the current
year. We intend to use the funds from these Debentures to implement our plan of
operation of researching and developing our compounds, the related patents and
any further intellectual property we may acquire. We intend to use the majority
of our capital resources to complete the next clinical trial for ANAVEX 2-73 and
ANAVEX PLUS, and to perform work necessary to prepare for further clinical
development. </P>
<P align="center">
24</P>

<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_29></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Cash Flows</B> </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="16%">&nbsp; </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="16%">&nbsp; </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="16%"><B>2014</B> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="16%"><B>2013</B> </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >&nbsp;Cash flows used in
      operating activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="16%" bgColor=#e6efff>&nbsp;(2,659,379</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="16%" bgColor=#e6efff>&nbsp;(777,573</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;Cash flows used in investing activities
    </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="16%">(3,015</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="16%">- </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff >&nbsp;Cash flows provided by
      financing activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="16%" bgColor=#e6efff>9,579,458 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="16%" bgColor=#e6efff>1,111,285 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;Increase in cash </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="16%">&nbsp;6,917,064 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="16%">&nbsp;333,712 </TD>
    <TD align=left width="2%" >&nbsp;</TD></TR></TABLE>
<P align=justify><I>Cash flow used in operating activities </I></P>
<P align=justify>Our cash used in operating activities for the year ended
September 30, 2014 was $2,659,379 compared to $777,573 used in operating
activities for the comparative year ended September 30, 2013. The increase in
cash used in operating activities was primarily as a result of the increased net
loss for the current period as a result of an increase in corporate activities
and research and development following the Debenture financing in March, 2014.
</P>
<P align=justify><I>Cash used in investing activities</I></P>
<P align=justify>Cash used in investing activities was $3,015 in the current
year ended September 30, 2014. This is as a result of small equipment purchases
in the current year.</P>
<P align=justify><I>Cash flow provided by financing activities </I></P>
<P align=justify>Our cash provided by financing activities for the year ended
September 30, 2014 was $9,579,458, mostly attributable to cash received from the
issuance of the Debentures in the aggregate principal amount of $10,000,000,
less related fees and expenses of $788,712 incurred in connection with the
closing of these Debentures. We also received cash from the issuance of common
shares under the Purchase Agreement with Lincoln Park Capital Fund, LLC
(described under <i>Other Financing</i> below).</P>
<P align=justify>In the comparative year ended September 30, 2013, we had cash
inflows of $1,111,285 from activities related to the issuance of short term debt
and a private placement equity financings. </P>
<P align=justify><B>Other Financing</B></P>
<P align=justify>On July 5, 2013, the Company entered into a Purchase Agreement
(&#147;Purchase Agreement&#148;) with Lincoln Park Capital Fund, LLC (&#147;Lincoln Park&#148;).
Pursuant to the Purchase Agreement, Lincoln Park initially purchased 250,000
shares of the Company&#146;s common stock for $100,000. During the nine months ended
June 30, 2014, we issued an aggregate of 402,510 shares of common stock under
the Purchase Agreement, including 400,000 shares of common stock for an
aggregate purchase price of $188,170 and 2,510 commitment shares.</P>
<P align=justify>The Company has the right, in its sole discretion over a
25-month period, to sell to Lincoln Park up to the additional aggregate
commitment of $9.9 Million of shares of common stock. There are no upper limits
on the per share price that Lincoln Park may pay to purchase such common stock.
Furthermore, the Company controls the timing and amount of any future sales, if
any, of shares of common stock to Lincoln Park except that, pursuant to the
terms of the Purchase Agreement, we would be unable to sell shares to Lincoln
Park if and when the closing sale price of our common stock is below $0.50 per
share, subject to adjustment as set forth in the Purchase Agreement. Lincoln
Park has no right to require any
sales and is obligated to purchase common stock as directed by the Company. </P>
<P align="center">
25</P>

<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_30"></A>
<P align="justify">
Other than our rights related to the Lincoln Park financing, there can be no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially reasonable terms. If we are not able to
obtain the additional financing on a timely basis, if and when it is needed, we will be forced to delay or scale down some or all of our research and development activities or perhaps even cease the operation of our business. </P>
<P align="justify">
We expect that we will be able to  fund our operations for the next 12 months through existing cash on hand and through equity and debt financings in the future.  If we raise additional financing by issuing equity securities, our existing stockholders&rsquo;
ownership will be diluted. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments. </P>
<P align="justify">
<B><I>Off-Balance Sheet Arrangements </I></B></P>
<P align="justify">
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures
or capital resources that is material to our stockholders. </P>
<P align="justify">
<B>APPLICATION OF CRITICAL ACCOUNTING POLICIES </B></P>
<P align="justify">
Our financial statements and accompanying notes are prepared in accordance with generally accepted accounting principles in the United States. Preparing financial statements requires management to make estimates and assumptions that affect the
reported amounts of assets, liabilities, revenue and expenses. These estimates and assumptions are affected by management&rsquo;s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions
involved with the following aspects of our financial statements is critical to an understanding of our financials. </P>
<P align="justify">
We base our assumptions and estimates on historical experience and other sources that we believe to be reasonable at the time. Actual results may vary from our estimates due to changes in circumstances, weather, politics, global economics,
mechanical problems, general business conditions and other factors. Our significant estimates are related to the valuation of warrants and options. </P>
<P align="justify">
There are accounting policies that we believe are significant to the presentation of our financial statements. The most significant of these accounting policies relates to the accounting for our research and development expenses and stock-based
compensation expense.</P>
<P align="justify">
<B><I>Research and Development Expenses </I></B></P>
<P align="justify">
Research and developments costs are expensed as incurred. These expenses are comprised of the costs of our proprietary research and development efforts, including salaries, facilities costs, overhead costs and other related expenses as well as costs
incurred in connection with third-party collaboration efforts. Milestone payments made by us to third parties are expensed when the specific milestone has been achieved.</P>
<P align="justify">
In addition, we incur expenses in respect of the acquisition of intellectual property relating to patents and trademarks. The probability of success and length of time in developing commercial applications of the
drugs subject to the acquired patents and trademarks is difficult to determine and numerous risks and uncertainties exist with respect to the timely completion of the development projects. There is no assurance the acquired patents and trademarks
will ever be successfully commercialized. Due to these risks and uncertainties, we expense the acquisition of patents and trademarks.</P>

<P align="center">
26</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_31"></A>
<P align="justify">
<B><I>Stock-based Compensation </I></B></P>
<P align="justify">
We account for all stock-based payments and awards under the fair value based method. </P>
<P align="justify">
Stock-based payments to non-employees are measured at the fair value of the consideration received, or the fair value of the equity instruments issued, or liabilities incurred, whichever is more reliably measurable. The fair value of stock-based
payments to non-employees is periodically re-measured until the counterparty performance is complete, and any change therein is recognized over the vesting period of the award and in the same manner as if we had paid cash instead of paying with or
using equity based instruments. The cost of the stock-based payments to non-employees that is fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which
case such compensation would be amortized over the contractual term.</P>
<P align="justify">
We account for the granting of share purchase options to employees using the fair value method whereby all awards to employees will be recorded at fair value on the date of the grant. The fair value of all share purchase options are expensed over
their vesting period with a corresponding increase to additional capital surplus. Upon exercise of share purchase options, the consideration paid by the option holder, together with the amount previously recognized in additional capital surplus, is
recorded as an increase to share capital. </P>
<P align="justify">
We use the Black-Scholes option valuation model to calculate the fair value of share purchase options at the date of the grant. Option pricing models require the input of highly subjective assumptions, including the expected price volatility.
Changes in assumptions can materially affect the fair value estimate and therefore the Black-Scholes model does not necessarily provide a reliable single measure of the fair value of our share purchase options.</P>
<P align="justify">
<B><I>Derivative Liabilities </I></B></P>
<P align="justify">
From time to time, we may issue convertible promissory notes which include embedded conversion options which, dependent on their specific contractual terms, may be required to be accounted for as separate derivative liabilities. These liabilities
are required to be measured at fair value. These instruments are then adjusted to reflect fair value at each period end. Any increase or decrease in the fair value is recorded in results of operations as change in fair value of derivative
liabilities. In determining the appropriate fair value, we use the binomial pricing model because these instruments are not quoted on an active market.</P>
<P align="justify">
Option pricing models require the input of highly subjective assumptions, including the expected price volatility. Changes in assumptions can materially affect the fair value estimate and therefore the binomial model does not necessarily provide a
reliable single measure of the fair value of these instruments. </P>

<P align="center">
27</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_32"></A>

<P align="justify">
<B><I>Recent Accounting Pronouncements</I></B></P>
<P align="justify">
In June 2014, the FASB issued Accounting Standards Updated No.  2014-10,  "Development  Stage Entities&rdquo; (&ldquo;ASU 2014-10&rdquo;) which removes the definition of a development stage entity from the Master Glossary of the  Accounting
Standards Codification,  thereby removing the financial  reporting distinction between development stage entities and other reporting entities from U.S. GAAP. In addition, the update eliminates the requirements for development stage entities to (1)
present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which
the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. During the year ended September 30, 2014, we elected to early adopt ASU
2014-10. The adoption of this ASU allowed our company to remove the inception to date information and all references to development stage. </P>
<P align="justify">
<B><I>Recent Accounting Pronouncements Not Yet Adopted</I></B></P>
<P align="justify">
In June 2014, the FASB issued ASU No. 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period ("ASU 2014-12"). ASU 2014-12 requires that a
performance target that affects vesting, and that could be achieved after the requisite service period, be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant date fair value of the
award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for
which the requisite service has already been rendered. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. We are currently evaluating the impact this
guidance on our financial condition, results of operations and cash flows. </P>
<P align="justify">
In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity&rsquo;s Ability to Continue as a Going Concern (&ldquo;ASU 2014-15&rdquo;). ASU 2014-15 will explicitly require management to assess an entity&rsquo;s
ability to continue as a going concern, and to provide related footnote disclosure in certain circumstances. The new standard will be effective for all entities in the first annual period ending after December 15, 2016. We are currently evaluating
the impact this guidance on our financial condition, results of operations and cash flows. </P>
<P align="justify">
In May, 2014, the FASB and the International Accounting Standards Board (IASB)
issued a converged standard on revenue recognition from contracts with
customers, ASU 2014-09 (Topic 606 and IFRS 15). This standard will supersede
nearly all existing revenue recognition guidance. ASU 2014-09 is effective for
fiscal years, and interim periods within those years, beginning after December
15, 2016. The Company is currently evaluating the impact this guidance will have
on its financial condition, results of operations and cash flows.</P>
<P align="justify">
Other than noted above, we do not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash flow. </P>
<P align="justify">
<B>ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></P>
<P align="justify">
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide information under this item. </P>

<P align="justify">
<B>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </B></P>
<P align="center">
28</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">
<A name=page_F-1></A>
<P align=justify>&nbsp;</P>
<P align=justify>&nbsp;</P>
<P align=center><B>A</B><B>NAVEX LIFE SCIENCES CORP. </B></P>
<P align=center>CONSOLIDATED FINANCIAL STATEMENTS </P>
<P align=center>September 30, 2014 and 2013 </P>
<P align=center>(<U>Stated in US Dollars</U>) </P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<P align=center>&nbsp;</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_con-1></A>&nbsp;<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><IMG
      src="consentx1x1.jpg"
      border=0></TD>
    <TD align=left width="33%">Tel: 212-885-8000 <BR>Fax: 212-697-1299
      <BR><B>www.bdo.com</B> </TD>
    <TD align=left width="33%">100 Park Avenue <BR>New York, NY 10017
  <BR></TD></TR></TABLE>
<P align=justify><B>Report of Independent Registered Public Accounting Firm
</B></P>
<P align=justify><BR>Board of Directors and Stockholders <BR>Anavex Life
Sciences Corp. <BR>New York, NY</P>
<P align=justify>We have audited the accompanying consolidated balance sheets of
Anavex Life Sciences Corp. as of September 30, 2014 and 2013 and the related
consolidated statements of operations, cash flows, and changes in stockholders&#146;
equity (capital deficit) for each of the two years in the period ended September
30, 2014. These financial statements are the responsibility of the Company&#146;s
management. Our responsibility is to express an opinion on these financial
statements based on our audits. </P>
<P align=justify>We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. The Company
is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. Our audits included consideration of
internal control over financial reporting as a basis for designing audit
procedures that are appropriate in the circumstances, but not for the purpose of
expressing an opinion on the effectiveness of the Company&#146;s internal control
over financial reporting. Accordingly, we express no such opinion. An audit also
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion. </P>
<P align=justify>In our opinion, the consolidated financial statements referred
to above present fairly, in all material respects, the financial position of
Anavex Life Sciences Corp. at September 30, 2014 and 2013, and the results of
its operations and its cash flows for each of the two years in the period ended
September 30, 2014<B>,</B> in conformity with accounting principles generally
accepted in the United States of America. </P>
<P align=justify>/s/ BDO USA, LLP </P>
<P align=justify>New York, NY </P>
<P align=justify>December 29, 2014 </P>
<P align=justify>&nbsp;</P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>BDO USA, LLP, a Delaware limited liability partnership, is
      the U.S. member of BDO International Limited, a UK company limited by
      guarantee, and forms part of the international BDO network of independent
      member firms. </TD></TR>
  <TR>
    <TD>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>BDO is the brand name for the BDO network and for each of
      the BDO Member Firms. </TD></TR></TABLE><BR>
<P align=center>F-1</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-2></A>
<P align=center><B>ANAVEX </B><B>LIFE </B><B>SCIENCES </B><B>CORP.</B><BR>
  CONSOLIDATED BALANCE SHEETS<BR>
  September 30, 2014 and
  2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=center></TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2014 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%" >&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD colspan="6" align=center
      bgColor=#e6efff>&nbsp;<STRONG><U>ASSETS</U></STRONG> </TD>
    <TD vAlign=bottom align=center width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD vAlign=bottom align=center width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="12%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="12%" >&nbsp;</TD>
    <TD vAlign=bottom align=center width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Current </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Cash </TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="12%">7,262,138 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >$</TD>
    <TD vAlign=bottom align=right width="12%">345,074 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Prepaid expenses </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>89,117 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>48,375 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">7,351,255 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">393,449 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>2,247 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%">7,353,502 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%">393,449 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD colspan="6" align=center><B><U>LIABILITIES</U></B> </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Current </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%">&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Accounts payable and accrued
      liabilities </TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>1,249,084 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>1,741,797 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Promissory notes payable </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">192,065 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">210,863 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>1,441,149 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>1,952,660 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Non&#150;interest bearing liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">5,719,727 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">904,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>7,160,876 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>2,856,660 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD></TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%"></TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%"></TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD colspan="6" align=center bgColor=#e6efff><B><U>STOCKHOLDERS' </U></B><B><U>EQUITY </U></B><B><U>(CAPITAL</U></B><B><U> DEFICIT)</U></B> </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Capital stock </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;&nbsp; Authorized: <BR>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      150,000,000 common shares, par value $0.001 per share <BR>
      &nbsp;&nbsp;
      Issued and outstanding: <BR>
      &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 47,200,237
      common shares (September 30, 2013 &#150; 37,237,588) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">47,201 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">37,238 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Additional paid&#150;in capital </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>52,078,750 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>38,644,523 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Common stock to be issued </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">640,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">60,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Accumulated deficit </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(52,573,325</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(41,204,972</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">192,626 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">(2,463,211</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>7,353,502 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>393,449 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES </P>
<P align=center>F-2</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-3></A>
<P align=center><B>ANAVEX </B><B>LIFE </B><B>SCIENCES </B><B>CORP.</B><BR>
  CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
  for the
  years ended September 30, 2014 and 2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2014 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Operating expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>General and administrative &#150; Notes 8 and 9 </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">2,236,580 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">1,873,520 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Research and development </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>732,395 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>263,847 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Total operating expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(2,968,975</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(2,137,367</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Other income (expenses) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Interest and finance expenses, net </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(7,089</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(51,341</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Gain (loss) on settlement of accounts
      payable </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>199,655 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(976,880</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Financing related charges and adjustments </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(8,624,986</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(480,328</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Foreign exchange loss </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>33,042 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(54,130</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Total other expenses, net </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(8,399,378</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(1,562,679</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net loss and comprehensive loss for the
      period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>(11,368,353</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>(3,700,046</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Loss per share </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Basic </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">(0.29</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">(0.12</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Diluted </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>(0.30</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>(0.12</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Weighted average number of shares
      outstanding </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Basic </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">39,727,731 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">31,908,441 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Diluted </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>39,727,731 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>31,908,441 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES </P>
<P align=center>F-3</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-4></A>
<P align=center><B>ANAVEX </B><B>LIFE </B><B>SCIENCES </B><B>CORP.</B><BR>
  CONSOLIDATED STATEMENTS OF CASH
  FLOWS<BR>
  fortheyearsendedSeptember30,2014and2013<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2014 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash Flows used in Operating Activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Net loss for the period </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">(11,368,353</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="12%">(3,700,046</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Adjustments to reconcile net loss to net
      cash used in operations: </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Amortization and depreciation </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">768 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">576 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Accretion of debt discount </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,917,615 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Stock&#150;based compensation </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">637,925 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">1,002,500 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Amortization of deferred
      financing charge </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,123,612 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,215 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Change in fair value of derivative financial
      instruments </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(2,956,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(15,000</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;(Gain) Loss on settlement of
      accounts payable </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(199,655</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>976,880 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Loss on extinguishment of debt </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">8,539,759 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">495,328 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Unrealized foreign exchange </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(18,798</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(4,937</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left colSpan=3>Changes in non&#150;cash working capital balances
      related to operations: </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="12%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Prepaid expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(33,234</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; &nbsp;Accounts payable and accrued liabilities </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">(303,018</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">465,911 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net cash used in operating activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(2,659,379</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(777,573</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash Flows used in Investing Activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Acquisition of equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
    width="12%">(3,015</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net cash used in investing activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(3,015</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash Flows provided by Financing Activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Issuance of common shares, net of share issue costs </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">368,170 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">801,285 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Share subscriptions received </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>60,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Proceeds from the issuance of promissory notes </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">&#150; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">250,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Financing fees paid </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(788,712</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Proceeds from the issuance of convertible debentures </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">10,000,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Net cash provided by financing activities </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>9,579,458 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>1,111,285 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Increase in cash during the period </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>6,917,064 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>333,712 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Cash, beginning of period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">345,074 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">11,362 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Cash, end of period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>7,262,138 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>345,074 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Supplemental Cash Flow Information &#150; Note
      11 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES </P>
<P align=center>F-4</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-5></A>
<P align=center><B>ANAVEX </B><B>LIFE </B><B>SCIENCES </B><B>CORP.</B><BR>
  CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#146; EQUITY (CAPITAL DEFICIT)<BR>
  for the years ended September 30, 2014 and 2013</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 8pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD colspan="10" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"> Common Stock </TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">Additional </TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">Common </TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">Paid&#150;in </TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">Shares to be </TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">Accumulated </TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom">&nbsp;</TD>
    <TD width="2%" align=center valign="bottom" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">&nbsp;</TD>
    <TD width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Shares </TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">ParValue </TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Capital </TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Issued </TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD
      width="8%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Deficit </TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    <TD width="8%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">Total </TD>
    <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
  </TR>
  <TR>
    <TD valign="bottom">&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Balance, October 1, 2012 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>30,240,687 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>30,241 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>34,599,514 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
    bgColor=#e6efff>&nbsp;(37,504,926</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD vAlign=bottom align=right width="8%"
      bgColor=#e6efff>(2,875,171</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Equity units issued for settlement of loans payable on July
      5, 2013 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">4,208,910 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">4,209 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,563,011 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,567,220 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash on July 5,
      2013 &#150; at $0.40 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>2,196,133 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>2,196 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>563,257 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>565,453 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Less: Share issue costs </TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(112,174</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(112,174</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Initial purchase shares issued under
      Purchase Agreement on July 5, 2013 &#150; at $0.40 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>591,858 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>592 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>99,750 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>100,342 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Less: Share issue costs </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(71,335</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(71,335</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Common stock to be issued for cash&#150;at $0.50 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>60,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>60,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Stock&#150;based compensation </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,002,500 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,002,500 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Net loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(3,700,046</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(3,700,046</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Balance, September 30, 2013 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">37,237,588 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">37,238 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">38,644,523 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">60,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(41,204,972</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(2,463,211</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Equity units issued under Purchase
      Agreement </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>400,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>400 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>187,770 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>188,170 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Commitment shares issued under terms of Purchase Agreement </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">2,510 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">3 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">(3</TD>
    <TD vAlign=bottom align=left width="2%" >) </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued for cash&#150;at$0.50 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>120,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>120 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>59,880 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(60,000</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=right width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Capital stock issued for cash&#150;at$0.30 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">500,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">500 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">149,500 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">30,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&nbsp;</TD>
    <TD vAlign=bottom align=right width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">180,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Share issue costs, net of recovery </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(2,452</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>)</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>(2,452</TD>
    <TD vAlign=bottom align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Issuance of detachable warrants </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">5,989,900 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">5,989,900 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Agent's warrants issued in connection with
      convertible debentures </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>334,900 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>334,900 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Beneficial conversion feature on convertible debentures
      issued </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">4,010,100 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">4,010,100 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Reclassification of derivative financial
      instruments upon modification of warrant terms </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>221,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>221,000 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Capital stock issued pursuant to debt conversions&#150;at$0.30 </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">6,378,426 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">6,378 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,907,149 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">1,913,527 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Capital stock issued pursuant to debt
      conversions&#150;at$0.25 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>2,561,713 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>2,562 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>548,558 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>&#150; </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%" bgColor=#e6efff>551,120 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Stock based compensation </TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">27,925 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">610,000 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">&#150; </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="8%">637,925 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom" bgColor=#e6efff>Net loss for the period </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(11,368,353</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" bgColor=#e6efff>(11,368,353</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left valign="bottom">Balance, September 30, 2014 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">47,200,237 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">47,201 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">52,078,750 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">640,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%">(52,573,325</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="8%" >192,626 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>SEE ACCOMPANYING NOTES </P>
<P align=center>F-5</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-6></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US Dollars) <BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 1 </TD>
    <TD align=left width="90%" ><P align=justify><U>Business Description and Basis of Presentation</U> </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>Business </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Anavex Life Sciences Corp. (the &#147;Company&#148;) is a clinical
      stage biopharmaceutical company engaged in the development of drug
      candidates to treat Alzheimer&#146;s disease, other central nervous system
      (CNS) diseases, and various types of cancer. The Company&#146;s lead compounds
      ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil
      (Aricept), are being developed to treat Alzheimer&#146;s disease and
      potentially other central nervous system (CNS) diseases. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>In December 2014 a Phase 2a clinical trial was initiated
      for ANAVEX 2-73, which is being evaluated for the treatment of Alzheimer&#146;s
      disease. The randomized trial is designed to assess the safety and
      exploratory efficacy of ANAVEX 2-73 alone as well as in combination with
      donepezil (ANAVEX PLUS) in patients with mild to moderate Alzheimer&#146;s
      disease. ANAVEX 2-73 targets sigma-1 and muscarinic receptors, which have
      been shown in preclinical studies to reduce stress levels in the brain and
      to reverse the pathological hallmarks observed in Alzheimer&#146;s disease.
      ANAVEX 2-73 showed no serious adverse events in a previously performed
      Phase 1 study. In pre-clinical studies, ANAVEX 2-73 demonstrated
      anti-amnesic and neuroprotective properties in various animal models
      including the transgenic mouse model Tg2576. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company intends to identify and initiate discussions
      with potential partners in the next 12 months. Further, the Company may
      acquire or develop new intellectual property and assign, license, or
      otherwise transfer our intellectual property to further its goals. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>Basis of Presentation </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>These financial statements have been prepared in
      accordance with generally accepted accounting principles in the United
      States of America and the instructions to Form 10-K. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Certain amounts for the prior periods have been
      reclassified to conform to the current period&#146;s presentation. These
      reclassifications did not impact reported results or earnings per share. </P></TD>
  </TR>
</TABLE>
<P align=center>F-6</P>
<BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-7></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 2</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%"><U>Summary of Significant Accounting
      Policies</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>Use of Estimates</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The preparation of financial statements in accordance
      with United States generally accepted accounting principles requires
      management to make estimates and assumptions that affect the reported
      amounts of assets and liabilities at the date of the financial statements
      and the reported amounts of revenue and expenses in the reporting period.
      The Company regularly evaluates estimates and assumptions related to
      deferred income tax asset valuations, asset impairment, conversion
      features embedded in convertible notes payable, derivative valuations,
      stock based compensation and loss contingencies. The Company bases its
      estimates and assumptions on current facts, historical experience and
      various other factors that it believes to be reasonable under the
      circumstances, the results of which form the basis for making judgments
      about the carrying values of assets and liabilities and the accrual of
      costs and expenses that are not readily apparent from other sources. The
      actual results experienced by the Company may differ materially and
      adversely from the Company&#146;s estimates. To the extent there are material
      differences between the estimates and the actual results, future results
      of operations will be affected.</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>Principles of Consolidation</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>These consolidated financial statements include the
      accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries,
      Anavex Life Sciences (France) SA, a company incorporated under the laws of
      France and Anavex Australia Pty Limited, a company incorporated under the
      laws of Australia. All inter-company transactions and balances have been
      eliminated.</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD><P align=justify>Equipment</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Equipment is recorded at cost and is depreciated at 33%
      per annum on the straight-line basis.</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD vAlign=top width="5%">d) </TD>
    <TD><P align=justify>Impairment of Long-Lived Assets</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company reviews the recoverability of its long-lived
      assets whenever events or changes in circumstances indicate that the
      carrying amount of such assets may not be recoverable. The estimated
      future cash flows are based upon, among other things, assumptions about
      future operating performance, and may differ from actual cash flows.
      Long-lived assets evaluated for impairment are grouped with other assets
      to the lowest level for which identifiable cash flows are largely
      independent of the cash flows of other groups of assets and liabilities.
      If the sum of the projected undiscounted cash flows (excluding interest)
      is less than the carrying value of the assets, the assets will be written
      down to the estimated fair value in the period in which the determination
      is made.</P></TD>
  </TR>
</TABLE>
<P align=center>F-7<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-8></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 3</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">e) </TD>
    <TD><P align=justify>Financial Instruments</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The carrying value of the Company&#146;s financial
      instruments, consisting of cash and accounts payable and accrued
      liabilities approximate their fair value due to the short- term maturity
      of such instruments. Based on borrowing rates currently available to the
      Company for similar terms and based on the short term duration of the debt
      instruments, the carrying value of the promissory notes payable
      approximate their fair value. Unless otherwise noted, it is management&#146;s
      opinion that the Company is not exposed to significant interest, currency
      or credit risks arising from these financial instruments.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">f) </TD>
    <TD><P align=justify>Foreign Currency Translation</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The functional currency of the Company is the US dollar.
      Monetary items denominated in a foreign currency are translated into US
      dollars at exchange rates prevailing at the balance sheet date and
      non-monetary items are translated at exchange rates prevailing when the
      assets were acquired or obligations incurred. Foreign currency denominated
      expense items are translated at exchange rates prevailing at the
      transaction date. Unrealized gains or losses arising from the translations
      are credited or charged to income in the period in which they
      occur.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">g) </TD>
    <TD><P align=justify>Research and Development Expenses</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Research and developments costs are expensed as incurred.
      These expenses are comprised of the costs of the Company&#146;s proprietary
      research and development efforts, including salaries, facilities costs,
      overhead costs and other related expenses as well as costs incurred in
      connection with third-party collaboration efforts. Milestone payments made
      by the Company to third parties are expensed when the specific milestone
      has been achieved.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In addition, the Company incurs expenses in respect of
      the acquisition of intellectual property relating to patents and
      trademarks. The probability of success and length of time to develop
      commercial applications of the drugs subject to the acquired patents and
      trademarks is difficult to determine and numerous risks and uncertainties
      exist with respect to the timely completion of the development projects.
      There is no assurance the acquired patents and trademarks will ever be
      successfully commercialized. Due to these risks and uncertainties, the
      acquisition of patents and trademarks does not meet the definition of an
      asset and thus are expensed as incurred.</P></TD>
  </TR>
</TABLE>
<P align=center>F-8<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-9></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 4<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">h) </TD>
    <TD><P align=justify>Income Taxes</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company has adopted the provisions of FASB ASC 740
      "Income Taxes" (&#147;ASC 740&#148;) which requires the asset and liability method
      of accounting for income taxes. Under the asset and liability method,
      deferred tax assets and liabilities are recognized for the future tax
      consequences attributable to temporary differences between the financial
      statements carrying amounts of existing assets and liabilities and their
      respective tax bases. Deferred tax assets and liabilities are measured
      using enacted tax rates expected to apply to taxable income in the years
      in which those temporary differences are expected to be recovered or
      settled.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company follows the provisions of ASC 740 regarding
      accounting for uncertainty in income taxes. The Company initially
      recognizes tax positions in the financial statements when it is more
      likely than not the position will be sustained upon examination by the tax
      authorities. Such tax positions are initially and subsequently measured as
      the largest amount of tax benefit that is greater than 50% likely of being
      realized upon ultimate settlement with the tax authority assuming full
      knowledge of the position and all relevant facts. Application requires
      numerous estimates based on available information. The Company considers
      many factors when evaluating and estimating our tax positions and tax
      benefits, and our recognized tax positions and tax benefits may not
      accurately anticipate actual outcomes. As additional information is
      obtained, there may be a need to periodically adjust the recognized tax
      positions and tax benefits. These periodic adjustments may have a material
      impact on the consolidated statements of operations.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD><P align=justify>Basic and Diluted Loss per Share</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The basic loss per common share is computed by dividing
      net loss available to common stockholders by the weighted average number
      of common shares outstanding. Diluted loss per common share is computed
      similar to basic loss per common share except that the denominator is
      increased to include the number of additional common shares that would
      have been outstanding if the potential common shares had been issued and
      if the additional common shares were dilutive. Additionally, the numerator
      is also adjusted for changes in fair value of the derivative financial
      instruments where it is presumed they will be share settled.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>For the year ended September 30, 2014, loss per share
      excludes 107,869,808 (2013 &#150; 12,224,479) potentially dilutive common
      shares related to outstanding options, warrants, and convertible
      debentures as their effect was anti-dilutive.</P></TD>
  </TR>
</TABLE>
<P align=center>F-9<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-10></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 5<BR>
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">j) </TD>
    <TD><P align=justify>Stock-based Compensation</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company accounts for all stock-based payments and
      awards under the fair value method.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Stock-based payments to non-employees are measured at the
      fair value of the consideration received, or the fair value of the equity
      instruments issued, or liabilities incurred, whichever is more reliably
      measurable. The fair value of stock-based payments to non-employees is
      periodically re-measured until the counterparty performance is complete,
      and any change therein is recognized over the vesting period of the award
      and in the same manner as if the Company had paid cash instead of paying
      with or using equity based instruments. Compensation costs for stock-based
      payments with graded vesting are recognized on a straight-line basis. The
      cost of the stock-based payments to non-employees that are fully vested
      and non-forfeitable at the grant date is measured and recognized at that
      date, unless there is a contractual term for services in which case such
      compensation would be amortized over the contractual term.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company accounts for the granting of share purchase
      options to employees using the fair value method whereby all awards to
      employees will be recorded at fair value on the date of the grant. The
      fair value of all share purchase options are expensed over their vesting
      period with a corresponding increase to additional paid-in
      capital.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company uses the Black-Scholes option valuation model
      to calculate the fair value of share purchase options at the date of the
      grant. Option pricing models require the input of highly subjective
      assumptions, including the expected price volatility. Changes in these
      assumptions can materially affect the fair value estimates.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">k) </TD>
    <TD><P align=justify>Fair Value Measurements</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The fair value hierarchy under GAAP is based on three
      levels of inputs, of which the first two are considered observable and the
      last unobservable, that may be used to measure fair value which are the
      following:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left  >Level 1 - </TD>
    <TD align=left width="75%"><P align=justify>quoted prices (unadjusted) in active markets for
      identical assets or liabilities; </P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD  >&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" ></TD>
    <TD align=left  >Level 2 - </TD>
    <TD align=left width="75%"><P align=justify>observable inputs other than Level I, quoted prices for
      similar assets or liabilities in active markets, quoted prices for
      identical or similar assets and liabilities in markets that are not
      active, and model-derived prices whose inputs are observable or whose
      significant value drivers are observable; and </P></TD>
  </TR>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD  >&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" ></TD>
    <TD align=left  >Level 3 - </TD>
    <TD align=left width="75%"><P align=justify>assets and liabilities whose significant value drivers
      are unobservable by little or no market activity and that are significant
      to the fair value of the assets or liabilities. </P></TD>
  </TR>
</TABLE>
<P align=center>F-10</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-11></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 6</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">l) </TD>
    <TD><P align=justify>Fair Value Measurements &#150; (cont&#146;d)</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The book value of cash and accounts payable and accrued
      liabilities approximate their fair values due to the short term maturity
      of those instruments. Based on borrowing rates currently available to the
      Company under similar terms, the book value of promissory notes payable
      approximates their fair values. The Company&#146;s promissory notes payable are
      based on Level 2 inputs in the ASC 820 fair value hierarchy.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>At September 30, 2014, the Company&#146;s Level 3 liabilities
      consisted of embedded conversion features that were required to be
      accounted for as liabilities pursuant to ASC 815 because the Company did
      not have sufficient authorized and unissued shares available to settle
      fully certain conversion features of such instruments.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>At September 30, 2013, the Company&#146;s Level 3 liabilities
      consisted of share purchase warrants that were required to be accounted
      for as liabilities pursuant to ASC 815 Derivatives and Hedging (&#147;ASC
      815&#148;)because the terms of the warrants contained provisions that were not
      in compliance with the fixed for fixed criteria of that
      guidance.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company calculated the fair value at the inception of
      those instruments, at September 30, 2014 and 2013, and at the date of
      reclassification of the warrants into equity using the binomial option
      pricing model to determine the fair value. The following assumptions were
      used for the respective instruments:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD align=left width="20%">&nbsp;</TD>
      <TD align=right width="20%">September 30, </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left ><B>Embedded </B><B>conversion </B><B>option</B> </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="20%">At
        Inception </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="20%">2014 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Risk&#150;free interest rate </TD>
      <TD align=right width="20%" bgColor=#e6efff>3.13% </TD>
      <TD align=right width="20%" bgColor=#e6efff>3.21% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Expected life of options (years) </TD>
      <TD align=right width="20%">29.58 </TD>
      <TD align=right width="20%">29.48 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Annualized volatility </TD>
      <TD align=right width="20%" bgColor=#e6efff>100.71% </TD>
      <TD align=right width="20%" bgColor=#e6efff>100.07% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Stock price </TD>
      <TD align=right width="20%">$0.26 </TD>
      <TD align=right width="20%">$0.18 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Dividend rate </TD>
      <TD align=right width="20%" bgColor=#e6efff>0.00% </TD>
      <TD align=right width="20%" bgColor=#e6efff>0.00% </TD>
    </TR>
  </TABLE>
</DIV>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD align=left width="18%">&nbsp;</TD>
      <TD align=right width="18%">September 30, </TD>
      <TD align=right width="18%">Reclassification </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left ><B>Warrants</B> </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="18%">At
        Inception </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="18%">2013 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="18%">Date </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Risk&#150;free interest rate </TD>
      <TD align=right width="18%" bgColor=#e6efff>0.28% </TD>
      <TD align=right width="18%" bgColor=#e6efff>0.10% </TD>
      <TD align=right width="18%" bgColor=#e6efff>0.13% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Expected life of options (years) </TD>
      <TD align=right width="18%">1.49 </TD>
      <TD align=right width="18%">1.25 </TD>
      <TD align=right width="18%">1.03 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Annualized volatility </TD>
      <TD align=right width="18%" bgColor=#e6efff>81.57% </TD>
      <TD align=right width="18%" bgColor=#e6efff>77.51% </TD>
      <TD align=right width="18%" bgColor=#e6efff>107.62% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Stock price </TD>
      <TD align=right width="18%">$0.61 </TD>
      <TD align=right width="18%">$0.65 </TD>
      <TD align=right width="18%">$0.25 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Dividend rate </TD>
      <TD align=right width="18%" bgColor=#e6efff>0.00% </TD>
      <TD align=right width="18%" bgColor=#e6efff>0.00% </TD>
      <TD align=right width="18%" bgColor=#e6efff>0.00% </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>F-11<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-12></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 7</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">l) </TD>
    <TD><P align=justify>Fair Value Measurements &#150; (cont&#146;d)</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Certain assets and liabilities are measured at fair value
      on a nonrecurring basis; that is, the instruments are not measured at fair
      value on an ongoing basis but are subject to fair value adjustments only
      in certain circumstances (for example, when there is evidence of
      impairment). There were no assets or liabilities measured at fair value on
      a nonrecurring basis during the periods ended September 30, 2014 and
      2013.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">m) </TD>
    <TD><P align=justify>Derivative Liabilities</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The Company evaluates its financial instruments and other
      contracts to determine if those contracts or embedded components of those
      contracts qualify as derivatives to be separately accounted for in
      accordance with ASC 815. The result of this accounting treatment is that
      the fair value of the embedded derivative is marked- to-market at each
      balance sheet date and recorded as a liability and the change in fair
      value is recorded in the consolidated statements of operations as other
      income or expense. Upon conversion or exercise of a derivative instrument,
      the instrument is marked to fair value at the conversion date and then
      that fair value is reclassified to equity.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>The classification of derivative instruments, including
      whether such instruments should be recorded as liabilities or as equity,
      is re-assessed at the end of each reporting period. Derivative instruments
      that become subject to reclassification are reclassified at the fair value
      of the instrument on the reclassification date. Derivative instrument
      liabilities will be classified in the balance sheet as current or
      non-current based on whether or not settlement of the derivative
      instrument is expected within 12 months of the balance sheet
      date.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>Certain of the Company&#146;s embedded conversion features on
      debt and outstanding warrants are treated as derivative liabilities for
      accounting purposes under ASC 815 due to insufficient authorized shares to
      fully settle conversion features of the instruments if exercised. In this
      case, the Company utilizes the latest inception date sequencing method to
      reclassify outstanding instruments as derivative instruments. These
      contracts are recognized at fair value with changes in fair value
      recognized in earnings until such time as the conditions giving rise to
      such derivative liability classification have been settled.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>These derivative instruments do not trade in an active
      securities market. The Company uses the binomial option pricing model to
      value derivative liabilities. This model uses Level 3 inputs in the fair
      value hierarchy established by ASC 820 Fair Value
      Measurement.</P></TD>
  </TR>
</TABLE>
<P align=center>F-12<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-13></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 8</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accounting Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">n) </TD>
    <TD><P align=justify>Recent Accounting Pronouncements</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify><I>Recently Adopted Accounting
      Pronouncements</I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In June 2014, the FASB issued Accounting Standards
      Updated No. 2014-10, "Development Stage Entities&#148; (&#147;ASU 2014-10&#148;) which
      removes the definition of a development stage entity from the Master
      Glossary of the Accounting Standards Codification, thereby removing the
      financial reporting distinction between development stage entities and
      other reporting entities from U.S. GAAP. In addition, the update
      eliminates the requirements for development stage entities to (1) present
      inception-to-date information in the statements of income, cash flows, and
      shareholder equity, (2) label the financial statements as those of a
      development stage entity, (3) disclose a description of the development
      stage activities in which the entity is engaged, and (4) disclose in the
      first year in which the entity is no longer a development stage entity
      that in prior years it had been in the development stage.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>During the year ended September 30, 2014, the Company has
      elected to early adopt ASU 2014-10. The adoption of this ASU allowed the
      Company to remove the inception to date information and all references to
      development stage.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify><I>Recent Accounting Pronouncements Not Yet
      Adopted</I></P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In June 2014, the FASB issued ASU No. 2014-12, Accounting
      for Share-Based Payments When the Terms of an Award Provide That a
      Performance Target Could Be Achieved after the Requisite Service Period
      ("ASU 2014-12"). ASU 2014-12 requires that a performance target that
      affects vesting, and that could be achieved after the requisite service
      period, be treated as a performance condition. As such, the performance
      target should not be reflected in estimating the grant date fair value of
      the award. This update further clarifies that compensation cost should be
      recognized in the period in which it becomes probable that the performance
      target will be achieved and should represent the compensation cost
      attributable to the period(s) for which the requisite service has already
      been rendered. The amendments in this ASU are effective for annual periods
      and interim periods within those annual periods beginning after December
      15, 2015. The Company is currently evaluating the impact this guidance
      will have on its financial condition, results of operations and cash
      flows.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In August 2014, the FASB issued ASU No. 2014-15,
      Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a
      Going Concern (&#147;ASU 2014-15&#148;). ASU 2014-15 will explicitly require
      management to assess an entity&#146;s ability to continue as a going concern,
      and to provide related footnote disclosure in certain circumstances. The
      new standard will be effective for all entities in the first annual period
      ending after December 15, 2016. The Company is currently evaluating the
      impact this guidance will have on its financial condition, results of
      operations and cash flows.</P></TD>
  </TR>
</TABLE>
<P align=center>F-13<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-14></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 9</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 2 </TD>
    <TD align=left width="90%" ><U>Summary of Significant
      Accountin g Policies </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="15%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">l) </TD>
    <TD><P align=justify>Recent Accounting Pronouncements &#150;
      (cont&#146;d)</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify><I>Recent Accounting Pronouncements
  Not Yet Adopted</I> &#150; (cont&#146;d)<I> </I></P>
<P style="MARGIN-LEFT: 15%" align=justify>In May, 2014, the FASB and the
  International Accounting Standards Board (IASB) issued a converged standard on
  revenue recognition from contracts with customers, ASU 2014-09 (Topic 606 and
  IFRS 15). This standard will supersede nearly all existing revenue recognition
  guidance. ASU 2014-09 is effective for fiscal years, and interim periods within
  those years, beginning after December 15, 2016. The Company is currently
  evaluating the impact this guidance will have on its financial condition,
  results of operations and cash flows. </P>
<P style="MARGIN-LEFT: 15%" align=justify>Other than noted above, the Company
  does not expect the adoption of recently issued accounting pronouncements to
  have a significant impact on our results of operations, financial position or
  cash flow. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 3 </TD>
    <TD align=left width="90%" ><U>Equipment</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">September 30, 2014 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Accumulated </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Cost</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Depreciation</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%"><U>Net</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>3,015 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>768 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>2,247 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">September 30, 2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Accumulated </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Cost </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Depreciation </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Net </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Computer equipment </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>5,631 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>5,631 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>F-14<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-15></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 10</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 4 </TD>
    <TD align=left width="90%" ><U>Promissory Notes Payable</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2014 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Promissory note dated December 31, 2012
      with a principal balance of $89,618 (CDN $100,000) bearing interest at 12%
      per annum, due on September 30, 2014 </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>89,618 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>100,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Promissory note dated January 9, 2013 with
      a principal balance of $77,679 (CDN $86,677), bearing interest at 12% per
      annum, secured by all the present and future assets of the Company; due on
      demand </TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>77,679 </TD>
    <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%" bgColor=#e6efff>84,060 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp;</TD>
    <TD vAlign=bottom width="2%" >&nbsp;</TD>
    <TD vAlign=bottom width="1%" >&nbsp;</TD>
    <TD vAlign=bottom width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Promissory note dated January 9, 2013 with
      a principal balance of $24,768 (CDN $27,639), bearing interest at 12% per
      annum, secured by all the present and future assets of the Company; due on
      demand </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>24,768 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>26,803 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">192,065 </TD>
    <TD vAlign=bottom align=left width="2%" >&nbsp;</TD>
    <TD vAlign=bottom align=left width="1%" >&nbsp;</TD>
    <TD vAlign=bottom align=right width="12%">210,863 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Less: current portion </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(192,065</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%" bgColor=#e6efff>(210,863</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="12%">&#150; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>On December 31, 2012, the Company
  issued a promissory note having a principal balance of $89,618 (CDN$100,000)
  with terms that included interest at 12% per annum and matured on June 30, 2013,
  in exchange for an accounts payable owing with respect to unpaid consulting
  fees. This note was not repaid on June 30, 2013 and the maturity date was
  extended to September 30, 2014. Subsequent to September 30, 2014, the Company
  repaid this note. </P>
<P style="MARGIN-LEFT: 10%" align=justify>On January 9, 2013, the Company issued
  two (2) promissory notes (the &#147;Secured Notes&#148;); </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>The Company issued a promissory note in the amount of
      $77,679 (CDN$86,677) to the former President, Secretary, Treasurer, CFO
      and director of the Company (the &#147;President&#148;) in exchange for unpaid
      consulting fees owing to the President. The note is bearing interest at
      12% per annum and was due June 30, 2013.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>The Company issued a promissory note in the amount of
      $24,768 (CDN$27,639) to a former director of the Company (the &#147;Director&#148;)
      in exchange for unpaid consulting fees owing to the Director. The note is
      bearing interest at 12% per annum and was due June 30,
      2013.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The Secured Notes are secured by a
  right to delay the transfer of any or all of the Company&#146;s assets until the
  obligations of the Secured Notes are satisfied, including a restriction on the
  transfer of cash by the Company and a security interest over the intellectual
  property of the Company. The security interests of the Secured Notes is ranked
  senior to any and all security interests granted prior to the issuance of the
  notes and to all subsequent security interests granted, unless the holders agree
  in writing to other terms.</P>
<P align=center>F-15<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-16></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 11</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 4 </TD>
    <TD align=left width="90%" ><P align=justify><U>Promissory Notes Payable </U>&#150; (cont&#146;d) </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>In addition, the Secured Notes contain a provision
      whereby if they are not repaid within 10 days of their maturity dates,
      they shall bear late fees in addition to interest accruing, at a rate of
      $100 per day per note. In an event of default by the Company, under the
      terms of the Secured Notes, the notes shall bear additional late fees of
      $500 per day per note. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Subsequent to the issuance of these Secured Notes, the
      former President resigned as President, Secretary, Treasurer, CFO and
      director of the Company and the former Director resigned as director of
      the Company. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company did not repay the notes on June 30, 2013. The
      Company has disputed the issuance and enforceability of the Secured Notes
      and should there be an attempt to enforce the Secured Notes or collection
      on them, the Company will consider a legal remedy. The Company has not
      accrued any late fees in connection with these Secured Notes as of
      September 30, 2014 or 2013, as the Company does not consider these amounts
      to be legally enforceable. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify><B>Extinguishment of promissory notes payable and
      accounts payable </B></P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>During the year ended September 30, 2013, the Company
      issued equity units in settlement of certain of its promissory notes and
      trade accounts payable. Each unit consisted of one common share and common
      share purchase warrant entitling the holder to purchase an additional
      common share at $0.75 until July 5, 2018. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>The promissory note and accounts payable settlements are
      summarized as follows: </P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=right>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="90%" border=0>
    <TR vAlign=top>
      <TD colspan="7" align=center style="BORDER-BOTTOM: #000000 1px solid"
      >Amount Settled </TD>
      <TD style="BORDER-BOTTOM: #000000 0px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD colspan="4" align=center style="BORDER-BOTTOM: #000000 1px solid">Units issued </TD>
      <TD align=center width="2%"
    >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp;</TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD width="23%" align=center >&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Accrued </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="12%">Loss on </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      >Date of Note </TD>
      <TD align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Principal </TD>
      <TD align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Interest </TD>
      <TD align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Number </TD>
      <TD align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">FairValue </TD>
      <TD align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="12%">Settlement </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >Promissory notes payable </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right >June 6, 2012 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">49,000 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">3,200 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">130,501 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">98,205 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">46,005 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >June 26, 2012 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>250,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>15,233 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>663,082 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>498,972 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>233,739 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right >October 17, 2012 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">150,000 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">5,425 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">388,562 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">292,394 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=right width="12%">136,969 </TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >November 14, 2012 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>50,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1,501 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>128,753 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>96,887 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>45,386 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right >February 8, 2013 </TD>
      <TD align=left width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">50,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%">699 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">126,747 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">95,377 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">44,678 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >&nbsp;</TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>549,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>26,058 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1,437,645 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>1,081,835 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="12%" bgColor=#e6efff>506,777 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR>
      <TD align=right >&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >Accounts payable </TD>
      <TD align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,108,506 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>&#150; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>2,771,265 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>2,085,386 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>976,880 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR>
      <TD align=right >&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
      <TD width="1%" >&nbsp;</TD>
      <TD width="12%">&nbsp;</TD>
      <TD width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff >&nbsp;</TD>
      <TD align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,657,506 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>26,058 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>4,208,910 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>3,167,221 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,483,657 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>F-16<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-17></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 12</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 4 </TD>
    <TD align=left width="90%" ><U>Promissory Notes Payable </U>&#150;
      (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The fair value of each unit issued was determined to be
      $0.753 determined by aggregating (i) the fair value of $0.61 for the
      Company&#146;s common shares based on their quoted market price on the date of
      settlement and (ii) the fair value of $0.143 for each warrant included in
      the Company&#146;s units. The fair value of the Company&#146;s warrants was
      determined using the Black Scholes option pricing model with the following
      assumptions: </P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="60%" border=0>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Stock price </TD>
      <TD align=right width="35%" bgColor=#e6efff >$0.61 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Exercise price </TD>
      <TD align=right width="35%" >$0.75 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Expected volatility </TD>
      <TD align=right width="35%" bgColor=#e6efff >81.57% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Risk&#150;free discountrate </TD>
      <TD align=right width="35%" >0.28% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Expected term </TD>
      <TD align=right width="35%" bgColor=#e6efff >1.49years </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Expected dividend yield </TD>
      <TD align=right width="35%" >0.00% </TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify>The loss on settlement of debt was
  recorded on the statement of operations for the year ended September 30, 2013
  and was reduced by an amount of $11,449 relating to the interest that accrued on
  the promissory notes that was forgiven upon settlement of the notes payable in
  exchange for shares. </P>
<P style="MARGIN-LEFT: 10%" align=justify>As discussed in Note 5, the warrants
  issued were required to be accounted for as derivative liabilities pursuant to
  the guidance of ASC 815. Consequently, the Company allocated the proceeds from
  the issuance of the units first to the warrants, at their fair value of $600,000
  with the remainder of $2,567,220 being allotted to equity. The fair value of the
  warrants of $600,000 was determined based on the binomial option pricing model
  using the following assumptions: risk-free interest rate 0.28%, expected life
  1.49 years, expected volatility 81.57%, dividend yield 0.00% .</P>
<P align=center>F-17<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-18></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 13</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><U>Non-interest Bearing
      Liabilities</U> </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%"  >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >Non-interest bearing liabilities
      consists of the following: </TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="80%" border=0>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%">2014 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%">2013 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Senior Convertible Debentures </TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="17%" bgColor=#e6efff>263,727 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>$</TD>
      <TD align=right width="17%" bgColor=#e6efff>&#150; </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Derivative Financial Instruments </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="17%">5,456,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="17%">904,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>5,719,727 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="17%"
    bgColor=#e6efff>904,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify><B>Senior Convertible Debentures </B></P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="80%" border=0>
    <TR vAlign=top>
      <TD align=left valign="bottom" >&nbsp;</TD>
      <TD width="1%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="17%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">2014 </TD>
      <TD width="2%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="1%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
      <TD width="17%" align=center valign="bottom" style="BORDER-BOTTOM: #000000 1px solid">2013 </TD>
      <TD width="2%" align=left valign="bottom" style="BORDER-BOTTOM: #000000 1px solid"
    >&nbsp;</TD>
    </TR>
    <TR>
      <TD valign="bottom" >&nbsp;</TD>
      <TD width="1%" valign="bottom" >&nbsp;</TD>
      <TD width="17%" valign="bottom">&nbsp;</TD>
      <TD width="2%" valign="bottom" >&nbsp;</TD>
      <TD width="1%" valign="bottom" >&nbsp;</TD>
      <TD width="17%" valign="bottom">&nbsp;</TD>
      <TD width="2%" valign="bottom" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left valign="bottom" bgColor=#e6efff >Senior Convertible
        Debentures, non&#150;interest bearing, unsecured, due March 18, 2044 </TD>
      <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>7,446,044 </TD>
      <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&#150; </TD>
      <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left valign="bottom" >Less: Debt Discount </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">(7,182,317</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">&#150; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left valign="bottom" bgColor=#e6efff >Total carrying value </TD>
      <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>263,727 </TD>
      <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD vAlign=bottom align=right width="17%" bgColor=#e6efff>&#150; </TD>
      <TD vAlign=bottom align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left valign="bottom" >Less: current portion </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">&#150; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%" >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%">&#150; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left valign="bottom" bgColor=#e6efff >Long term liability </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>263,727 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="1%"  bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=right
    width="17%" bgColor=#e6efff>&#150; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" vAlign=bottom align=left
    width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify>On March 13, 2014, the Company entered
  into a Securities Purchase Agreement (the &#147;Purchase Agreement&#148;) with certain
  purchasers (the &#147;Purchasers&#148;) pursuant to which the Company issued senior
  convertible debentures in the aggregate principal amount of $10,000,000 (the
  &#147;Debentures&#148;).</P>
<P style="MARGIN-LEFT: 10%" align=justify>In connection with the issuance of the
  Debentures, the Company issued an aggregate of 67,666,666 share purchase
  warrants as follows:</P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="80%" border=0>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD align=left width="1%" >&nbsp;</TD>
      <TD align=center width="15%">&nbsp;</TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="15%">Non&#150; </TD>
      <TD align=center width="2%" >&nbsp;</TD>
      <TD align=center width="1%" >&nbsp;</TD>
      <TD align=center width="15%">&nbsp;</TD>
      <TD align=left width="2%" >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">Purchasers </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">purchasers </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">Total </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Series A Warrants </TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="15%" bgColor=#e6efff>33,333,333 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="15%" bgColor=#e6efff>500,000 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="15%" bgColor=#e6efff>33,833,333 </TD>
      <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Series B Warrants </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="15%">33,333,333 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="15%">500,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="15%">33,833,333 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>66,666,666 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>1,000,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>67,666,666 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify>Each Series A warrant is exercisable
  into one common share of the Company at $0.30 per share until March 18, 2019. </P>
<P style="MARGIN-LEFT: 10%" align=justify>Each Series B warrant is exercisable
  into one common share of the Company at $0.42 per share until March 18, 2019 </P>
<P style="MARGIN-LEFT: 10%" align=justify>The
  Debentures are unsecured, non-interest bearing and are due on March 18, 2044.
  The Debentures were convertible, in whole or in part, at the option of the
  holder into common shares of the Company at $0.30 per share (&#147;the Conversion
  Price&#148;). The Conversion Price of the debenture will be adjusted in the event of
  common stock dividend, split or consolidation. The Conversion Price was later
  amended to $0.25 per share, as set forth below. </P>
<P align=center>F-18<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-19></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 14</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><P align=justify><U>Non-interest Bearing Liabilities </U>&#150; (cont&#146;d) </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify><B>Senior Convertible Debentures </B>&#150; (cont&#146;d) </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Pursuant to the guidance of ASC 470-20 Debt with
      Conversion and Other Options, the Company allocated the proceeds from the
      issuance of the Debentures between the Debentures and the detachable
      Purchaser warrants using the relative fair value method. The fair value of
      the Purchaser warrants of $22,326,200 at issuance resulted in a debt
      discount at issuance of $5,989,900. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD></TD>
    <TD width="90%" ><P align=justify>The Company recorded a beneficial conversion feature
      discount of $4,010,100 in respect of the Debentures issued, based on the
      intrinsic value of the conversion feature limited to a maximum of the
      total proceeds of the Debentures allocated to the Debentures. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The total debt discount at issuance of $10,000,000 was
      being amortized using the effective interest method over the term of the
      Debentures. During the year ended September 30, 2014, the Company recorded
      accretion expense of $1,914,433 (2013: $Nil) in respect of the accretion
      of this discount, which is included in other financing related charges and
      adjustments on the consolidated statement of operations. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>In consideration for the Debentures issued, the Company
      issued an aggregate of 1,000,000 share purchase warrants to non-lenders as
      described above. The fair value of the Non-Purchaser Warrants of $334,900,
      along with finder&#146;s fees and other financing costs directly associated
      with the issuance of the Debentures in the amount of $788,712, was
      recorded as a deferred financing charge and is being amortized to income
      over the term of the Debentures using the effective interest method.
      During the year ended September 30, 2014, the Company had recorded
      financing expense of $13,044 (2013: $Nil) in respect of the amortization
      of these charges. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The fair value of the Purchaser and Non-Purchaser
      warrants at issuance was determined using the Black Scholes option pricing
      model with the following weighted average assumptions: </P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Risk-free interest rate </TD>
      <TD align=left width="35%" bgColor=#e6efff >1.56% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Expected life (years) </TD>
      <TD align=left width="35%" >5.00 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Expected volatility </TD>
      <TD align=left width="35%" bgColor=#e6efff >97.16% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Dividend yields </TD>
      <TD align=left width="35%" >0.00% </TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify>In connection with the Purchase
  Agreement, the Company also entered into a registration rights agreement with
  each Purchaser (the &#147;RRA&#148;) whereby the Company agreed to file a registration
  statement with the Securities and Exchange Commission (the &#147;SEC&#148;) covering the
  resale of the shares of the Company&#146;s common stock issuable upon conversion of
  the Debentures and upon exercise of the Purchaser warrants.</P>
<P style="MARGIN-LEFT: 10%" align=justify>On July 23, 2014, the registration
  statement was declared effective by the SEC. </P>
<P align=center>F-19<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-20></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 15</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><U>Non-interest Bearing
      Liabilities </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><B>Senior Convertible Debentures </B>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><U>Amendment Agreements</U> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On August 25, 2014, the Company entered into amendment
      agreements with each Purchaser, pursuant to which all provisions regarding
      liquidating damages and the accrual of damages with respect to the
      obligations for, and rights enforceable against, the Company, were
      eliminated from the RRAs. As consideration for entering into the amendment
      agreements and for the Purchasers agreeing to forego an amount of $459,912
      in liquidating damages that had accrued and were accruing pursuant to the
      terms of the original RRAs, the Company agreed to adjust the fixed
      conversion price of the remaining outstanding debentures from $0.30 per
      share to $0.25 per share (the &#147;Debenture Amendment&#148;). </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company assessed the guidance under ASC 470-60 <I>Troubled Debt Restructurings</I> and determined that this guidance did
      not apply to the Debenture Amendment. The Debenture Amendment was
      considered a substantial change in the terms of the debentures pursuant to
      ASC 470-50 <I>Modifications and Extinguishments </I>and accordingly, the
      Company was required to apply debt extinguishment accounting.
      Consequently, the Company calculated a net non-cash loss on extinguishment
      of debt of $8,099,137 as the premium of the aggregate fair value of the
      amended debentures over their aggregate carrying values of $906
      immediately prior to the Debenture Amendment and the gain from the
      forgiveness of accrued liquidating damages of $459,912. This amount is
      included in other financing related charges and adjustments on the
      consolidated statement of operations for the year ended September 30,
      2014. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company calculated the fair value of the amended
      Debentures by discounting future cash flows using rates representative of
      current borrowing rates for debt instruments without a conversion feature
      and by using the binomial option pricing model to determine the fair value
      of the conversion features, using the following assumptions: </P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Risk-free interest rate </TD>
      <TD align=left width="25%" bgColor=#e6efff >3.13% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Expected life (years) </TD>
      <TD align=left width="25%" >29.58 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Expected volatility </TD>
      <TD align=left width="25%" bgColor=#e6efff >100.71% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Dividend yields </TD>
      <TD align=left width="25%" >0.00% </TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 10%" align=justify>The net loss was recorded as part of
  financing related charges and adjustments in the consolidated statement of
  operations during the year ended September 30, 2014. In addition, in accordance
  with debt extinguishment accounting, remaining unamortized financing costs of
  $1,110,568 associated with the original Debentures were immediately amortized
  through earnings upon entering into the amendments. This amount is also included
  in other financing related charges and adjustments in the consolidated statement
  of operations for the year ended September 30, 2014. </P>
<P align=center>F-20<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-21></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 16</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%" ><U>Non-interest Bearing
      Liabilities </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><B>Senior Convertible Debentures </B>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>During the year ended September 30, 2014, the Company
      issued an aggregate of 8,940,139 shares of common stock pursuant to
      conversion notices received from the Purchasers as follows: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD><P align=justify>An aggregate of 6,378,426 shares of common stock were
      issued at a conversion price of $0.30 per share pursuant to the conversion
      of $1,913,527 in outstanding principal amounts due under the Debentures,
      prior to the Debenture Amendment.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD><P align=justify>An aggregate of 2,561,713 shares of common stock were
      issued at a conversion price of $0.25 per share pursuant to the conversion
      of $640,428 in outstanding principal amounts due under the Debentures,
      subsequent to the Debenture Amendments.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>As a result of the bifurcation of the
  embedded conversion option subsequent to the Debenture Amendments as discussed
  above, for accounting purposes, two instruments are considered outstanding and,
  upon exercise of the contractual conversion option, extinguishment accounting
  has been applied. Consequently, the embedded conversion feature is marked to
  fair value at the conversion date and the shares issued pursuant to conversion
  are recorded at their fair value on the date of issuance, determined with
  reference to the quoted market price of the Company&#146;s shares on the issuance
  date. The resulting difference is recorded as a gain or loss on the consolidated
  statement of operations. During the year ended September 30, 2014, the Company
  recorded $19,290 (2013: $Nil) in respect of net gains on these conversion of the
  Debentures. </P>
<P style="MARGIN-LEFT: 10%" align=justify><B>Embedded conversion options and
  warrants </B></P>
<P style="MARGIN-LEFT: 10%" align=justify>The following table presents the
  components of the Company&#146;s embedded conversion options and warrants being
  accounted for as derivative liabilities. These instruments have no observable
  market data and are derived using an option pricing model measured at fair value
  on a recurring basis, using Level 3 inputs to the fair value hierarchy:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD colspan="4" align=center>September 30, </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2014 </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="12%">2013 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Warrants </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>904,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Embedded conversion features </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">5,456,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="12%">&#150; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Derivative financial instruments </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>5,456,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>904,000 </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>These derivative financial instruments
  arise as a result of applying ASC 815 <I>Derivatives and Hedging</I> (&#147;ASC
  815&#148;), which requires the Company to make a determination whether an
  equity-linked financial instrument, or embedded feature, is indexed to the
  entity&#146;s own stock. This guidance applies to any freestanding financial
  instrument or embedded features that have the characteristics of a derivative,
  and to any freestanding financial instruments that are potentially settled in an
  entity&#146;s own stock. </P>
<P align=center>F-21<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-22></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 17</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 5 </TD>
    <TD align=left width="90%"><U>Non-interest Bearing Liabilities </U>&#150;
      (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%"><B>Embedded conversion options and warrants </B>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>During the year ended September 30, 2014, the Company
      issued debentures with fixed price embedded conversion features and,
      subsequent to certain amendments as discussed above, the Company did not
      have a sufficient number of authorized and available shares of common
      stock to fully settle the conversion feature of such instruments if
      exercised. As such, the Company was required to account for these
      instruments as derivative financial instruments. On the commitment date of
      the related convertible debentures, the Company recorded a debt discount
      to the extent of the fair value of the embedded conversion features
      required to be accounted for as liabilities under ASC 815. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>During the year ended September 30, 2013, the Company
      issued an aggregate of 6,448,966 common stock purchase warrants that were
      required to be accounted for as liabilities pursuant to ASC 815 as a
      result of certain features embedded in those instruments. During the year
      ended September 30, 2014, the Company amended the terms of these common
      stock purchase warrants. As of the modification date, these warrants were
      no longer required to be accounted for as liabilities. Pursuant to the
      guidance of ASC 815, the Company reclassified the fair value of these
      instruments on the date of modification into equity, with the change in
      fair value up to the date of modification being recorded on the
      consolidated statements of operations as other income. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>As a result of the application of ASC 815, the Company
      has recorded these liabilities at their fair values as follows: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD colspan="4" align=center>September 30, </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%">2014 </TD>
    <TD align=center width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
    width="1%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%">2013 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="17%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Balance, beginning of the period </TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>904,000 </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%" bgColor=#e6efff>$</TD>
    <TD align=right width="17%" bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Fair value at issuance </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">8,277,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">919,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Change in fair value during the period </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>(2,956,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="17%" bgColor=#e6efff>(15,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Transfer to equity upon modification of warrant terms </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">(221,000</TD>
    <TD align=left width="2%">) </TD>
    <TD align=left width="1%">&nbsp;</TD>
    <TD align=right width="17%">&#150; </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Transfer to equity upon exercise </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>(548,000</TD>
    <TD align=left width="2%" bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%">&nbsp;</TD>
    <TD align=left>Balance, end of the period </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="17%">5,456,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%">$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="17%">904,000 </TD>
    <TD align=left width="2%">&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The embedded conversion features and
  warrants accounted for as derivative financial instruments have no observable
  market and the Company estimated their fair values at September 30, 2014 and
  2013 using the binomial option pricing model based on the following weighted
  average management assumptions: </P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD align=left width="20%"><U>2014</U> </TD>
      <TD align=left width="20%"><U>2013</U> </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Risk-free interest rate </TD>
      <TD align=left width="20%" bgColor=#e6efff>3.21% </TD>
      <TD align=left width="20%" bgColor=#e6efff>0.10% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Expected life (years) </TD>
      <TD align=left width="20%">29.48 </TD>
      <TD align=left width="20%">1.25 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Expected volatility </TD>
      <TD align=left width="20%" bgColor=#e6efff>100.07% </TD>
      <TD align=left width="20%" bgColor=#e6efff>77.51% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Stock price </TD>
      <TD align=left width="20%">$0.184 </TD>
      <TD align=left width="20%">$0.65 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Dividend yields </TD>
      <TD align=left width="20%" bgColor=#e6efff>0.00% </TD>
      <TD align=left width="20%" bgColor=#e6efff>0.00% </TD>
    </TR>
  </TABLE>
</DIV>
<P align=center>F-22<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-23></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 18</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock</U> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>As at September 30, 2014, the Company&#146;s authorized share
      capital, consisting of 150,000,000 share of common stock, was insufficient
      to fully settle the conversion or exercise of all outstanding convertible
      debentures, stock purchase warrants and stock options at that date. As a
      result, and in accordance with ASC 815, the Company has recorded
      derivative liabilities in connection with certain embedded conversion
      options contained in convertible debentures outstanding at September 30,
      2014, as more fully described in Note 5. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>Year ended September 30, 2014 </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On February 24, 2014, the Company issued 120,000 units at
      $0.50 per unit for gross proceeds of $60,000, which was received during
      the year ended September 30, 2013. Each unit consisted of one common share
      and one common share purchase warrant entitling the holder to purchase
      additional common shares at $1.00 per share for a period of five years
      from the date of issuance. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On February 24, 2014, the Company issued 500,000 units at
      $0.30 per unit for gross proceeds of $150,000. Each unit consisted of one
      common share and one common share purchase warrant entitling the holder to
      purchase additional common shares at $0.75 per share for a period of five
      years from the date of issuance. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>Year ended September 30, 2013 </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On July 5, 2013, the Company issued 4,208,910 units in
      settlement of $549,000 in promissory notes, $26,058 of accrued interest on
      these notes, which was included in accounts payable and accrued
      liabilities, and $1,108,506 in other accounts payable and accrued
      liabilities. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase an additional common
      share at $0.75 per share until July 5, 2018. (Note 4). </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On July 5, 2013, the Company issued 2,196,133 units at
      $0.40 per unit for gross proceeds of $878,453 pursuant to private
      placement agreements. Each unit consisted of one common share and one
      common share purchase warrant entitling the holder to purchase an
      additional common share at $0.75 per share until July 5, 2018. As
      discussed in Note 5, the warrants issued were required to be accounted for
      as derivative liabilities pursuant to the guidance of ASC 815.
      Consequently, the Company allocated the proceeds from the issuance of the
      units first to the warrants, at their fair value of $313,000 with the
      remainder of $565,453 being allotted to equity. The fair value of the
      warrants of $313,000 was determined based on the binomial option pricing
      model using the following assumptions: risk-free interest rate 0.28%,
      expected life 1.49 years, expected volatility 81.57%, dividend yield
      0.00%. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>In addition, the Company paid finder&#146;s fees of $95,680 in
      connection with the issuance of the units, consisting of cash of $89,680
      and $6,000 in warrants to purchase 43,923 shares of common stock at $0.75
      per share until July 5, 2018 in connection with this private placement.
      The fair value of the warrants of $6,000 was determined using the binomial
      option pricing model using the following assumptions: risk-free interest
      rate 0.28%, expected life 1.49 years, expected volatility 81.57%, dividend
      yield 0.00%. In addition, the Company incurred share issuance costs of
      $16,494. </P></TD>
  </TR>
</TABLE>
<P align=center>F-23<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-24></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 19</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 6 </TD>
    <TD align=left width="90%" ><U>Capital Stock </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >Common stock to be issued </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On February 28, 2014, the Company received $30,000 in
      share subscriptions in respect of the issuance of 100,000 units at $0.30
      per unit. Each unit consisted of one common share and one common share
      purchase warrant entitling the holder to purchase additional common shares
      at $0.75 per share for a period of five years from the date of issuance. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 7 </TD>
    <TD align=left width="90%" ><P align=justify><U>Lincoln Park Purchase Agreement</U> </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>On July 5, 2013, the Company entered into a $10,000,000
      purchase agreement (the &#147;Purchase Agreement&#148;) with Lincoln Park Capital
      Fund, LLC, (&#147;Lincoln Park&#148;) an Illinois limited liability company (the
      &#147;Financing&#148;) pursuant to which the Company may sell and issue to Lincoln
      Park, and Lincoln Park is obligated to purchase, up to $10,000,000 in
      value of its shares of common stock from time to time over a 25 month
      period. In connection with the Financing, the Company also entered into a
      registration rights agreement with Lincoln Park whereby the Company agreed
      to file a registration statement with the Securities and Exchange
      Commission (the &#147;SEC&#148;) covering the shares of the Company&#146;s common stock
      that may be issued to Lincoln Park under the Purchase Agreement. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company will determine, at its own discretion, the
      timing and amount of its sales of common stock, subject to certain
      conditions and limitations. The purchase price of the shares that may be
      sold to Lincoln Park under the Purchase Agreement will be based on the
      market price of the Company&#146;s shares of common stock immediately preceding
      the time of sale without any fixed discount, provided that in no event
      will such shares be sold to Lincoln Park when the closing sale price is
      less than $0.50 per share. There are no upper limits on the per share
      price that Lincoln Park may pay to purchase such common stock. The
      purchase price will be equitably adjusted for any reorganization,
      recapitalization, non-cash dividend, stock split or similar transaction
      occurring during the business days used to compute such price. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Pursuant to the Purchase Agreement, Lincoln Park
      initially purchased 250,000 shares of the Company&#146;s common stock for
      $100,000. In consideration for entering into the Purchase Agreement, the
      Company issued to Lincoln Park 341,858 shares of common stock as a
      commitment fee and shall issue up to 133,409 shares pro rata, when and if,
      Lincoln Park purchases, at the Company&#146;s discretion, the remaining
      $10,000,000 aggregate commitment. The Purchase Agreement may be terminated
      by the Company at any time at its discretion without any cost to the
      Company. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>On October 23, 2013, the registration statement was
      declared effective by the SEC. </P></TD>
  </TR>
</TABLE>
<P align=center>F-24<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-25></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 20</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 7 </TD>
    <TD align=left width="90%"><U>Lincoln Park Purchase Agreement </U>&#150;
      (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>The Company incurred a net $73,787 in direct expenses in
      connection with the Purchase Agreement and registration statement, of
    which $71,335 was incurred during the year ended September 30, 2013. These
      were recorded as share issuance costs as a charge against additional paid
      in capital during the year ended September 30, 2014 and during the nine
      months ended June 30, 2014. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>During the year ended September 30, 2014, the Company
      issued to Lincoln Park an aggregate of 402,510 shares of common stock
      under the Purchase Agreement, including 400,000 shares of common stock for
      an aggregate purchase price of $188,170 and 2,510 commitment shares. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 8 </TD>
    <TD align=left width="90%"><P align=justify><U>Related Party Transactions</U> </P></TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%"><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>During the year ended September 30, 2014, the Company was
      charged general and administrative expenses totaling $1,041,140 in respect
      of directors fees, management bonuses and share and stock option based
      compensation charges paid or accrued to directors and officers of the
      Company, inclusive of amounts noted below (2013: $81,072 in respect of
      consulting fees paid to directors, officers, and a company controlled by a
      director and officer of the Company). </P></TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%"><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>As at September 30, 2014, included in accounts payable
      and accrued liabilities was $28,232 (2013: $30,447) owing to directors and
      officers of the Company for director fees and reimbursable expenses, and a
      former director and officer of the Company for unpaid fees. </P></TD>
  </TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%"><P align=justify>&nbsp;</P></TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%"><P align=justify>During the year ended September 30, 2013, pursuant to an
      employment agreement with the President, Chief Executive Officer, Chief
      Financial Officer, Secretary and Treasurer, and Director, of the Company,
      the Company: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">i) </TD>
    <TD><P align=justify>granted 2,000,000 fully vested share purchase options
      exercisable at $0.40 per share until July 5, 2023. The Company recognized
      stock based compensation expense of $1,002,500 during the year ended
      September 30, 2013 in connection with these options.</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD vAlign=top width="5%">ii) </TD>
    <TD><P align=justify>issued 4,000,000 shares of restricted common stock that
      vest as follows:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="80%"><P align=justify>25% upon the Company starting a Phase Ib/IIb human study </P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="80%"><P align=justify>25% upon the Company in-licensing additional assets in
      clinical or pre- clinical stage (vested during the year ended September
      30, 2014) </P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%"></TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="80%"><P align=justify>25% upon the Company securing additional non-dilutive
      equity funding in 2013 of at least $5,000,000 with a share price higher
      than the previous funding </P></TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%">&nbsp;</TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="80%"><P align=justify>25% upon the Company obtaining a listing on a major stock
      exchange </P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>Included in operating results for the
  year ended September 30, 2014 is an amount of $610,000 relating to the vesting
  of 1,000,000 shares of restricted common stock upon the achievement of certain
  performance conditions. The fair value of $0.61 per share was determined with
  reference to the quoted market price of the Company&#146;s shares on the commitment
  date. This amount has been included in common stock to be issued at September
  30, 2014.</P>
<P align=center>F-25<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-26></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 21</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%"><U>Commitments</U> </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>Share Purchase Warrants</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>A summary of the Company&#146;s share purchase warrants
      outstanding is presented below:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=left width="17%">&nbsp;</TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=center width="17%">Weighted </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=left width="17%">&nbsp;</TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=center width="17%">Average </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=left width="17%">&nbsp;</TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=center width="17%">Exercise </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="17%">Number of Shares </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="17%">Price </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
    </TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD width="17%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
      <TD width="1%">&nbsp;</TD>
      <TD align=center width="17%">&nbsp;</TD>
      <TD width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Balance, October 1, 2012 </TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>4,250,141 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=center width="17%" bgColor=#e6efff>1.16 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Expired </TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="17%">(1,549,628</TD>
      <TD align=left width="2%">) </TD>
      <TD align=left width="1%">$</TD>
      <TD align=center width="17%">2.56 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>6,448,966 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%"
    bgColor=#e6efff>0.75 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Balance, September 30, 2013 </TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="17%">9,149,479 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">$</TD>
      <TD align=center width="17%">0.75 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Expired </TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>(2,700,513</TD>
      <TD align=left width="2%" bgColor=#e6efff>) </TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=center width="17%" bgColor=#e6efff>0.75 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left>Issued </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="17%">68,466,666 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%">$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%">0.36 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff>Balance, September 30, 2014 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="17%"
    bgColor=#e6efff>74,915,632 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="17%"
    bgColor=#e6efff>0.40 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>At September 30, 2014, the Company has
  74,915,632 currently exercisable share purchase warrants outstanding as follows: </P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="50%" border=0>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>Number </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="21%">Exercise Price </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="35%">Expiry Date </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>6,448,966 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=right width="21%" bgColor=#e6efff>0.75 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="35%" bgColor=#e6efff>July 5, 2018 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>500,000 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">$</TD>
      <TD align=right width="21%">0.75 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="35%">February 14, 2019 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>120,000 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=right width="21%" bgColor=#e6efff>1.00 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="35%" bgColor=#e6efff>February 24, 2019 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>33,833,333 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">$</TD>
      <TD align=right width="21%">0.30 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="35%">March 13, 2019 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>33,833,333 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=right width="21%" bgColor=#e6efff>0.42 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="35%" bgColor=#e6efff>March 13, 2019 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right>180,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
      <TD align=left width="1%">$</TD>
      <TD align=right width="21%">0.31 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="35%">May 31, 2019 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      bgColor=#e6efff>74,915,632 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="21%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="35%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>All of the 6,448,966 warrants expiring
  on July 5, 2018 and the 500,000 warrants expiring February 14, 2019 contain a
  contingent call provision whereby the Company may have the option to call for
  cancellation of all or any portion of the warrants for consideration equal to
  $0.001 per share, provided the quoted market price of the Company&#146;s common stock
  exceeds $1.50 for a period of twenty consecutive trading days, subject to
  certain minimum volume restrictions and other restrictions as provided in the
  warrant agreements. </P>
<P align=center>F-26<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-27></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 22</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>Stock&#150;based Compensation Plan</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>In April, 2007, the Company adopted a stock option plan
      which provides for the granting of stock options to selected directors,
      officers, employees or consultants in an aggregate amount of up to
      3,000,000 common shares of the Company and, in any case, the number of
      shares to be issued to any one individual pursuant to the exercise of
      options shall not exceed 10% of the issued and outstanding share capital.
      The granting of stock options, exercise prices and terms are determined by
      the Company's Board of Directors. If no vesting schedule is specified by
      the Board of Directors on the grant of options, then the options shall
      vest over a 4-year period with 25% of the granted options vesting each
      year commencing 1 year from the grant date. For stockholders who have
      greater than 10% of the outstanding common shares of the Company and who
      have granted options, the exercise price of their options shall not be
      less than 110% of the fair of the stock on grant date. Otherwise, options
      granted shall have an exercise price equal to their fair value on grant
      date.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>On February 2, 2011, the Company amended and restated the
      2007 stock option plan to increase the number of options authorized to
      4,000,000.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>A summary of the status of Company&#146;s outstanding stock
      purchase options for the years ended September 30, 2014 and 2013 is
      presented below:</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="15%"  >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%">&nbsp;</TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Weighted </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Weighted </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Number of </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Average </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="15%">Average Grant </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">Shares </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center
      width="15%">Exercise Price </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="15%">Date
      fair value </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Outstanding at October 1,
      2012 </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>1,775,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>2.94 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Expired </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">(550,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="15%">3.86 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Forfeited </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="15%" bgColor=#e6efff>(150,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>3.72 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      width="15%">2,000,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%">0.40 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="15%">0.50 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Outstanding at September 30,
      2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>3,075,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>1.26 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Expired </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="15%">(705,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >$</TD>
    <TD align=right width="15%">2.70 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Granted </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>800,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="15%"
    bgColor=#e6efff>0.32 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="15%" bgColor=#e6efff>0.25 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Outstanding at September 30, 2014 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="15%">3,170,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%">0.70 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff >Exercisable at September 30,
      2014 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>2,100,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%"
    bgColor=#e6efff>0.56 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="15%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="15%" >&nbsp;</TD>
    <TD align=left >Exercisable at September 30, 2013 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="15%">2,305,000 </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="2%"
    >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
    >$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="15%">0.79 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=left width="15%">&nbsp;</TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
</TABLE>
<P align=center>F-27<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-28></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 23</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%"><U>Commitments </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>Stock&#150;based Compensation Plan &#150; (cont&#146;d)</P></TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD width="5%"></TD>
    <TD><P align=justify>At September 30, 2014, the following stock options were
      outstanding:</P></TD>
  </TR>
</TABLE>
<BR>
<DIV align=right>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="85%" border=0>
    <TR vAlign=top>
      <TD colspan="6" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Number of Shares </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="11%" align=center nowrap>&nbsp;</TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="17%" align=center nowrap>&nbsp;</TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="11%" align=center nowrap>Aggregate </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="11%" align=center nowrap>Remaining </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="5%" align=center nowrap>&nbsp;</TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="11%" align=center nowrap>Number </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="11%" align=center nowrap>Exercise </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="17%" align=center nowrap>&nbsp;</TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="11%" align=center nowrap>Intrinsic </TD>
      <TD width="2%" align=center nowrap>&nbsp;</TD>
      <TD width="1%" align=center nowrap>&nbsp;</TD>
      <TD width="11%" align=center nowrap>Contractual </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Total </TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="5%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="11%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Vested </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="11%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Price </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="17%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">ExpiryDate </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
      width="11%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Value </TD>
      <TD
    width="2%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD
    width="1%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">&nbsp;</TD>
      <TD width="11%" align=center nowrap style="BORDER-BOTTOM: #000000 1px solid">Life
        (yrs) </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>&nbsp; &nbsp; &nbsp;100,000 </TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=center width="5%" bgColor=#e6efff><SUP>(1)</SUP></TD>
      <TD align=center width="2%" bgColor=#e6efff></TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>100,000 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=right width="11%" bgColor=#e6efff>3.67 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>March 30, 2016 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>&#150; </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>1.50 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>&nbsp; &nbsp; &nbsp;270,000 </TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=center width="5%"><SUP>(2)</SUP></TD>
      <TD align=center width="2%"></TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="11%">&#150; </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">$</TD>
      <TD align=right width="11%">3.00 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="17%">February 8, 2017 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="11%">&#150; </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="11%">2.36 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right bgColor=#e6efff>2,000,000 </TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=center width="5%" bgColor=#e6efff><SUP>(3)</SUP></TD>
      <TD align=center width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>2,000,000 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>$</TD>
      <TD align=right width="11%" bgColor=#e6efff>0.40 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>July 5 ,2023 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>&#150; </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>8.77 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD align=right>&nbsp; &nbsp; &nbsp;300,000 </TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=center width="5%"><SUP>(4)</SUP></TD>
      <TD align=center width="2%"></TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="11%">&#150; </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">$</TD>
      <TD align=right width="11%">0.30 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="17%">May 7, 2024 </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="11%">&#150; </TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=right width="11%">9.61 </TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right
      bgColor=#e6efff>&nbsp; &nbsp; &nbsp;500,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="5%"
    bgColor=#e6efff><SUP>(5)</SUP></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="2%"
    bgColor=#e6efff></TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="11%"
    bgColor=#e6efff>&#150; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>$</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="11%"
    bgColor=#e6efff>0.33 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="17%" bgColor=#e6efff>May 8, 2024 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="11%"
    bgColor=#e6efff>&#150; </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="2%"
    bgColor=#e6efff>&nbsp;</TD>
      <TD align=left width="1%" bgColor=#e6efff>&nbsp;</TD>
      <TD align=right width="11%" bgColor=#e6efff>9.61 </TD>
      <TD align=left width="2%" bgColor=#e6efff>&nbsp;</TD>
    </TR>
    <TR vAlign=top>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right>3,170,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=center
      width="5%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=center
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right
      width="11%">2,100,000 </TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left
    width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="11%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=left
    width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=left width="17%">&nbsp;</TD>
      <TD align=left width="2%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left
    width="1%">&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="11%">&#150;</TD>
      <TD style="BORDER-BOTTOM: #000000 3px double" align=left
    width="2%">&nbsp;</TD>
      <TD align=left width="1%">&nbsp;</TD>
      <TD align=left width="11%">&nbsp;</TD>
      <TD align=left width="2%">&nbsp;</TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>The aggregate intrinsic value is
  calculated as the difference between the exercise price of the underlying awards
  and the quoted market price of the Company&#146;s stock for the options that were
  in-the-money at September 30, 2014. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="15%" >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(1)</SUP> </TD>
    <TD><P align=justify>As of September 30, 2014 and September 30, 2013, these
      options had fully vested. These options were granted during the year ended
      September 30, 2011 and vested over a period of one year from the date of
      grant. The fair value of these options at issuance was calculated to be
      $267,000. The Company did not recognize any stock-based compensation
      during the year ended September 30, 2014 (2013: $Nil).</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(2)</SUP> </TD>
    <TD><P align=justify>As of September 30, 2014 and 2013, none of these options
      had vested. The options vest upon one or more compounds: entering Phase II
      trial &#150; 90,000 options; entering Phase III trial &#150; 90,000 options; and
      receiving FDA approval &#150; 90,000 options. No stock-based compensation has
      been recorded in the financial statements as none of the performance
      conditions have yet been met.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(3)</SUP> </TD>
    <TD><P align=justify>As of September 30, 2014 and 2013 these options had fully
      vested. These options were granted during the year ended September 30,
      2013 and vested immediately upon granting. The Company recognized stock
      based compensation expense of $Nil during the year ended September 30,
      2014 (2013: $1,002,500) in connection with these options. These amounts
      have been included in general and administrative expenses on the Company&#146;s
      statement of operations.</P></TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="15%">&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(4)</SUP> </TD>
    <TD><P align=justify>As of September 30, 2014 none of these options had
      vested. These options were issued during the year ended September 30, 2014
      and vest annually over a three year period commencing on the first
      anniversary of the date of the grant. The Company recognized stock based
      compensation expense of $9,252 during the year ended September 30, 2014,
      (2013: $Nil) in connection with these options. These amounts have been
      included in general and administrative expenses on the Company&#146;s statement
      of operations.</P></TD>
  </TR>
</TABLE>
<P align=center>F-28<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-29></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 24</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 9 </TD>
    <TD align=left width="90%" ><U>Commitments </U>&#150; (cont&#146;d) </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>Stock&#150;based Compensation Plan &#150;
      (cont&#146;d)</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="15%"  >&nbsp;</TD>
    <TD vAlign=top width="5%"><SUP>(5)</SUP> </TD>
    <TD><P align=justify>As of September 30, 2014 none of these options had
      vested. These options were issued during the year ended September 30, 2014
      and vest annually over a four year period commencing on the first
      anniversary of the date of the grant. The Company recognized stock based
      compensation expense of $16,905 during the year ended September 30, 2014
      (2013: $Nil) in connection with these options.</P></TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 15%" align=justify>During the year ended September 30,
  2014, 705,000 options expired for which the Company had recognized stock-based
  compensation of $Nil (2013: $Nil) during the year ended September 30, 2014. </P>
<P style="MARGIN-LEFT: 15%" align=justify>The fair value of stock options
  granted has been determined using the Black-Scholes option pricing model using
  the following weighted average assumptions applied to stock options granted
  during the periods: </P>
<DIV align=center>
  <TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>
    <TR vAlign=top>
      <TD align=left >&nbsp;</TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="20%">2014 </TD>
      <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="20%">2013 </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Risk&#150;free interestrate </TD>
      <TD align=right width="20%" bgColor=#e6efff>2.17% </TD>
      <TD align=right width="20%" bgColor=#e6efff>2.73% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Expected life of options (years) </TD>
      <TD align=right width="20%">6.50 </TD>
      <TD align=right width="20%">10.0years </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left bgColor=#e6efff >Annualized volatility </TD>
      <TD align=right width="20%" bgColor=#e6efff>91.21% </TD>
      <TD align=right width="20%" bgColor=#e6efff>71.39% </TD>
    </TR>
    <TR vAlign=top>
      <TD align=left >Dividend rate </TD>
      <TD align=right width="20%">0.00% </TD>
      <TD align=right width="20%">0.00% </TD>
    </TR>
  </TABLE>
</DIV>
<P style="MARGIN-LEFT: 15%" align=justify>There has been no stock-based
  compensation recognized in the financial statements for the year ended September
  30, 2014 (2013: $nil) for options that will vest upon the achievement of
  performance milestones because the Company has determined that satisfaction of
  the performance milestones was not probable. Compensation relating to stock
  options exercisable upon achieving performance milestones will be recognized in
  the period the milestones are achieved. </P>
<P align=center>F-29<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-30></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 25</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD align=left width="90%" ><U>Income Taxes</U> </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The tax effects of the temporary differences that give
      rise to the Company&#146;s estimated deferred tax assets and liabilities are as
      follows: </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2014</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2013</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff><I>Tax</I><I>rate</I> </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff><I>34%</I> </TD>
    <TD align=center width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=center width="12%" bgColor=#e6efff><I>34%</I> </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Net operating loss carry forwards </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>8,270,000&nbsp; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%"  bgColor=#e6efff>7,141,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Research and development tax credits </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">745,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%" >705,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Foreign exchange </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(23,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%"  bgColor=#e6efff>(19,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Accrued bonuses </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">170,000</TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%" >34,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Intangible asset costs </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>70,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%"  bgColor=#e6efff>51,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Stock&#150;based compensation </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">441,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%" >633,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Valuation allowance for deferred tax assets </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>(9,673,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
     bgColor=#e6efff>(8,545,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Net deferred tax assets </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
     bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>The provision for income taxes differ
  from the amount established using the statutory income tax rate as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD width="10%"  >&nbsp;</TD>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2014</U> </TD>
    <TD align=center width="2%" >&nbsp;</TD>
    <TD align=center width="1%" >&nbsp;</TD>
    <TD align=center width="12%"><U>2013</U> </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Income benefit at statutory rate of 34% </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>(3,865,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>$</TD>
    <TD align=right width="12%" bgColor=#e6efff>(1,258,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Foreign income taxed at other rates </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">13,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">&#150; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Permanent differences </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="12%" bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; &nbsp;Effect of stock based compensation </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">202,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">&#150; </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Debt extinguishment </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>2,736,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>501,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; &nbsp;Mark&#150;to&#150;market deriative liability adjustment </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(994,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">7,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>&nbsp; &nbsp;Non&#150;deductible finance and
      accretion expenses </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>808,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>&nbsp; &nbsp;Other permanent differences </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(16,000</TD>
    <TD align=left width="2%" >) </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(5,000</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Research and development tax credit </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(26,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
    <TD align=left width="1%"  bgColor=#e6efff>&nbsp;</TD>
    <TD align=right width="12%" bgColor=#e6efff>(17,000</TD>
    <TD align=left width="2%"  bgColor=#e6efff>) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left>Adjustment and true up to prior years' tax provision </TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">14,000 </TD>
    <TD align=left width="2%" >&nbsp;</TD>
    <TD align=left width="1%" >&nbsp;</TD>
    <TD align=right width="12%">(161,000</TD>
    <TD align=left width="2%" >) </TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Change in valuation allowance </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>1,128,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="1%"
     bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="12%"
    bgColor=#e6efff>933,000 </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
    <TD width="1%" >&nbsp;</TD>
    <TD width="12%">&nbsp;</TD>
    <TD width="2%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD width="10%" >&nbsp;</TD>
    <TD align=left bgColor=#e6efff>Income Tax Expense </TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"  bgColor=#e6efff>&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=left width="1%"
     bgColor=#e6efff>$</TD>
    <TD style="BORDER-BOTTOM: #000000 3px double" align=right width="12%"
    bgColor=#e6efff>&#150; </TD>
    <TD align=left width="2%"
  bgColor=#e6efff>&nbsp;</TD>
  </TR>
</TABLE>
<P style="MARGIN-LEFT: 10%" align=justify>As of September 30, 2014, the Company
  had net operating loss carry-forwards of approximately $24,000,000 (2013:
  $21,000,000) available to offset future taxable income. The carry-forwards will
  begin to expire in 2027 unless utilized in earlier years. The Company has not
  yet filed any tax returns in France or Australia. </P>
<P align=center>F-30<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-31></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 26</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 10 </TD>
    <TD align=left width="90%" ><U>Income Taxes </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company evaluates its valuation allowance
      requirements based on projected future operations. When circumstances
      change and this causes a change in management&#146;s judgment about the
      recoverability of deferred tax assets, the impact of the change on the
      valuation allowance is reflected in current income. Because management of
      the Company does not currently believe that it is more likely than not
      that the Company will receive the benefit of these assets, a valuation
      allowance equal to the deferred tax asset has been established at both
      September 30, 2014 and 2013. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>Uncertain Tax Positions </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>The Company files income tax returns in the U.S. federal
      jurisdiction and various state and foreign jurisdictions. The Company&#146;s tax
      returns are subject to tax examinations by U.S. federal and state tax
      authorities, or examinations by foreign tax authorities until the respective
      statutes of limitation expire. The Company is subject to tax examinations by tax
      authorities for all taxation years commencing on or after 2006. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>Note 11 </TD>
    <TD align=left width="90%" ><P align=justify><U>Supplemental Cash Flow Information</U> </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left></TD>
    <TD align=left width="90%" ><P align=justify>Investing and financing activities that do not have a
      direct impact on current cash flows are excluded from the statement of
      cash flows. </P></TD>
  </TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" ><P align=justify>During the year ended September 30, 2014; </P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>the Company reclassified an amount of $221,000 into
      equity upon modification of the terms of certain derivative
      instruments.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>the Company issued 6,378,426 shares of common stock of
      the Company pursuant to the conversion of $1,913,528 face value of
      convertible debentures at $0.30 per share;</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD><P align=justify>the Company issued 2,561,713 shares of common stock of
      the Company at a fair value of $551,120 pursuant to the conversion of
      convertible debentures at a conversion price of $0.25 per
      share.</P></TD>
  </TR>
</TABLE>
<P align=center>F-31<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_F-32></A>
<P align=justify>Anavex Life Sciences Corp. <BR>
  Notes to the Consolidated
  Financial Statements <BR>
  September 30, 2014 and 2013 <BR>
  (Stated in US
  Dollars)&nbsp; &#150; Page 27</P>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 11 </TD>
    <TD align=left width="90%" ><U>Supplemental Cash Flow
      Information </U>&#150; (cont&#146;d) </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%"  >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >During the year ended September
      30, 2013; </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>the Company issued three promissory notes in the
      principal amounts of $100,000, $87,865 (CDN$86,677) and $28,017
      (CDN$27,639) in exchange for accounts payable owing to three vendors in
      respect of unpaid consulting fees.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>The Company issued 4,208,910 units of the Company at
      their fair value of $1.02 per unit to settle (i) interest bearing notes
      payable outstanding in the amount of $549,000; (ii) accrued interest in
      connection with the notes payable of $26,058 included in accounts payable
      and accrued liabilities; and (iii) accounts payable of $1,108,506. Each
      unit consisted of one common share and one common share purchase warrant
      exercisable into one additional common share for $0.75 per share until
      July 5, 2018. In addition, in connection with the settlement of $11,449 of
      accrued interest with respect to the notes payable was forgiven. The
      Company recorded a loss on debt settlement of $1,472,208 as a result of
      this transaction.</P></TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>
  <TR vAlign=top>
    <TD align=left>Note 12 </TD>
    <TD align=left width="90%" ><U>Subsequent Events</U> </TD>
  </TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%" >&nbsp;</TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&nbsp;</TD>
    <TD align=left width="90%" >Subsequent to September 30, 2014; </TD>
  </TR>
</TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="10%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD><P align=justify>On October 22, 2014, the Company entered into a
      Securities Purchase Agreement (the &#147;Purchase Agreement&#148;) with one investor
      for an equity investment of $500,000 at a price of $0.25 per unit.
      Pursuant to the terms of the Purchase Agreement, the Company agreed to
      sell, and Lincoln Park agreed to purchase, 2,000,000 shares of common
      stock. In addition, the Company agreed to issue an aggregate of 4,000,000
      stock purchase warrants, of which 2,000,000 are exercisable at $0.30 per
      share and 2,000,000 are exercisable at $0.42 per share, each for a period
      of five years, subject to adjustment for stock splits, combinations, and
      reclassification events.</P></TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD>
  </TR>
  <TR>
    <TD width="10%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD><P align=justify>The Company issued an aggregate of 5,484,668 shares of
      common stock pursuant to the conversion of $1,371,167 face value of
      convertible debentures at $0.25 per share.</P></TD>
  </TR>
</TABLE>
<P align=center>F-32<BR>
</P>
<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">




<A name="page_34"></A>

<P align="justify">
<B>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL MATTERS</B></P>
<P align="justify">
Not Applicable </P>
<P align="justify">
<B>ITEM 9A. CONTROLS AND PROCEDURES </B></P>
<P align="justify">
<B><I>Disclosure Controls and Procedures </I></B></P>
<P align="justify">
As required by Rule 13a-15 under the Securities Exchange Act of 1934, our management, with the participation of our principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rule
13a-15(e) of the Securities Exchange Act of 1934) as of the end of the period covered by this Annual Report on Form 10-K. </P>
<P align="justify">
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized
and reported, within the time periods specified in the Securities and Exchange Commission&rsquo;s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our
reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to our principal executive officer and principal financial officer to allow timely decisions regarding required disclosure.</P>
<P align="justify">
Based on its evaluation, our management, with the participation of our principal
executive officer and principal financial officer, concluded that as of the end
of the period covered by this Annual Report on Form 10-K, our disclosure
controls and procedures were not effective. The ineffectiveness of our
disclosure controls and procedures was due to internal control weaknesses
further described below in Management&#146;s Report on Internal Control over
Financial Reporting.</P>
<P align="justify">
<B><I>Management&rsquo;s Annual Report on Internal Control over Financial Reporting</I></B></P>
<P align="justify">
Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. Our chief executive officer and chief financial
officer assessed the effectiveness of our internal control over financial reporting as of September 30, 2014.</P>
<P align="justify">
Based on its evaluation under the framework in Internal Control&mdash;Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission, our management, with the participation of our principal executive officer and
principal financial officer, concluded that our internal control over financial reporting was not effective as of September 30, 2014. The ineffectiveness of our internal control over financial reporting was due to the existence of significant
deficiencies constituting material weaknesses, as described in greater detail below. A material weakness is a control deficiency, or combination of control deficiencies, such that there is a reasonable possibility that a material misstatement of the
annual or interim financial statements will not be prevented or detected on a timely basis.</P>
<P align="center">
29</P>
<hr noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">
<a name=page_35></a>
<P align="justify"><B><I>Material Weaknesses Identified </I></B></P>
<P align=justify>(1) Control environment - We did not maintain an effective
control environment. The control environment, which is the responsibility of
senior management, sets the tone of the organization, influences the control
consciousness of its people, and is the foundation for all other components of
internal control over financial reporting. Each of the following control
environment material weaknesses also contributed to the material weaknesses
discussed in items (2) and (3) below. Our control environment was ineffective
because of the following material weaknesses:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>We did not maintain a sufficient complement of personnel
      with an appropriate level of accounting knowledge, experience, and
      training in the application of Generally Accepted Accounting Principles
      (GAAP) commensurate with our financial reporting requirements and business
      environment.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>There was insufficient segregation of duties in our
      finance and accounting functions due to limited personnel. During the
      fiscal year ended September 30, 2014, we had limited staff that performed
      nearly all aspects of our financial reporting process, including, but not
      limited to, access to the underlying accounting records and systems, the
      ability to post and record journal entries and responsibility for the
      preparation of the financial statements. This creates certain incompatible
      duties and a lack of review over the financial reporting process that
      would likely result in a failure to detect errors in spreadsheets,
      calculations, or assumptions used to compile the financial statements and
      related disclosures as filed with the Securities and Exchange Commission.
      These control deficiencies could result in a material misstatement to our
      interim or annual financial statements that would not be prevented or
      detected; and</P></TD></TR></TABLE>
<P align=justify>(2) Monitoring of internal control over financial reporting &#151;
we did not maintain effective monitoring controls to determine the adequacy of
our internal control over financial reporting and related policies and
procedures because of the following material weaknesses:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Our policies and procedures with respect to the review,
      supervision and monitoring of our accounting operations throughout the
      organization were either not designed and in place or not operating
      effectively.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>We did not maintain an effective internal control
      monitoring function. Specifically, there were insufficient policies and
      procedures to effectively determine the adequacy of our internal control
      over financial reporting and to monitoring the ongoing effectiveness
      thereof.</P></TD></TR></TABLE>
<P align=justify><B><I>Plan for Remediation of Material Weaknesses </I></B></P>
<P align=justify>We intend to take appropriate and reasonable steps to make
improvements to remediate these deficiencies&nbsp; through implementation of
more robust review, supervision and monitoring of the financial reporting
process as the adoption of the appropriate resources becomes economically
feasible. We intend to consider the results
of our remediation efforts and related testing as part of our year-end 2015
assessment of the effectiveness of our internal control over financial reporting
in light of our strategic plan.</P>
<P align=justify>Due to our size and nature, segregation of all conflicting
duties has not always been possible and may not be economically feasible.
However, we are in the process of implementing processes and procedures intended
to mitigate any material weaknesses identified. </P>
<P align=center>30</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_36"></A>

<P align="justify">
We believe that the foregoing steps will remediate the deficiencies identified above, and we intend to continue to monitor the effectiveness of these steps and make any changes that our management deems appropriate.</P>
<P align="justify">
<B><I>Limitations on Effectiveness of Controls </I></B></P>
<P align="justify">
 Our principal executive officer and principal financial officer does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well
conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of
controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have
been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additional controls can be circumvented by the individual acts of
some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance
that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may
deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</P>
<P align="justify">
<B><I>Changes in Internal Control over Financial Reporting </I></B></P>
<P align="justify">
There were no changes in our internal control over financial reporting during the fiscal quarter ended September 30, 2014 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.</P>
<P align="justify">
<B>ITEM 9B OTHER INFORMATION </B></P>
<P align="justify">
None. </P>

<P align=center>31</P>

<HR noshade align="center" width="100%" size=5 color="black" style="page-break-after:always;">

<A name=page_37></A>
<P align=justify><B>PART III </B></P>
<P align=justify><B>ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE
GOVERNANCE </B></P>
<P align=justify><B><I>Directors and Executive Officers </I></B></P>
<P align=justify>Our directors are to be elected at our annual meeting and each
director elected is to hold office until his or her successor is elected and
qualified. Our board of directors may remove our officers at any time.</P>
<P align=justify>Our directors and executive officers, their age, positions
held, and duration of such, are as follows:</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>Name </TD>
    <TD align=left width="40%" >Position </TD>
    <TD align=left width="10%" >Age </TD>
    <TD align=left width="25%">Date first appointed </TD></TR>
  <TR vAlign=top>
    <TD align=left>Christopher Missling, PhD </TD>
    <TD align=left width="40%" >Director, President, Chief
      Executive Officer, Chief Financial Officer, Secretary, Treasurer </TD>
    <TD align=left width="10%" >49 </TD>
    <TD align=left width="25%">July 5, 2013 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Athanasios Skarpelos </TD>
    <TD align=left width="40%" >Director </TD>
    <TD align=left width="10%" >47 </TD>
    <TD align=left width="25%">January 9, 2013 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Bernd Metzner, PhD </TD>
    <TD align=left width="40%" >Director </TD>
    <TD align=left width="10%" >44 </TD>
    <TD align=left width="25%">May 7, 2014 </TD></TR>
  <TR vAlign=top>
    <TD align=left>Elliot Favus, MD </TD>
    <TD align=left width="40%" >Director </TD>
    <TD align=left width="10%" >39 </TD>
    <TD align=left width="25%">May 7, 2014 </TD></TR></TABLE></DIV>
<P align=justify><B><I>Business Experience </I></B></P>
<P align=justify>The following is a brief account of the education and business
experience of directors and executive officers during at least the past five
years, indicating their principal occupation during the period, and the name and
principal business of the organization by which they were employed. </P>
<P align=justify><U>Christopher Missling, PhD</U>. Christopher Missling has over
twenty (20) years of healthcare industry experience in big pharmaceutical,
biotech industry and investment banking. Most recently, from March, 2007 until
his appointment by our company, Mr. Missling served as the head of healthcare
investment banking at Brimberg &amp; Co. in New York, New York. Also, Mr.
Missling served as the Chief Financial Officer of Curis, Inc. (NASDAQ:CRIS) and
ImmunoGen, Inc. (NASDAQ:IMGN). Mr. Missling earned his MS and PhD from the
University of Munich and an MBA from Northwestern University Kellogg School of
Management and WHU Otto Beisheim School of Management. </P>
<P align=justify><U>Athanasios Skarpelos</U>. Athanasios (Tom) Skarpelos is a
self-employed investor with 17 years of experience working with private and
public companies. For the past 10 years, he has been focused on biotechnology
companies involved in drug discovery and drug development projects. Mr.
Skarpelos was engaged as a consultant to our company for one year effective
August 2, 2010. His experience has led to relationships with researchers at
academic institutes in Europe and North America. Mr. Skarpelos is a founder of
Anavex. </P>
<P align=justify><U>Bernd Metzner, PhD.</U> Bernd Metzner is currently Chief
Financial Officer of the Doehler Group, a global producer and provider of
technology-based natural ingredients for the food and beverage industry with
sales activities in more than 130 countries. Previously, he was Chief
Administration Officer and member of the Board of Management of Bayer Schering
Pharma AG, the pharmaceutical division of $100+ billion market cap company Bayer
AG. In this position, Dr. Metzner had worldwide financial responsibility for
the Bayer Pharma Group. During his almost 10-years with Bayer
AG, Dr. Metzner also held several senior international management positions in
the corporate finance organization of Bayer AG, including Chief Financial
Officer of Bayer S.p.A. Italy and heading the coordination of the successful
spin-off of Lanxess, a specialty chemicals group. Dr. Metzner started his career
at the law firm Flick Gocke Schaumburg and has a degree in business
administration from the University of Siegen. After obtaining his doctorate, he
became a chartered accountant. </P>
<P align=center>32</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_38></A>
<P align=justify><U>Elliot Favus, MD.</U> Elliot Favus is Chief Executive
Officer of Favus Institutional Research, a healthcare research firm serving
institutional investors. He has been a healthcare equity research analyst on
Wall Street since 2006, starting at Lazard Capital Markets and subsequently at
Och-Ziff Capital Management Group. Prior to working on Wall Street, Dr. Favus
was an Instructor in medicine at Mount Sinai School of Medicine in New York. He
attended the University of Michigan (BA, 1996), the University of Chicago
Pritzker School of Medicine (MD, 2001) and the NYU-Bellevue Hospital Internal
Medicine Residency Program (2004). He is board-certified in Internal Medicine
(2004) and has 10 years of basic science laboratory experience working on human
genetics projects at Harvard Medical School, the University of Chicago and the
University of Pittsburgh. </P>
<P align=justify><B><I>Family Relationships </I></B></P>
<P align=justify>There are no family relationships between any director or
executive officer. </P>
<P align=justify><B><I>Involvement in Certain Legal Proceedings </I></B></P>
<P align=justify>There are no material proceedings to which any director or
executive officer or any associate of any such director or officer is a party
adverse to our company or has a material interest adverse to our company.</P>
<P align=justify>No director or executive officer has been involved in any of
the following events during the past ten years:</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify>any bankruptcy petition filed by or against any business
      of which such person was a general partner or executive officer either at
      the time of the bankruptcy or within two years prior to that
  time;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">2. </TD>
    <TD>
      <P align=justify>any conviction in a criminal proceeding or being subject
      to a pending criminal proceeding (excluding traffic violations and other
      minor offences);</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify>being subject to any order, judgment, or decree, not
      subsequently reversed, suspended or vacated, of any court of competent
      jurisdiction, permanently or temporarily enjoining, barring, suspending or
      otherwise limiting his involvement in any type of business, securities or
      banking activities;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify>being found by a court of competent jurisdiction (in a
      civil action), the Securities and Exchange Commission or the Commodity
      Futures Trading Commission to have violated a federal or state securities
      or commodities law, and the judgment has not been reversed, suspended, or
      vacated;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">5. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any federal or state
      judicial or administrative order, judgment, decree, or finding, not
      subsequently reversed, suspended or vacated, relating to an alleged
      violation of: (i) any federal or state securities or commodities law or
      regulation; or (ii) any law or regulation respecting financial
      institutions or insurance companies including, but not limited to, a
      temporary or permanent injunction, order of disgorgement or restitution,
      civil money penalty or temporary or permanent cease- and- desist order, or
      removal or prohibition order; or (iii) any law or regulation prohibiting
      mail or wire fraud or fraud in connection with any business entity;
  or</P></TD></TR></TABLE>
<P align=center>33<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_39></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">6. </TD>
    <TD>
      <P align=justify>being the subject of, or a party to, any sanction or
      order, not subsequently reversed, suspended or vacated, of any
      self-regulatory organization (as defined in Section 3(a)(26) of the
      Securities Exchange Act of 1934), any registered entity (as defined in
      Section 1(a)(29) of the Commodity Exchange Act), or any equivalent
      exchange, association, entity or organization that has disciplinary
      authority over its members or persons associated with a
  member.</P></TD></TR></TABLE>
<P align=justify><B><I>Compliance with Section 16(a) of the Securities Exchange
Act of 1934</I></B></P>
<P align=justify>Section 16(a) of the Securities Exchange Act of 1934 requires
our executive officers and directors and persons who own more than 10% of our
common stock to file with the Securities and Exchange Commission initial
statements of beneficial ownership, reports of changes in ownership and annual
reports concerning their ownership of our common stock and other equity
securities, on Forms 3, 4 and 5 respectively. Executive officers, directors and
greater than 10% shareholders are required by the Securities and Exchange
Commission regulations to furnish us with copies of all Section 16(a) reports
that they file.</P>
<P align=justify>Based solely on our review of the copies of such forms received
by us, or written representations from certain reporting persons, we believe
that during fiscal year ended September 30, 2014, all filing requirements
applicable to our officers, directors and greater than 10% percent beneficial
owners were complied. </P>
<P align=justify><B><I>Code of Ethics </I></B></P>
<P align=justify>We have adopted a code of ethics that applies to our principal
executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions. We have posted our policy
on our website at <U>www.anavex.com</U>. </P>
<P align=justify><B><I>Audit Committee and Audit Committee Financial
Experts</I></B></P>
<P align=justify>We do not have a standing audit committee at the present time.
We believe that our board of directors is capable of analyzing and evaluating
our financial statements and understanding internal controls and procedures for
financial reporting. The board of directors of our company does not believe that
it is necessary to have an audit committee at this time because management
believes the functions of an audit committee can be adequately performed by the
board of directors.<B> </B></P>
<P align=justify>Except for Dr. Metzner, we do not deem any of our directors as an &#147;audit committee
financial expert&#148; as defined in Item 407(d)(5)(ii) of Regulation S-K.</P>
<P align=justify><B><I>Nominating and Compensation Committees </I></B></P>
<P align=justify>We do not have standing nominating or compensation committees,
or committees performing similar functions. Our board of directors believes that
it is not necessary to have a standing compensation committee at this time
because the functions of such committee are adequately performed by our board of
directors. Our board of directors has not adopted a charter for the compensation
committee.</P>
<P align=center>34</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_40></A>
<P align=justify>Our board of directors also is of the view that it is
appropriate for us not to have a standing nominating committee because our board
of directors has performed and is expected to perform adequately the functions
of a nominating committee. Our board of directors has not adopted a charter for
the nominating committee. There has not been any defined policy or procedure
requirements for stockholders to submit recommendations or nomination for
directors. Our board of directors does not believe that a defined policy with
regard to the consideration of candidates recommended by stockholders is
necessary at this time because we believe that, at this stage of our
development, a specific nominating policy would be premature and of little
assistance until our business operations are at a more advanced level. There are
no specific, minimum qualifications that our board of directors believes must be
met by a candidate recommended by our board of directors. There is neither a
defined, nor a typical process of identifying and evaluating nominees for
director.</P>
<P align=justify><B>ITEM 11. EXECUTIVE COMPENSATION </B></P>
<P align=justify><B><I>Summary Compensation</I></B></P>
<P align=justify>The particulars of compensation paid to the following persons
for the last two completed fiscal years: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">a) </TD>
    <TD>
      <P align=justify>our principal executive officers;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">b) </TD>
    <TD>
      <P align=justify>each of our two most highly compensated executive
      officers who were serving as executive officers at the end of the fiscal
      year ended September 30, 2014 who had total compensation exceeding
      $100,000; and</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">c) </TD>
    <TD>
      <P align=justify>up to two additional individuals for whom disclosure
      would have been provided under (b) but for the fact that the individual
      was not serving as our executive officer at the end of the most recently
      completed financial year, who we will collectively refer to as the named
      executive officers, for our fiscal years ended September 30, 2014 and
      2013, are set out in the following summary compensation
  table:</P></TD></TR></TABLE><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=center width="11%"><B>Other</B> </TD>
    <TD align=left width="11%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=center width="11%"><B>Annual</B> </TD>
    <TD align=left width="11%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=center width="11%"><B>Stock</B> </TD>
    <TD align=center width="11%"><B>Option</B> </TD>
    <TD align=center width="11%"><B>Compen-</B> </TD>
    <TD align=left width="11%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Name and Principal</B> </TD>
    <TD align=left width="11%">&nbsp; </TD>
    <TD align=center width="11%"><B>Salary</B> </TD>
    <TD align=center width="11%"><B>Bonus</B> </TD>
    <TD align=center width="11%"><B>Awards</B> </TD>
    <TD align=center width="11%"><B>Awards</B> </TD>
    <TD align=center width="11%"><B>sation</B> </TD>
    <TD align=center width="11%"><B>Total</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Position</B> </TD>
    <TD align=center width="11%"><B>Year</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Christopher Missling, </TD>
    <TD align=center width="11%" bgColor=#e6efff>2014 </TD>
    <TD align=center width="11%" bgColor=#e6efff>240,000 </TD>
    <TD align=center width="11%" bgColor=#e6efff>400,000<SUP>(2)</SUP> </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>16,888 </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>656,888 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>PhD<SUP>(1)</SUP> </TD>
    <TD align=center width="11%" bgColor=#e6efff>2013 </TD>
    <TD align=center width="11%" bgColor=#e6efff>60,000 </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>1,600,000<SUP>(3)</SUP> </TD>
    <TD align=center width="11%" bgColor=#e6efff>1,002,500 </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>2,662,500 </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>President, Chief </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Executive Officer, Chief </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Financial Officer and </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Director </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp; </TD>
    <TD align=left width="11%" bgColor=#e6efff>&nbsp;
</TD></TR></TABLE></DIV><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>Christopher Missling was appointed as director,
      President, Chief Executive Officer, Chief Financial Officer, Secretary and
      Treasurer on July 5, 2013.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>The bonus was a result of the successful financing in
      March, 2014.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(3) </TD>
    <TD>
      <P align=justify>Mr. Missling was granted 4,000,000 shares of restricted
      common stock that vest upon the occurrence of certain financial and
      clinical milestones. The value of stock awards issued to Christopher
      Missling is presented at the quoted market price of these shares on the
      date of issuance in accordance with FASB ASC Topic 718 for the awards that
      were expected to vest at the date of issuance.</P></TD></TR></TABLE>
<P align=center>35<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_41></A>
<P align=justify><B><I>Consulting Agreements</I></B></P>
<P align=justify><B>Christopher Missling</B> </P>
<P align=justify>In connection with Mr. Missling&#146;s appointment as Chief
Executive Officer, the Company and Mr. Missling entered into an employment
agreement commencing on July 5, 2013 and ending on July 5, 2016, whereby: (a)
the Company shall pay to Mr. Missling an initial monthly base salary of $20,000
with Mr. Missling being eligible for bonuses and salary increases; (b) Mr.
Missling received a sign-on stock option grant; (c) Mr. Missling shall receive a
restricted stock grant subject to certain vesting milestones; (d) Mr. Missling
shall be able to participate in the Company&#146;s employee benefit plans; and (e)
the Company agreed to indemnify Mr. Missling in connection with his provision of
services to the Company. </P>
<P align=justify><B><I>Outstanding Equity Awards at Fiscal Year-End</I></B></P>
<P align=justify>The following table sets forth for each named executive officer
and director certain information concerning the outstanding equity awards as of
September 30, 2014.</P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center vAlign=bottom bgcolor="#EEEEEE">&nbsp; </TD>
    <TD colspan="5" align=center vAlign=bottom bgcolor="#EEEEEE"> Option Awards   </TD>
    <TD colspan="4" align=center vAlign=bottom bgcolor="#EEEEEE"> Stock Awards  </TD>
    </TR>
  <TR>
    <TD align=center vAlign=bottom bgcolor="#EEEEEE"></TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"></TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"></TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"></TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"></TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"></TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"></TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"></TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"></TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"></TD></TR>
  <TR vAlign=top>
    <TD align=center vAlign=bottom bgcolor="#EEEEEE">Name </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"><BR>Number of <BR>Securities
      <BR>Underlying <BR>Exercisable <BR>Options <BR>(#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Number of <BR>Securities
      <BR>Underlying <BR>Unexercisable <BR>Options <BR>(#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Equity <BR>Incentive <BR>Plan
      <BR>Awards: <BR>Number of <BR>Securities <BR>Underlying
      <BR>Unexercised<BR>Unearned <BR>Options <BR>(#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Option <BR>Exercise <BR>Price
      <BR>($) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"><BR>Option <BR>Expiration
      <BR>Date </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"><BR>Number <BR>of <BR>Shares of
      <BR>Units of <BR>Stock <BR>that have <BR>not <BR>Vested <BR>(#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE"><BR>Market <BR>Value of
      <BR>Shares or <BR>Units of <BR>Stock that <BR>have not <BR>Vested <BR>($)    </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Equity <BR>Incentive<BR>Plan
      <BR>Awards: <BR>Number <BR>of <BR>Unearned<BR>Shares, <BR>Units or
      <BR>Other <BR>Rights <BR>that <BR>have <BR>not <BR>Vested <BR>(#) </TD>
    <TD width="10%" align=center vAlign=bottom bgcolor="#EEEEEE">Equity <BR>Incentive <BR>Plan
      <BR>Awards: <BR>Market or <BR>Payout <BR>Value of <BR>Unearned <BR>Shares,
    <BR>Units or <BR>Other <BR>Rights that <BR>have not <BR>Vested <BR>($)  </TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#E6EFFF">Christopher </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">2,000,000 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">0.40 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">July 5, 2023 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">3,000,000 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">540,000 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#E6EFFF">Missling </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">500,000 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">0.33 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">May 8, 2024 </TD>
    <TD width="10%" align=left bgcolor="#E6EFFF">&nbsp; </TD>
    <TD width="10%" align=left bgcolor="#E6EFFF">&nbsp; </TD>
    <TD width="10%" align=left bgcolor="#E6EFFF">&nbsp; </TD>
    <TD width="10%" align=left bgcolor="#E6EFFF">&nbsp; </TD></TR>
  <TR>
    <TD align=left>&nbsp;</TD>
    <TD align=center width="10%">&nbsp;</TD>
    <TD align=center width="10%">&nbsp;</TD>
    <TD align=center width="10%">&nbsp;</TD>
    <TD align=center width="10%">&nbsp;</TD>
    <TD align=center width="10%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD>
    <TD align=left width="10%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#E6EFFF">Athanasios Skarpelos </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#E6EFFF">Bernd Metzner </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">150,000 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">0.30 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD>
    <TD width="10%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgcolor="#E6EFFF">Elliot Favus </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">150,000 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">0.30 </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">Nil </TD>
    <TD width="10%" align=center bgcolor="#E6EFFF">N/A </TD></TR></TABLE>
</DIV>
<P align=justify>We have not adopted any other equity compensation plan other
than our 2007 Stock Option Plan. </P>
<P align=justify><B><I>Compensation of Directors</I></B></P>
<P align=center>36</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_42></A>
<P align=justify>The table below shows the compensation of our directors who
were not our named executive officers for the fiscal year ended September 30,
2014: </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%"><B>Non-Equity</B> </TD>
    <TD align=center width="11%"><B>Nonqualified</B> </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="11%"><B>Fees Earned</B> </TD>
    <TD align=center width="11%"><B>Stock</B> </TD>
    <TD align=center width="11%"><B>Option</B> </TD>
    <TD align=center width="11%"><B>Incentive Plan</B> </TD>
    <TD align=center width="11%"><B>Deferred</B> </TD>
    <TD align=center width="11%"><B>All Other</B> </TD>
    <TD align=center width="11%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="11%"><B>or Paid in</B> </TD>
    <TD align=center width="11%"><B>Awards</B> </TD>
    <TD align=center width="11%"><B>Awards</B> </TD>
    <TD align=center width="11%"><B>Compensation </B></TD>
    <TD align=center width="11%"
      ><STRONG>Compensation&nbsp;</STRONG>&nbsp;</TD>
    <TD align=center width="11%"
      ><STRONG>Compensation&nbsp;</STRONG>&nbsp;</TD>
    <TD align=center width="11%"><B>Total</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Name</B> </TD>
    <TD align=center width="11%"><B>Cash</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%"><B>Earnings ($)</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%"><B>($)</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>&nbsp; </TD>
    <TD align=center width="11%"><B>($)</B> </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Athanasios Skarpelos </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Bernd Metzner </TD>
    <TD align=center width="11%" bgColor=#e6efff>5,000 </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>4,626 </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>9,626 </TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD>
    <TD align=center width="11%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#e6efff>Elliot Favus </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>4,626 </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>Nil </TD>
    <TD align=center width="11%" bgColor=#e6efff>4,626
</TD></TR></TABLE></DIV>
<P align=justify>We reimburse our directors for expenses incurred in connection
with attending board meetings. </P>
<P align=justify>During the fiscal year ended September 30, 2014, there were no
standard arrangements pursuant to which any of our directors were compensated
for services provided in their capacity as directors.</P>
<P align=justify>We currently have no formal plan for compensating our directors
for their services in their capacity as directors, although we may elect to
issue stock options to such persons in the future. Directors are entitled to
reimbursement for reasonable travel and other out-of-pocket expenses incurred in
connection with attendance at meetings of our board of directors. Our board of
directors may award special remuneration to any director undertaking any special
services on our behalf other than services ordinarily required of a director.
</P>
<P align=justify><B><I>Retirement or Similar Benefit Plans </I></B></P>
<P align=justify>There are no arrangements or plans in which we provide
retirement or similar benefits for our directors or executive officers. </P>
<P align=justify><B><I>Resignation, Retirement, Other Termination, or Change in
Control Arrangements </I></B></P>
<P align=justify>Our employment agreement with Christopher Missling, PhD
contains provisions regarding our obligations to Mr. Missling upon his
termination and upon a change of control. In the event of a change of control,
as such term is defined in the employment agreement, all of the restricted stock
granted to Mr. Missling shall vest. Depending on the nature of the termination
of Mr. Missling&#146;s services, certain of his salary, bonus and granted securities
shall vest in the amounts at such time as set forth in the agreement. A copy of
the employment agreement is set forth in its entirety as an exhibit to the
Company&#146;s Quarterly Report on Form 10-Q filed with the SEC on August 14,
2013.</P>
<P align=center>37</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_43></A>
<P align=justify><B>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></P>
<P align=justify>The following table sets forth, as of December 15, 2014,
certain information with respect to the beneficial ownership of our common stock
by each stockholder known by us to be the beneficial owner of more than 5% of
our common stock and by each of our current directors and our named executive
officers and by our current directors and executive officers as a group. We have
determined the number and percentage of shares beneficially owned by such person
in accordance with Rule 13d-3 under the Securities Exchange Act of 1934. This
information does not necessarily indicate beneficial ownership for any other
purpose.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><BR><B>Title of class</B> </TD>
    <TD align=center width="35%"><B>Name and address of</B> <BR><B>beneficial
      owner</B> </TD>
    <TD colspan="2" align=center><B>Amount and nature of</B> <BR><B>beneficial
      ownership</B> <BR></TD>
    <TD align=center width="19%"><B>Percent of</B> <BR><B>class
      </B><B><SUP>(1)</SUP></B> </TD></TR>
  <TR>
    <TD align=center>&nbsp; </TD>
    <TD width="35%">&nbsp; </TD>
    <TD width="19%">&nbsp; </TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="19%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock <BR><BR><BR></TD>
    <TD align=left width="35%" bgColor=#e6efff>Athanasios Skarpelos
      <BR>(Director) <BR>2, Place du Port <BR>Geneva, Switzerland CH 1204 </TD>
    <TD align=right width="19%" bgColor=#e6efff>5,225,832<BR><BR><BR></TD>
    <TD align=center width="7%" bgColor=#e6efff>Direct <BR><BR><BR></TD>
    <TD align=center width="19%" bgColor=#e6efff>9.4% <BR><BR><BR></TD></TR>
  <TR>
    <TD align=center>&nbsp; </TD>
    <TD width="35%">&nbsp; </TD>
    <TD width="19%">&nbsp; </TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="19%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock <BR><BR><BR><BR></TD>
    <TD align=left width="35%" bgColor=#e6efff>Christopher Missling
      <BR>(Officer/Director) <BR>51 W 552nd Street, <BR>7th floor <BR>New York,
      NY 10019 </TD>
    <TD align=right width="19%" bgColor=#e6efff>3,000,000<SUP>(2)</SUP><BR>
    <BR><BR></TD>
    <TD align=right width="7%" bgColor=#e6efff><BR><BR><BR><BR></TD>
    <TD align=center width="19%" bgColor=#e6efff>5.2% <BR><BR><BR><BR></TD></TR>
  <TR>
    <TD align=center>&nbsp;</TD>
    <TD align=left width="35%">&nbsp;</TD>
    <TD align=right width="19%">&nbsp;</TD>
    <TD align=right width="7%">&nbsp;</TD>
    <TD align=center width="19%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock <BR><BR><BR></TD>
    <TD align=left width="35%" bgColor=#e6efff>Bernd Metzner (Director) <BR>51
      W 552<SUP>nd </SUP>Street, <BR>7<SUP>th </SUP>Floor <BR>New York, NY 10019    </TD>
    <TD align=right width="19%" bgColor=#e6efff>Nil<BR><BR></TD>
    <TD align=right width="7%" bgColor=#e6efff><BR><BR><BR></TD>
    <TD align=center width="19%" bgColor=#e6efff>Nil <BR><BR><BR></TD></TR>
  <TR>
    <TD align=center>&nbsp;</TD>
    <TD align=left width="35%">&nbsp;</TD>
    <TD align=right width="19%">&nbsp;</TD>
    <TD align=right width="7%">&nbsp;</TD>
    <TD align=center width="19%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock <BR><BR><BR></TD>
    <TD align=left width="35%" bgColor=#e6efff>Elliot Favus(Director) <BR>51 W
      552<SUP>nd </SUP>Street, <BR>7<SUP>th </SUP>Floor <BR>New York, NY 10019    </TD>
    <TD align=right width="19%" bgColor=#e6efff>Nil<BR><BR></TD>
    <TD align=right width="7%" bgColor=#e6efff><BR><BR><BR></TD>
    <TD align=center width="19%" bgColor=#e6efff>Nil <BR><BR><BR></TD></TR>
  <TR>
    <TD align=center>&nbsp;</TD>
    <TD align=left width="35%">&nbsp;</TD>
    <TD align=right width="19%">&nbsp;</TD>
    <TD align=right width="7%">&nbsp;</TD>
    <TD align=center width="19%">&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff>Common Stock </TD>
    <TD align=left width="35%" bgColor=#e6efff><B>Directors &amp;
      Executive</B> <B>Officers as a group (4</B> <B>persons)</B> </TD>
    <TD align=right width="19%" bgColor=#e6efff>8,225,832 </TD>
    <TD align=right width="7%" bgColor=#e6efff></TD>
<TD align=center width="19%" bgColor=#e6efff>14.3%</TD></TR></TABLE>
<BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">(1) </TD>
    <TD>
      <P align=justify>Percentage of ownership is based on 54,684,905 shares of
      our common stock issued and outstanding as of December 15, 2014. Except as
      otherwise indicated, we believe that the beneficial owners of the common
      stock listed above, based on information furnished by such owners, have
      sole investment and voting power with respect to such shares, subject to
      community property laws where applicable. Beneficial ownership is
      determined in accordance with the rules of the Securities and Exchange
      Commission and generally includes voting or investment power with respect
      to securities. Shares of common stock subject to options or warrants
      currently exercisable or exercisable within 60 days, are deemed
      outstanding for purposes of computing the percentage ownership of the
      person holding such option or warrants, but are not deemed outstanding for
      purposes of computing the percentage ownership of any other
  person.</P></TD></TR></TABLE>
<P align=center>38<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_44></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">(2) </TD>
    <TD>
      <P align=justify>Includes 2,000,000 stock options that have vested and
      1,000,000 shares of restricted common stock that have vested pursuant to
      the achievement of certain objectives. Does not include 3,000,000 shares
      of restricted common stock that vest pursuant to the achievement of
      certain objectives.</P></TD></TR></TABLE>
<P align=justify><B><I>Changes in Control </I></B></P>
<P align=justify>We are unaware of any contract or other arrangement the
operation of which may at a subsequent date result in a change of control of our
company. </P>
<P align=justify><B>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND
DIRECTOR INDEPENDENCE</B></P>
<P align=justify><B><I>Transactions with related persons </I></B></P>
<P align=justify>There have been no other transactions, since October 1, 2013,
or currently proposed transactions, in which we were or are to be a participant
and the amount involved exceeds the lesser of $120,000 or one percent of the
average of our total assets at year end for the last two completed fiscal years,
and in which any of the following persons had or will have a direct or indirect
material interest.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top align=right width="4%">i. </TD>
    <TD vAlign=top align=right width="4%" >&nbsp;</TD>
    <TD >
      <P align=justify>any director or executive officer of our
  company;</P></TD></TR>
  <TR>
    <TD width="4%">&nbsp;</TD>
    <TD width="4%" >&nbsp;</TD>
    <TD >&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top align=right width="4%">ii. </TD>
    <TD vAlign=top align=right width="4%" >&nbsp;</TD>
    <TD >
      <P align=justify>any beneficial owner of shares carrying more than 5% of
      the voting rights attached to our outstanding shares of common stock;
      and</P></TD></TR>
  <TR>
    <TD width="4%">&nbsp;</TD>
    <TD width="4%" >&nbsp;</TD>
    <TD >&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top align=right width="4%">iii. </TD>
    <TD vAlign=top align=right width="4%" >&nbsp;</TD>
    <TD >
      <P align=justify>any member of the immediate family (including spouse,
      parents, children, siblings and in-laws) of any of the foregoing
      persons.</P></TD></TR></TABLE>
<P align=justify><B><I>Compensation of Named Executive Officers and Directors
</I></B></P>
<P align=justify>For information regarding compensation of named executive
officers and directors, please see &#147;Item 11. Executive Compensation.&#148;</P>
<P align=justify><B><I>Director Independence </I></B></P>
<P align=justify>We deem that Christopher Missling, PhD is not independent as
that term is defined by NASDAQ 5605(a)(2) because Mr. Missling serves as our
President, Chief Executive Officer, Secretary, Treasurer and Chief Financial
Officer. We have also determined that Athanasios Skarpelos is not independent as
that term is defined by NASDAQ 5605(a)(2).</P>
<P align=justify>We deem that Bernd Metzner and Elliot Favus are independent as
that term is defined by NASDAQ 5605(a)(2). </P>
<P align=center>39</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_45></A>
<P align=justify><B>ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</B></P>
<P align=justify><B><I>Fees Paid to Our Independent Registered Public Accounting
Firm</I></B></P>
<P align=justify>The following table sets forth the aggregate fees billed or
expected to be billed to our company for professional services rendered by our
independent registered public accounting firm, for the fiscal years ended
September 30, 2014 and 2013:</P>
<DIV align=center>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="70%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="20%">2014
    </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=right width="20%">2013
    </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Audit Fees </TD>
    <TD align=right width="20%" bgColor=#e6efff>$86,000 </TD>
    <TD align=right width="20%" bgColor=#e6efff>$50,000 </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Audit Related Fees </TD>
    <TD align=right width="20%" bgColor=#e6efff>$29,125 </TD>
    <TD align=right width="20%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Tax Fees </TD>
    <TD align=right width="20%" bgColor=#e6efff>Nil </TD>
    <TD align=right width="20%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >All Other Fees </TD>
    <TD align=right width="20%" bgColor=#e6efff>Nil </TD>
    <TD align=right width="20%" bgColor=#e6efff>Nil </TD></TR>
  <TR>
    <TD align=center >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD>
    <TD align=right width="20%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=center bgColor=#e6efff >Total Fees </TD>
    <TD align=right width="20%" bgColor=#e6efff>$115,125 </TD>
    <TD align=right width="20%" bgColor=#e6efff>$50,000
</TD></TR></TABLE></DIV>
<P align=justify><U>Audit Fees</U>. Consist of fees billed for professional
services rendered for the audits of our financial statements, reviews of our
interim financial statements included in quarterly reports, services performed
in connection with regular filings with the Securities and Exchange Commission
and other services that are normally provided by our independent registered
public accounting firm for the fiscal years ended September 30, 2014 and 2013,
in connection with statutory and regulatory filings or engagements. </P>
<P align=justify><U>Audit Related Fees</U>. Consists of fees billed for
professional services rendered in connection with the Company&#146;s filings on form
S-1 Registration Statement. </P>
<P align=justify><U>Tax Fees</U>. Consist of fees billed for the preparation of
corporate tax returns </P>
<P align=justify><B><I>Policy on Pre-Approval by Audit Committee of Services
Performed by Independent Registered Public Accounting Firm</I></B></P>
<P align=justify>Our board of directors pre-approves all services provided by
our independent registered public accounting firm. All of the above services and
fees were reviewed and approved by our board of directors before the respective
services were rendered. </P>
<P align=justify>Our board of directors has considered the nature and amount of
fees billed or expected to be billed by BDO USA, LLP and believes that the
provision of services for activities unrelated to the audit was compatible with
maintaining BDO USA, LLP&#146;s independence. </P>
<P align=center>40</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_46></A>
<P align=justify><B>PART IV </B></P>
<P align=justify><B>ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES </B></P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(3)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;<B>Articles of Incorporation and Bylaws</B>
  </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Articles of Incorporation (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.2 </TD>
    <TD align=left width="90%" >
      <P align=justify>Bylaws (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on September 28, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>3.3 </TD>
    <TD align=left width="90%" >
      <P align=justify>Articles of Merger filed with the Secretary of State of
      Nevada on January 10, 2007 and which is effective January 25, 2007
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on January 25, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(4)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify><B>Instruments defining rights of security holders,
      including indentures</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Specimen Stock Certificate (incorporated by reference to
      an exhibit to our Registration Statement on Form SB-2 filed on January 13,
      2005) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.2 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.3 </TD>
    <TD align=left width="90%" >
      <P align=justify>8% Convertible Loan Agreement dated June 3, 2009
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>4.4 </TD>
    <TD align=left width="90%" >
      <P align=justify>8% Convertible Loan Agreement dated June 19, 2009
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(10)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;<B>Material Contracts</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Agreement between Anavex Life Sciences Corp. and Dr.
      Alexandre Vamvakides dated January 31, 2007 (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on February 7, 2007)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.2 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Stock Option Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on February 22,
      2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.3 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services and Subscription Agreement dated
      September 11, 2007 between our company and Eurogenet Labs S.A.
      (incorporated by reference to an exhibit to our Current Report on Form 8-
      K filed on September 27, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.4 </TD>
    <TD align=left width="90%" >
      <P align=justify>2007 Stock Option Plan (incorporated by reference to an
      exhibit to our Current Report on Form 8- K filed on September 28, 2007)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.5 </TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement with Cameron Durrant dated May 20,
      2008 (incorporated by reference to an exhibit to our Quarterly Report on
      Form 10-QSB filed on August 18, 2008 </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.6 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.7 </TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement with Tariq Arshad dated March 2,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.8 </TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement with Dr. Mark Smith dated January
      13, 2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on April 3, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.9 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
      </P></TD></TR></TABLE></DIV>
<P align=center>41<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_47></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" ><BR><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>10.10 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 3, 2009)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.11 </TD>
    <TD align=left width="90%" >
      <P align=justify>Amended Consulting Agreement with Cameron Durrant dated
      May 14, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.12 </TD>
    <TD align=left width="90%" >
      <P align=justify>CEO Consulting Agreement with Dr. Herve de Kergrohen
      dated June 12, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.13 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Private Placement subscription agreement dated
      June 15, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.14 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement with Andreas Eleuthariadis
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.15 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement with Vasileios Kourafalos
      dated June 10, 2009 (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.16 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement with George Kalkanis dated
      June 10, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.17 </TD>
    <TD align=left width="90%" >
      <P align=justify>Stock Option Agreement with Alexandre Vamvakides dated
      June 11, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 23, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.19 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Private Placement Subscription Agreement
      Convertible Loan (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.20 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Private Placement Subscription Agreement for
      Units (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on June 26, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.21 </TD>
    <TD align=left width="90%" >
      <P align=justify>Consultant Services Agreement with NAD Ltd. dated July 1,
      2009 (incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on November 24, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.22 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on November 24,
      2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.23 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on August 12, 2009)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.24 </TD>
    <TD align=left width="90%" >
      <P align=justify>Stock Option Agreement with Alexander Vamvakides dated
      October 19, 2009 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on November 24, 2009) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.25 </TD>
    <TD align=left width="90%" >
      <P align=justify>Promissory note issued to Stonehedge Limited on January
      1, 2010 (incorporated by reference to an exhibit to our Quarterly Report
      on Form 10-Q filed on March 31, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.26 </TD>
    <TD align=left width="90%" >
      <P align=justify>Second Amended Consulting Agreement with Dr. Cameron
      Durrant dated January 2, 2010 (incorporated by reference to an exhibit to
      our Current Report on Form 8-K filed on April 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.27 </TD>
    <TD align=left width="90%" >
      <P align=justify>Contract Lease Agreement with Euro Genet Labs SA dated
      February 1, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on April 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.28 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
      </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.29 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on April 9, 2010)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.30 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Convertible Loan Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on April
      9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.31 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement for US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR></TABLE></DIV>
<P align=center>42<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_48></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" ><BR><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>10.32 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement for non-US subscribers
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.33 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate for US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.34 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 6, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.35 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement dated July 5, 2010 with
      Eurogenet Labs SA (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.36 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate for non-US warrant holders
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on July 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.37 </TD>
    <TD align=left width="90%" >
      <P align=justify>Agreement for Services with Genesis Biopharma Group LLC
      dated August 10, 2010 (incorporated by reference to an exhibit of our
      Current Report on Form 8-K filed on August 18, 2010) <I>(portions</I>
      <I>of the exhibit have been omitted pursuant to a request for confidential
      treatment)</I> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.38 </TD>
    <TD align=left width="90%" >
      <P align=justify>Agreement for Services with ABX-CRO Advanced
      Pharmaceutical Services dated August 10, 2010 (incorporated by reference
      to an exhibit of our Current Report on Form 8-K filed on August 18, 2010)
      <I>(portions of the exhibit have been omitted pursuant to a request for
      confidential</I> <I>treatment)</I> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.39 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.40 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (Canadian and Offshore
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.41 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (US warrant
      holders)(incorporated by reference to an exhibit to our Current Report on
      Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.42 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (Canadian and Offshore
      warrant holders) (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 9, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.43 </TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement dated August 2, 2010 with Tom
      Skarpelos (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.44 </TD>
    <TD align=left width="90%" >
      <P align=justify>Independent Contractor Agreement dated September 1, 2010
      with David Tousley (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.45 </TD>
    <TD align=left width="90%" >
      <P align=justify>Sublease Contract with Genesis Research LLC dated
      September 15, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.46 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.47 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (non-US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.48 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (US Warrant Holders) (US
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.49 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (non-US Warrant Holders) (US
      Purchasers) (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.50 </TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Service and Subscription Agreement dated
      November 1, 2010 with Eurogenet Labs SA (incorporated by reference to an
      exhibit to our Current Report on Form 8-K filed on November 22, 2010)
    </P></TD></TR></TABLE></DIV>
<P align=center>43<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_49></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>Exhibit</B> <BR><B>Number</B> </P></TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.51 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Subscription Agreement with Stonehedge Limited dated
      November 17, 2010 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on November 22, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.52 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (incorporated by reference
      to an exhibit to our Current Report on Form 8-K filed on November 30,
      2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.53 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate Form of Subscription
      Agreement (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 30, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.54 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Shares for Services Agreement Form of Subscription
      Agreement (incorporated by reference to an exhibit to our Current Report
      on Form 8-K filed on November 30, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.55 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Subscription Agreement (non-US Purchasers)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.56 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant Certificate (non-US Warrant Holders)
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.57 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Termination Agreement dated February 2, 2011 with Genesis
      BioPharma Group, LLC (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.58 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Independent Contractor Agreement with Harvey Lalach dated
      February 1, 2011 (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.59 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Independent Contractor Agreement with Dr. Angelos
      Stergiou dated February 1, 2011 (incorporated by reference to an exhibit
      to our Current Report on Form 8-K filed on February 7, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.60 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Amended and Restated 2007 Stock Option Plan (incorporated
      by reference to an exhibit to our Current Report on Form 8-K filed on
      February 8, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.61 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Advisory Board Consulting Agreement (incorporated
      by reference to an exhibit to our Current Report on Form 8-K filed on
      February 28, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.62 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement dated March 30, 2011 with Shackleton
      Consulting Corp. (incorporated by reference to an exhibit to our Current
      Report on Form 8-K filed on April 13, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.63 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreement for convertible debenture
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on April 26, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.64 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreement for convertible debenture
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on May 9, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.65 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of warrant certificate (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on May 9, 2011)
  </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.66 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Amended Stock Option Agreement dated September 16, 2011
      with Cameron Durrant (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on September 21, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.67 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Consulting Agreement dated effective October 10, 2011,
      with George Tidmarsh (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on October 14, 2011) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.68 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreement for services (US
      purchaser) (incorporated by reference to our current report on Form 8-K
      filed on February 10, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.69 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreement for units (Offshore
      purchasers) (incorporated by reference to our current report on Form 8-K
      filed on February 10, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.70 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Unsecured Promissory Note dated April 20, 2012 issued to
      Georgia Georgopoulou (incorporated by reference to our quarterly report on
      Form 10-Q filed on May 15, 2012) </P></TD></TR></TABLE></DIV>
<P align=center>44<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_50></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left>
      <P align=justify><B>Exhibit</B> <BR><B>Number</B> </P></TD>
    <TD align=left width="90%" >
      <P align=justify><BR><B>Description</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.71 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of subscription agreements for convertible debenture
      and promissory notes (incorporated by reference to an exhibit to our
      Current Report on Form 8-K filed on June 7, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.72 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Promissory Note dated October 17, 2012 issued to Akira
      International Limited (incorporated by reference to an exhibit to our
      Annual Report on Form 10-K filed on December 31, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.73 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Promissory Note dated November 12, 2012 issued to Akira
      International Limited (incorporated by reference to an exhibit to our
      Annual Report on Form 10-K filed on December 31, 2012) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.74 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of SPA (incorporated by reference to an exhibit to
      our Current Report on Form 8-K filed on July 8, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.75 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Exchange Agreement (incorporated by reference to
      an exhibit to our Current Report on Form 8- K filed on July 8, 2013)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.76 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Warrant (incorporated by reference to an exhibit
      to our Current Report on Form 8-K filed on July 8, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.77 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Registration Rights Agreement (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on July 8,
      2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.78 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Purchase Agreement, dated as of July 5, 2013, by and
      between the Company and Lincoln Park Capital Fund, LLC (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on July 8,
      2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.79 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Registration Rights Agreement, dated as of July 5, 2013,
      by and between the Company and Lincoln Park Capital Fund, LLC
      (incorporated by reference to an exhibit to our Current Report on Form 8-
      K filed on July 8, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.80 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Employment Agreement, dated as of July 5, 2013, by and
      between the Company and Christopher Missling, PhD (incorporated by
      reference to an exhibit to our Quarterly Report on Form 10-Q filed on
      August 14, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.81 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>2012 Addendum to the Contract for the Transfer of a
      Patent Invention and Scientific Collaboration dated January 11, 2013
      (incorporated by reference to an exhibit to our Annual Report on Form 10-
      K filed on December 30, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.82 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Appendix A to the 2012 Addendum to the Contract for the
      Transfer of a Patent Invention and Scientific Collaboration dated January
      11, 2013 (incorporated by reference to an exhibit to our Annual Report on
      Form 10-K filed on December 30, 2013) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.83 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Amendment No. 1 to Common Stock Securities
      Purchase Warrant, entered into December 21, 2013 Agreement, dated March
      13, 2014, by and among the Company and the Purchasers named therein
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on March 19, 2014) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.84 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Registration Rights Agreement, dated March 13,
      2014, by and among the Company and the parties identified therein
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on March 19, 2014) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.85 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Senior Convertible Debenture (incorporated by
      reference to an exhibit to our Current Report on Form 8-K filed on March
      19, 2014) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.86 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Series A/B Warrant (incorporated by reference to
      an exhibit to our Current Report on Form 8-K filed on March 19, 2014)
    </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>
      <P align=justify>10.87 </P></TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Amendment No. 1 to Registration Rights Agreement
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on August 25, 2014 </P></TD></TR></TABLE></DIV>
<P align=center>45<BR>
</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_51></A><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left><B>Exhibit</B> <BR><B>Number</B> </TD>
    <TD align=left width="90%" ><BR><B>Description</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left>10.88 </TD>
    <TD align=left width="90%" >
      <P align=justify>Securities Purchase Agreement, dated October 22, 2014, by
      and between the Company and Lincoln Park Capital Fund, LLC (incorporated
      by reference to an exhibit to our Current Report on Form 8- K filed on
      October 23, 2014) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.89 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Series A Common Stock Purchase Warrant
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on October 23, 2014) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>10.90 </TD>
    <TD align=left width="90%" >
      <P align=justify>Form of Series B Common Stock Purchase Warrant
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on October 23, 2014) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(14)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;<B>Code of Ethics</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>14.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Code of Conduct (incorporated by reference to an exhibit
      to our Current Report on Form 8-K filed on September 28, 2007) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(21)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;<B>Subsidiaries</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>21.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;Anavex Life Sciences (France) SA, incorporated
      under the laws of France </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>21.2 </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;Anavex Australia Pty Limited, a company
      incorporated under the laws of Australia </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(31)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;<B>Section 302 Certifications</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="exhibit31-1.htm">31.1* </a></TD>
    <TD align=left width="90%" >
      <P align=justify><a href="exhibit31-1.htm">&nbsp;Section 302 Certification of Christopher Missling,
    PhD. </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(32)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;<B>Section 906 Certifications</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="exhibit32-1.htm">32.1* </a></TD>
    <TD align=left width="90%" >
      <P align=justify><a href="exhibit32-1.htm">&nbsp;Section 906 Certification of Christopher Missling,
      PhD. </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(99)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;<B>Additional Exhibits</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left>99.1 </TD>
    <TD align=left width="90%" >
      <P align=justify>Insider Trading Policy Adopted August 27, 2010
      (incorporated by reference to an exhibit to our Current Report on Form 8-K
      filed on September 27, 2010) </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><B>(101)</B> </TD>
    <TD align=left width="90%" >
      <P align=justify>&nbsp;<B>XBRL</B> </P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="avxl-20140930.xml">101.INS* </a></TD>
    <TD align=left width="90%" >
      <P align=justify><a href="avxl-20140930.xml">&nbsp;XBRL INSTANCE DOCUMENT </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="avxl-20140930.xsd">101.SCH* </a></TD>
    <TD align=left width="90%" >
      <P align=justify><a href="avxl-20140930.xsd">&nbsp;XBRL TAXONOMY EXTENSION SCHEMA </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="avxl-20140930_cal.xml">101.CAL* </a></TD>
    <TD align=left width="90%" >
    <P align=justify><a href="avxl-20140930_cal.xml">&nbsp;XBRL TAXONOMY EXTENSION CALCULATION LINKBASE </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="avxl-20140930_def.xml">101.DEF* </a></TD>
    <TD align=left width="90%" >
    <P align=justify><a href="avxl-20140930_def.xml">&nbsp;XBRL TAXONOMY EXTENSION DEFINITION LINKBASE </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="avxl-20140930_lab.xml">101.LAB* </a></TD>
    <TD align=left width="90%" >
      <P align=justify><a href="avxl-20140930_lab.xml">&nbsp;XBRL TAXONOMY EXTENSION LABEL LINKBASE </a></P></TD></TR>
  <TR vAlign=top>
    <TD align=left><a href="avxl-20140930_pre.xml">101.PRE* </a></TD>
    <TD align=left width="90%" >
    <P align=justify><a href="avxl-20140930_pre.xml">&nbsp;XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE </a></P></TD></TR></TABLE>
</DIV>
<P align=justify>* Filed herewith.</P>
<P align=center>46</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_52></A>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned thereunto duly authorized. </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Date: December 29, 2014</B> </TD>
    <TD align=left width="50%"><B>ANAVEX LIFE SCIENCES CORP.</B>
</TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >By: </TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="45%"
    ><I>/s/ Christopher Missling, PhD</I> </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >Name: </TD>
    <TD align=left width="45%"  >Christopher
      Missling, PhD </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >Title: </TD>
    <TD align=left width="45%" >Chief Executive Officer and Chief
      Financial </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >&nbsp; </TD>
    <TD align=left width="45%" >Officer (Principal Executive
      Officer, Principal </TD></TR>
  <TR vAlign=bottom>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >&nbsp;</TD>
    <TD align=left width="45%"  >Financial Officer,
      Principal Accounting </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="5%" >&nbsp; </TD>
    <TD align=left width="45%" >Officer) </TD></TR></TABLE>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons on behalf of
the registrant and in the capacities and on the dates indicated. </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><B>Signatures</B>
    </TD>
    <TD align=center width="2%"  >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="45%"
    ><B>Title(s)</B> </TD>
    <TD align=left width="2%"  >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=center width="15%"
    ><B>Date</B> </TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="45%" >&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/</I>
      <I>Christopher Missling</I> </TD>
    <TD align=left width="2%"  rowSpan=2 ></TD>
    <TD align=left width="45%" rowSpan=2 >Chief Executive
      Officer, Chief Financial Officer (Principal Executive Officer, Principal
      Financial Officer, Principal Accounting Officer) </TD>
    <TD align=left width="2%"  rowSpan=2 ></TD>
    <TD align=left width="15%" rowSpan=2 >December 29, 2014
    </TD></TR>
  <TR vAlign=top>
    <TD align=left>Christopher Missling </TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="45%" >&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/</I>
      <I>Athanasios Skarpelos</I> </TD>
    <TD align=left width="2%"  rowSpan=2 ></TD>
    <TD align=left width="45%" rowSpan=2 >Director </TD>
    <TD align=left width="2%"  rowSpan=2 ></TD>
    <TD align=left width="15%" rowSpan=2 >December 29, 2014
    </TD></TR>
  <TR vAlign=top>
    <TD align=left>Athanasios Skarpelos </TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="45%" >&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/</I>
      <I>Bernd Metzner</I> </TD>
    <TD align=left width="2%"  rowSpan=2 ></TD>
    <TD align=left width="45%" rowSpan=2 >Director </TD>
    <TD align=left width="2%"  rowSpan=2 ></TD>
    <TD align=left width="15%" rowSpan=2 >December 29, 2014
    </TD></TR>
  <TR vAlign=top>
    <TD align=left>Bernd Metzner </TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="45%" >&nbsp; </TD>
    <TD width="2%"  >&nbsp;</TD>
    <TD width="15%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/</I>
      <I>Elliot Favus</I> </TD>
    <TD align=left width="2%"  rowSpan=2 ></TD>
    <TD align=left width="45%" rowSpan=2 >Director </TD>
    <TD align=left width="2%"  rowSpan=2 ></TD>
    <TD align=left width="15%" rowSpan=2 >December 29, 2014
    </TD></TR>
  <TR vAlign=top>
    <TD align=left>Elliot Favus </TD></TR></TABLE></DIV>
<P align=center>47<BR>
</P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>
</TEXT>
</DOCUMENT>
